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Chapter 1
1.1 Psoriasis
Introduction
Psoriasis is a common chronic inflammatory skin disease. Psoriasis often impairs physical, 
psychological and social functioning. The impact of psoriasis on health-related quality of 
life was shown to be similar to that of other major medical diseases.1 Due to the negative 
impact of psoriasis on employment and income and the costs of treatment, psoriasis is 
also an important health problem from a societal perspective.2 In recent years, important 
advances have been made in elucidating the pathogenesis of psoriasis. 
This chapter describes the history, epidemiology, clinical and histological features, 
pathogenesis and comorbidities in psoriasis.
History 
Psoriasis is an ancient skin disease, described for the first time in the Corpus Hippocraticum 
by Hippocrates. The word psoriasis is derived from the Greek word ‘psora’, meaning ‘to 
itch’.3 Psoriasis was confused with leprosy for many centuries. Only in the 19th century, 
psoriasis was recognized as a separate entity.3, 4 
Epidemiology
A recent systematic review showed that the prevalence of psoriasis in Europe in individuals 
of all ages varies between 0.7% and 2.9%.5 The prevalence of psoriasis in studies in 
populations with different ethnic backgrounds ranged from 0.6% to 4.8%.6 Psoriasis tends 
to occur more frequently in Caucasians than in other races and more frequently at higher 
latitudes than lower latitudes.7 
In a recent study performed in the United States, the prevalence of psoriasis was 3.2%. 
From these patients, 17% had moderate to severe disease, in this study defined as an 
affected body surface area of at least 3%.6 In another study, 21% of patients had extensive 
disease, defined as an affected body surface area of at least 10%.8 
Psoriasis can appear at any age. Nevitt et al. found the mean age at onset to be 33 years, 
with 75% of cases appearing before the age of 46.9 However, there also appears to be a 
bimodal distribution, with a peak at the age of 16-22 years and a peak at the age of 57-60 
years.10 There is no gender predilection, although women do appear to have an earlier 
age of onset.6, 11 The higher proportion of men with psoriasis treated with biologics may 
be explained by more severe disease in men.12
12
Clinical and histological features
Psoriasis is a heterogeneous disease, with several clinical phenotypes. Different forms 
of psoriasis can coexist. The most common form of psoriasis, which is found in 90% of 
psoriasis patients, is chronic plaque psoriasis (also known as psoriasis vulgaris). Chronic 
plaque psoriasis is characterized by well-demarcated erythematous plaques of variable 
size with white or silvery scale, typically in a symmetrical distribution. Predilection sites 
are the extensor surfaces of the elbows and knees, the scalp, the lumbosacral region and 
the umbilicus. The face is infrequently affected. Site-specific variants of plaque psoriasis 
are inverse psoriasis (also known as flexural psoriasis), scalp psoriasis, seborrhoeic 
psoriasis (sebopsoriasis) and palmoplantar psoriasis (nonpustular).
Other forms of psoriasis include guttate psoriasis, erythroderma and pustular psoriasis. 
Pustular psoriasis can be subdivided into localized forms of pustular psoriasis (palmoplantar 
pustulosis and acrodermatitis continua of Hallopeau) and generalized pustular psoriasis 
(von Zumbusch). Palmoplantar pustulosis may be a distinct entity rather than a form of 
psoriasis.4, 13-15 Furthermore, about 50% of patients have nail psoriasis, most commonly 
seen in patients with psoriatic arthritis.14, 16
Histologically, the psoriatic plaque is characterized by epidermal hyperproliferation, 
increased vascularity and a predominantly dermal inflammatory infiltrate. The epidermis 
is characterized by acanthosis with regular elongation of rete ridges, thinning of the 
suprapapillary plate, parakeratosis and loss of the granular layer. Highly characteristic for 
psoriasis but infrequently seen, are micropustels of Kogoj and microabcesses of Munro.4, 14, 17
The papillary dermis contains dilated and tortuous capillaries. The inflammatory infiltrate 
mainly contains T-cells, dendritic cells, macrophages and neutrophils.17, 18
Pathogenesis
Psoriasis is a multifactorial disease, resulting from a combination of genetic and 
environmental factors. Evidence for a genetic component comes from population studies, 
showing that the incidence of psoriasis is greater in first and second degree relatives of 
patients in the general population. In addition, the risk of psoriasis is two to three times 
higher in monozygotic twins compared with dizygotic twins.14, 17, 19 
At present, at least nine chromosomal psoriasis susceptibility loci have been identified 
through linkage analysis, called psoriasis susceptibility 1 through 9 (PSORS1 through 
PSORS9). By far the major genetic determinant of psoriasis is PSORS1, which probably 
accounts for 35-50% of the heritability of the disease.14, 17, 20 The PSORS1 region contains 
HLA-Cw6, which is involved in antigen presentation. Current data suggest that HLA-Cw6 is 
the susceptibility locus within the PSORS1 region.21 This indicates a role for the adaptive 
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immune system in psoriasis. HLA-Cw6 also is a strong marker for early-onset psoriasis.14
In addition, several other genes related to adaptive immunity, innate immunity and skin 
barrier function have been identified by genome wide association studies. As an example, 
variants in the interleukin-23 receptor (IL23R) gene and the interleukin-12B (IL12B) 
gene, both involved in adaptive immunity, have been identified. Tumour necrosis factor 
α-induced protein 3 (TNFAIP3) is an example of a susceptibility gene related to innate 
immunity.
Most genetic data available support an immune-based pathogenesis. However, copy-
number variation in the β-defensin cluster and deletions in the late cornified envelope 
(LCE) genes have also been associated with psoriasis and support a role for the 
epidermis.17, 22, 23
In paediatric-onset psoriasis, an association was demonstrated with established and 
recently discovered genetic risk factors, including genes involved in epidermal barrier 
function and adaptive immunity (ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-
Cw6). Data from this study suggest that heritable factors may play a more important role 
in paediatric-onset psoriasis than in adult-onset psoriasis.24 It had already been shown 
that guttate psoriasis (an acute onset form, usually occurring in adolescents), is strongly 
associated with PSORS1, whereas late onset psoriasis vulgaris (age > 50 years) is not.17, 25
Environmental triggering factors for psoriasis are infections (especially streptococcal 
Figure 1. Pathogenesis of psoriasis.17
14
pharyngitis), certain medications, stress, smoking, obesity and trauma to the skin (Koebner 
phenomenon).26
Figure 1 and Figure 2 show a proposed scheme of the evolution of a psoriatic lesion. 
Triggers such as physical trauma or bacterial products and the production of cytokines by 
innate immune cells (including tumour necrosis factor α (TNF-α)), lead to the activation of 
myeloid dendritic cells that migrate into draining lymph nodes. The dendritic cells present 
antigens to naïve T-cells and induce the differentiation of naïve T cells into effector cells 
such as type 1 helper T cells (Th1) and type 17 helper T cells (Th17) by the release of 
interleukin-12 (IL-12) and interleukin-23 (IL-23). T-cells in turn, secrete mediators (TNF-α, 
interleukin-17A (IL-17A), interleukin-17F (IL-17F) and interleukin-22 (IL-22)), that lead to 
activation and proliferation of keratinocytes. Activated keratinocytes produce antimicrobial 
peptides, proinflammatory cytokines (including TNF-α), chemokines and S100 proteins, 
thereby creating a feedback loop.
Chapter 1
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The high efficacy of the former biological therapies directed against T-cells (alefacept 
and efalizumab) and the current biologics directed against cytokines involved in the 
IL-23/Th17 pathway, demonstrates the importance of these cells and cytokines in the 
pathogenesis of psoriasis.
Comorbidities
Psoriasis is associated with comorbidities like psoriatic arthritis, the metabolic syndrome, 
Crohn’s disease, diabetes mellitus, depression and cancer.14 About 25% of patients with 
psoriasis have psoriatic arthritis.14, 27 Psoriatic arthritis is nowadays seen as a comorbidity 
rather than a different manifestation of the same disease, which is supported by genetic 
and immunological differences and differences in responses to various therapies.14
Many observational studies have shown an association between psoriasis and 
comorbidities, especially the metabolic syndrome and cardiovascular disease.28, 29 The 
cardiovascular risk seems to increase with the severity of the disease.29 However, the 
association between psoriasis and comorbidities is complex.28 The question is whether 
there is a direct link between psoriasis and many of the associated diseases through 
chronic systemic inflammation (the inflammatory hypothesis). Another possibility is that 
the associated diseases are in fact comorbidities, indirectly linked to psoriasis through 
unhealthy lifestyle factors leading to the metabolic syndrome or shared genes increasing 
the risk for psoriasis as well as for comorbidities.28, 30 Conversely, smoking and obesity 
may increase the risk of developing psoriasis.28, 31, 32
Many studies that corrected for available confounders have shown an independent 
association between psoriasis and cardiovascular disease, which has led to the promotion 
of early aggressive treatment of psoriasis to reduce the risk of cardiovascular disease 
by some. In contrast, other studies have not shown an independent association.28, 33 In 
addition, the coexistence of psoriatic arthritis with psoriasis is an important confounder, 
which is not corrected for in almost all studies.34 Large prospective studies specifically 
designed to investigate a possible causal link between psoriasis and cardiovascular 
disease are needed.
Recently, a numerical excess of major adverse cardiovascular events (MACE) in phase II/III
studies of briakinumab prompted concerns about a possible increased risk of MACE in 
patients with psoriasis receiving anti-IL-12/IL-23 agents.35 MACE is a composite endpoint 
of myocardial infarction, cerebrovascular accident, or cardiovascular death. The clinical 
development program of briakinumab for psoriasis was discontinued in 2011 because 
of this finding. A meta-analysis of RCTs of anti-IL-12/IL-23 antibodies and analyses of 
16
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pooled data from phase II/III studies for ustekinumab did not show an increased risk for 
MACE.36, 37
Some studies have suggested an increased risk for cancer, especially lymphoma and NMSC 
in patients with psoriasis.38-43 However, it is unclear whether these conditions are related 
to the disease itself or to previous immunosuppressive treatments or phototherapy.14, 17
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1.2 Treatment of psoriasis
Introduction
Psoriasis is a chronic inflammatory skin disease that presently is not curable, implying 
lifelong treatment in the majority of patients. Although a number of well-established 
therapies are available for psoriasis, unmet clinical needs remain, including insufficient 
efficacy, tolerability and practicability. 
The therapeutic modalities available for the treatment of psoriasis can be placed on a so 
called ‘treatment ladder’.44, 45 This concept reflects the preferential use of therapies with 
the least potential for side effects. In case of insufficient efficacy, therapies with greater 
potential toxicity can be used. At the bottom of the ladder, topical therapies are situated. 
Ascending the ladder, phototherapy followed by conventional systemic treatments and 
subsequently biological therapies are encountered. 
Mild psoriasis can usually be controlled with topical therapies. In patients with refractory 
mild psoriasis, phototherapy can be applied. In patients with moderate to severe psoriasis, 
topical therapies often do not suffice. This patient category often needs phototherapy or 
systemic treatments.46
In recent years, new insights into the pathogenesis of inflammatory diseases including 
psoriasis, have led to the development of biological therapies, also called ‘biologics’. 
These are large molecules produced by living organisms. At this moment, biological 
therapies are placed at the top of the treatment ladder for psoriasis and can only be 
prescribed to patients with moderate to severe psoriasis who have not responded to 
phototherapy and methotrexate ór ciclosporin, or who have contraindications to, or do 
not tolerate these therapies.
Topical therapies
Topical therapies commonly applied for the treatment of psoriasis include topical 
corticosteroids, vitamin D3 analogues, calcineurin inhibitors, dithranol and coal tar.47
Since their introduction in 1952, topical corticosteroids have become a mainstay in 
the treatment of psoriasis.26, 47 Many different topical corticosteroids with different 
potencies and vehicles exist. Depending on the severity and the location of psoriasis, 
corticosteroids with different potencies are used. The mechanism of action of 
corticosteroids is based on influencing the synthesis of different proteins resulting in anti-
inflammatory, vasoconstrictive and anti-mitotic effects.48 Topical corticosteroids can be 
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used as monotherapy or in combination with vitamin D3 analogues, dithranol or tar.26 
Topical corticosteroids are associated with tachyphylaxis and with well-described local 
side effects, such as the development of cutaneous atrophy, telangiectasias, striae, and 
perioral dermatitis. As tachyphylaxis can occur quite rapidly with topical corticosteroid 
therapy, intermittent treatment is advised for prolonged treatment.26, 48 
Commercially available vitamin D3 analogues in the Netherlands were calcipotriol 
(Daivonex®), and calcitriol (Silkis®). Calcipotriol is not available anymore in the Netherlands. 
The antipsoriatic effect of vitamin D3 analogues can mainly be ascribed to inhibition 
of keratinocyte proliferation and induction of normal keratinocyte differentiation.26, 47
Irritation of the skin is the most frequently observed adverse event, especially when 
used for flexural psoriasis and facial psoriasis.47 Vitamin D3 analogues can be applied 
as monotherapy, as a combination therapy (calcipotriol/betamethasone dipropionate 
ointment and calcipotriol/betamethasone dipropionate gel) or intermittently and 
alternating with topical corticosteroids.26, 47, 49, 50 Practical use in psoriasis patients usually 
involves combination therapy with topical corticosteroids. 
Topical calcineurin inhibitors (tacrolimus ointment (Protopic®) and pimecrolimus cream 
(Elidel®)) are only approved for the treatment of atopic dermatitis, but are sometimes also 
prescribed for flexural psoriasis and psoriasis affecting the face.47 Calcineurin inhibitors 
act by inhibiting the calcium-dependent signal transduction in T-cells. As a consequence, 
they inhibit the transcription and synthesis of inflammatory cytokines resulting in an anti-
inflammatory effect.48 The most frequent side effect is irritation of the skin.47 
Dithranol (synonyms anthralin and cignolin) has been available since 1916.26 The exact 
mechanism of action is unknown. Dithranol induces a cascade of free radicals in the skin, 
resulting in antiproliferative effects and a modulation of inflammation in psoriasis.49 After 
the introduction of other topical therapies like corticosteroids and vitamin D3 analogues, 
dithranol was increasingly replaced by these agents because of dithranol’s irritating and 
staining effects. Nevertheless, dithranol still is an important second-line therapy for 
psoriasis. Dithranol is mainly applied in the context of daycare or inpatient treatment. 
Coal tar has been used in the treatment of dermatologic diseases for many decades. Its 
exact mechanism of action is unclear. A recent study in atopic dermatitis showed that 
coal tar activates the aryl hydrocarbon receptor (AHR), resulting in induction of epidermal 
differentiation.26, 51, 52 Coal tar has antiproliferative effects and, like dithranol, modulates 
inflammatory events in psoriasis.49 Coal tar is not a first choice therapy for psoriasis due 
to its odour and staining properties. However, it can be valuable in patients with pruritic 
psoriasis.47 
Chapter 1
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Phototherapy
Phototherapy modalities applied for the treatment of psoriasis are broadband UVB 
(280-320 nm), narrowband UVB (emission peak at 311 nm) and UVA (320-400 nm) plus 
psoralens (PUVA). Photochemotherapy (PUVA) is the combined use of photosensitizing 
psoralens and UVA radiation. Different types of photochemotherapy exist, namely 
systemic (oral) PUVA and topical bath and cream PUVA.53 Phototherapy induces several 
biological effects that probably contribute to its therapeutic effect in psoriasis. UV induced 
immunosuppression may account for the major part of the antipsoriatic effect.
Long-term UVB and PUVA phototherapy result in actinic damage and premature aging 
of the skin.47, 53 The carcinogenic effect of long-term oral PUVA therapy with respect 
to the induction of  squamous cell carcinoma of the skin and to a lesser extent basal 
cell carcinoma, is well established.54, 55 However, the potential carcinogenic effect of 
UVB phototherapy and topical PUVA is controversial.47, 53, 56-58 For adults with high UVB 
exposure levels, UVB may confer a modest increase in nonmelanoma skin cancer risk, 
but much less than that observed with PUVA.47, 56 The risk of developing squamous cell 
carcinoma with PUVA therapy is further increased by the subsequent use of ciclosporin.59 
The risk of melanoma with long-term PUVA therapy might be increased as well.26, 47, 60-62 
Narrow-band UVB proved more effective than broad-band UVB and is currently 
recommended as a first choice phototherapy for psoriasis.47, 53, 63 PUVA is recommended 
in case UVB is not sufficiently effective.47, 53 The use of long-term phototherapy, especially 
PUVA, has diminished in the last decades due to its cumulative carcinogenic potential. 
The practicability of phototherapy is sometimes limited by time and travel constraints on 
the part of the patient. Currently, it is not recommended to combine phototherapy with 
biologics, because of the risk of photocarcinogenesis.53, 64-66
Conventional systemic treatments
The conventional or classical systemic treatments most widely used for the treatment of 
plaque psoriasis are methotrexate, ciclosporin, acitretin and fumarates. 
Methotrexate
Methotrexate (MTX) is the oldest drug used today for the systemic treatment of psoriasis 
and is widely used because of its high efficacy in all clinical variants of psoriasis. MTX 
is a folic acid analogue and competitively inhibits the enzyme dihydrofolate reductase 
(DHFR) and several other folate-dependent enzymes.26, 47, 53 MTX inhibits the synthesis 
of thymidylate and purine nucleotides, which are required for DNA and RNA synthesis. 
20
Inhibition of nucleic acid synthesis in activated T cells and in keratinocytes probably 
accounts for the antiproliferative and immunomodulatory effects of MTX. MTX is a slow-
acting drug and it may take several weeks to achieve a complete clinical response. MTX is 
also effective for psoriatic arthritis.
There is some evidence that the concomitant administration of folic acid with MTX 
therapy may reduce side effects without affecting efficacy,53, 67-69 and suppletion of folic 
acid is therefore advised.47 The two most important side effects associated with MTX 
therapy are myelosuppression in the early phase of treatment and hepatotoxicity with 
high cumulative dosages of MTX. The most common side effects are subjective side 
effects like gastrointestinal complaints.
The combination of methotrexate and biologic agents used for psoriasis (etanercept, 
infliximab and adalimumab) is common in rheumatology. In psoriasis, this has not been 
systematically investigated, although some studies have shown greater efficacy with a 
similar safety profile with combination therapy.70-81 There is increasing evidence that the 
combination of infliximab and low-dose methotrexate reduces antibody formation and 
related infusion reactions. This combination is therefore increasingly advised in patients 
with psoriasis.47, 53, 64, 70 Whether this holds true for adalimumab as well is still under 
investigation.47, 82
Ciclosporin
The efficacy of ciclosporin was investigated in immune-mediated diseases like psoriasis 
after experiences obtained with ciclosporin in transplantation medicine. The efficacy 
of ciclosporin in the treatment of psoriasis supported the view that T-cell-mediated 
immunomodulation was important in the pathogenesis of psoriasis.4 Ciclosporin binds 
to cyclophilin, a member of the family of intracytoplasmic proteins called immunophilins. 
This complex blocks the dephosphorylation of nuclear factor of activated T cells (NFAT) 
and the subsequent upregulation of IL-2 and IL-2 receptors, resulting in a decrease in the 
number of CD4+ and CD8+ T cells in the skin.26
Ciclosporin is indicated in patients with the most severe or therapy-resistant forms of 
psoriasis. Ciclosporin treatment can result in dramatic rapid improvement of psoriasis, 
but long-term use is limited by its cumulative toxicity.26 Ciclosporin is most often used as 
a short-term therapy lasting 2-4 months to control flares of psoriasis. Treatment courses 
can be repeated at intervals. Ciclosporin therapy should not be given for more than 1-2 
years.4, 26, 47, 53 Discontinuation of ciclosporin treatment often leads to a relapse of psoriasis, 
especially with abrupt discontinuation.4, 47, 53 Important side effects are nephrotoxicity, 
hypertension and malignancies (especially squamous cell carcinomas of the skin and 
lymphomas).47, 83 Hyperlipidaemia is a frequently observed but unwanted side effect of 
ciclosporin as the cardiovascular risk in patients with psoriasis is already increased. 
Chapter 1
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There are very limited data on the use of ciclosporin in combination with biologics.76, 78, 84, 85
A small 24-week study showed that the addition of ciclosporin to etanercept seemed to 
be a safe and effective treatment for patients with psoriatic arthritis with uncontrolled 
cutaneous psoriasis.84 Other etanercept/ciclosporin combination studies focused on the 
transition from ciclosporin to etanercept and showed that a short overlapping period 
may be useful to maintain disease control previously established by ciclosporin.72, 86-88
Combination therapy with adalimumab has only been described in two reports.81, 89 
Because of the lack of data and possible shared toxicities of ciclosporin and biologics, 
specifically with regard to infections and malignancies, combination therapy should by 
applied with caution and preferably during short periods (e.g. as bridge therapy).66, 90
Acitretin
Acitretin is synthetic retinoid and a member of the retinoid family. Retinoids are naturally 
occurring molecules and also synthetic derivatives with structural and functional 
characteristics closely related to vitamin A. Retinoids exert their effects primarily by 
regulating gene transcription via intracellular nuclear receptors.4, 26 
Retinoids have antiproliferative and immunomodulatory properties. However, the exact 
mechanism of action of acitretin is still not clearly understood. In the skin, acitretin 
reduces the proliferation and stimulates the differentiation of epidermal keratinocytes.53 
Acitretin has a special position within the group of systemic antipsoriatic therapies, as 
it is nonimmunosuppressive and can therefore also be applied in immunosuppressed 
patients with psoriasis.4, 45 
Plaque-type psoriasis responds variably to acitretin. Therefore in these patients, acitretin 
is often used in combination with topical treatment or phototherapy to achieve sufficient
efficacy. As monotherapy, acitretin is highly effective in erythrodermic and pustular psoriasis.26, 53
Dose-dependent reversible mucocutaneous toxicity like dryness of mucosa and skin and 
cheilitis are the most commonly observed side effects of oral retinoids. At the same time, 
these side effects are also a parameter for the drug’s bioavailability due to the fairly 
narrow therapeutic window of retinoids.4, 26, 53 Hyperlipidaemia is a frequently observed 
but unwanted side effect of acitretin in patients with psoriasis. Acitretin is teratogenic 
and should be avoided in women of childbearing age.
Acitretin is unique to dermatology and data about the combination of acitretin and 
biologics are sparse. Gisondi et al. showed that a combined therapeutic regimen with 
etanercept 25 mg once weekly and acitretin 0.4 mg/kg daily was as effective as etanercept 
25 mg twice weekly, and more effective than acitretin alone, suggesting that concomitant 
use of acitretin can lower the required dose of etanercept.91 The safety profile was similar 
for the three groups. The effect of adding acitretin to a standard dose of etanercept 
(25 mg twice a week) was not investigated in this study. Small clinical case series have 
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also evaluated the use of etanercept, infliximab or adalimumab in combination with 
acitretin.78, 87, 92, 93 In all cases, combination therapy resulted in better disease control.
Fumarates
Fumarates were specifically developed for the treatment of psoriasis.47 Fumarates are not 
registered in the Netherlands. Fumarates are available in different preparations. Dimethyl 
fumarate (DMF) is considered to be the active ingredient.53
The mode of action of fumarates can be attributed to a number of effects. DMF inhibits the 
activity of the transcription factor NF-кB. This leads to an inhibition of the transcription of 
a variety of NF-кB-dependent intracellular mediators and adhesion molecules. DMF and 
its metabolite monomethyl fumarate inhibit the maturation of dendritic cells. DMF can 
induce apoptosis, particularly in activated T cells. Furthermore, there is evidence that 
monomethyl fumarate stimulates the shift of a Th1-type of immune response towards a 
Th2-type by stimulating the production of Th2 specific cytokines.4, 47, 53
Treatment of psoriasis with fumarates follows an established dosing regimen, with a 
slow increase in dose to improve tolerance, especially with regard to gastrointestinal 
complaints. The dose is increased until a clinical response is achieved. Thereafter tapering 
down to an individual maintenance dose is recommended. The most frequent side effects 
observed during treatment with fumarates are gastrointestinal complaints (particularly 
in the first weeks after initiation of therapy) and flushing.4, 47, 53 Combination therapy of 
fumarates and biologics for psoriasis has not been systematically investigated.53, 78
Biologics
During the last decade a number of biological therapies have become part of the 
therapeutic arsenal for psoriasis. According to the United States Food and Drug 
Administration (FDA), biologics, also called biologicals, are components derived from 
living organisms used for the treatment, prevention or cure of disease in humans.94, 95 
The biologics prescribed for psoriasis are therapeutic proteins produced by recombinant 
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from the market. 
The biological therapies for psoriasis can be classified according to their mechanism of 
action (Figure 3).17, 26 The two main classes are the T-cell targeted therapies (alefacept 
and efalizumab) and the cytokine inhibitors (etanercept, infliximab, adalimumab and 
ustekinumab). The anti-cytokine therapies for psoriasis consist of the tumour necrosis 
factor-α (TNF-α) antagonists etanercept, infliximab and adalimumab and an inhibitor of 
interleukin (IL)-12 and IL-23, ustekinumab. The application for a marketing authorization 
for briakinumab (Ozespa®), another inhibitor of IL-12 and IL-23, was withdrawn in 2011 
awaiting additional new data and analyses after a signal of a possible increased risk of 
major cardiovascular events (MACE). 
The World Health Organization (WHO) has developed a nomenclature scheme for naming 
biologics, so that each substance would be recognized globally by a unique name (Table 1).96, 97 
In names of compounds related by structure and/or function, specific letter groups, called 
stems, are included to aid recognition by healthcare professionals. 
Alefacept and etanercept are receptor molecules. The common stem for receptor molecules 
is ‘cept’, placed as a suffix. A preceding infix designates the target, which is lymphocyte 
function-associated antigen 3 (‘-lefa-’) in case of alefacept, and tumour necrosis factor (‘-ner-’)
in case of etanercept. Efalizumab, infliximab, adalimumab, ustekinumab and briakinumab 
are monoclonal antibodies. The common stem for monoclonal antibodies is ‘-mab’, placed 
as a suffix. The names of monoclonal antibodies are composed of a prefix, a substem A, 
a substem B and a suffix. Substem A (infix) indicates the target class (molecule, cell or 
organ). Substem B (infix) indicates the species on which the immunoglobulin sequence of 
the monoclonal antibody is based. 
Stem Indicating
Suffix
-cept Receptor molecules
-mab Monoclonal antibodies
Infix
-lefa- lymphocyte function-associated antigen
-ner- tumour necrosis factor
-k(i)- interleukin
-l(i)- immunomodulating
-u- human
-xi- chimeric
-zu- humanized
Table 1. Nomenclature of biological substances.DNA technology, which selectively 
interfere in the pathogenesis of 
psoriasis.
The biologics that are approved and 
reimbursed for the treatment of 
psoriasis in Europe at this moment 
are etanercept (Enbrel®), infliximab 
(Remicade®), adalimumab (Humira®) 
and ustekinumab (Stelara®). The 
market authorization of efalizumab 
(Raptiva®) was withdrawn in 
February 2009 due to a risk of serious 
side effects. In November 2011, 
alefacept was voluntarily withdrawn 
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In the Netherlands, biological treatment was reimbursed for the treatment of patients 
with moderate to severe plaque psoriasis who had not responded to phototherapy, 
methotrexate (at a dose of 22.5 mg per week) and ciclosporin, or who had contra-
indications to, or did not tolerate these therapies since 2005.98 In September 2010, the 
reimbursement criteria were changed into moderate to severe plaque psoriasis with 
nonresponse, contraindications or intolerance to phototherapy and methotrexate (at a 
dose of 22.5 mg per week) or ciclosporin. Furthermore, a Psoriasis Area and Severity 
Index (PASI)99 of at least 10 or a PASI ≥ 8 and a Skindex-29 score ≥ 35 (quality of life 
index)100 is required since 2005.
T-cell inhibitors
Alefacept
Alefacept is a human fusion protein consisting of the extracellular CD2-binding portion of 
the human lymphocyte function-associated antigen-3 (LFA-3) linked to the Fc portion of 
human immunoglobulin G1 (IgG1). Alefacept interferes with T-cell activation by binding 
to the T-cell antigen CD2, thereby inhibiting the interaction between CD2 on T-cells and 
its ligand LFA-3 on antigen-presenting cells.17, 101 
The recommended dose of alefacept was 7.5 mg given once weekly as an intravenous (iv) 
bolus or 15 mg given once weekly as an intramuscular injection in 12-week courses. The 
half-life of intravenously administered alefacept is approximately 270 hours. Antibodies 
to alefacept have been detected in some patients treated with alefacept. However, no 
correlation between antibody development and clinical response or adverse events was 
observed.
Common adverse events reported in randomized controlled trials (RCTs) were pharyngitis, 
chills, headache, pruritis and infection. The most common serious adverse events in RCTs 
were coronary artery disorder, cellulitis and myocardial infarction.102 Treatment with 
alefacept results in a reduction in circulating total CD4+ and CD8+ T lymphocyte counts. 
Therefore, monitoring lymphocyte counts was an important safety measure.53, 101
Alefacept (Amevive®) was approved in only a few countries including the United States 
of America, Canada, and Switzerland. In November 2011, alefacept was voluntarily 
withdrawn from the market due to business needs.
Efalizumab
Efalizumab is a humanized monoclonal antibody. It is an IgG1 kappa (IgG1κ) 
immunoglobulin, containing human constant region sequences and murine light- and 
heavy-chain complementary determining region (CDR) sequences. Efalizumab binds 
specifically to the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1), 
a T-cell cell surface protein.17, 26, 103 By this mechanism, efalizumab inhibits the binding of 
LFA-1 to intercellular adhesion molecule 1 (ICAM-1) on antigen-presenting cells, which 
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interferes with T-cell activation. Efalizumab also interferes with T-cell trafficking in the 
skin by blocking the adhesion of LFA-1 on circulating T-cells to ICAM-1 on endothelial 
cells, which normally allows T-cell migration into the skin.
The recommended dose of efalizumab was an initial single dose of 0.7 mg/kg body weight 
subcutaneously (sc) followed by weekly injections of 1.0 mg/kg body weight.103 The half-
life of efalizumab is approximately 5.5-10.5 days. Antibodies to efalizumab have been 
detected in some patients treated with efalizumab. However, antibody formation did not 
lead to clinically noteworthy adverse events or diminished clinical efficacy.
The most frequent adverse events observed during efalizumab therapy were mild to 
moderate dose-related acute flu-like symptoms including headache, fever, chills, nausea and 
myalgia.103 Serious adverse events like serious infections, malignancies, thrombocytopenia, 
arthritis and flare of psoriasis have been observed with efalizumab therapy.53, 64, 102, 103 
Efalizumab was approved for psoriasis by the European Medicines Agency (EMA) in 
September 2004. The EMA withdraw its marketing authorization in February 2009 because 
of concerns about the development of progressive multifocal leukoencephalopathy (PML).
Cytokine inhibitors
Etanercept
Etanercept is a human fusion protein consisting of the extracellular ligand binding domain 
of the human 75-kilodalton (p75) tumour necrosis factor receptor linked to the Fc domain 
of human IgG1. Etanercept is a competitive inhibitor of TNF-α binding to its cell surface 
receptors, and thereby inhibits the biological activity of TNF-α.53, 104 Etanercept also 
binds to members of the lymphotoxin family (LTα3 (also known as TNF-β) and LTα2β1).64 
TNF-α and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell 
surface receptors: the 55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor 
receptors.104 The biological significance of lymphotoxin binding is unclear.64, 105
Etanercept was approved for plaque psoriasis by the EMA in September 2004. Other 
therapeutic indications of etanercept are rheumatoid arthritis, juvenile idiopathic arthritis, 
psoriatic arthritis, ankylosing spondylitis and paediatric plaque psoriasis. Etanercept, in 
contrast with adalimumab and infliximab, lacks efficacy in granulomatous diseases, such 
as Crohn’s disease.105, 106
The recommended dose of etanercept for psoriasis is 25 mg sc administered twice weekly 
or 50 mg sc administered once weekly. Alternatively, 50 mg given twice weekly may be 
used for up to 12 weeks followed, if necessary, by a dose of 25 mg twice weekly or 50 
mg once weekly. The half-life of etanercept is approximately 70 hours. Antibodies to 
etanercept have been detected in some patients. However, these antibodies have all been 
non-neutralizing and there appears to be no correlation between antibody development 
and clinical response or adverse events.
26
The most common adverse events reported in RCTs were injection-site reactions, headache 
and upper respiratory tract infections.102 Serious adverse events like serious infections, 
malignancies, hepatitis B virus reactivation, congestive heart failure, demyelinating 
diseases, systemic lupus erythematosus/lupus-like syndrome and serious haematological 
reactions have also been reported with etanercept use and TNF-α blockers as a class.53, 64, 104
Infliximab
Infliximab is a chimeric human-murine IgG1 monoclonal antibody. Infliximab contains 
approximately 30% murine variable region amino acid sequence, which confers antigen-
binding specificity to human TNF-α. The remaining 70% correspond to a human IgG1 
heavy chain constant region and a human kappa light chain constant region.64, 107 
Infliximab binds with high affinity to TNF-α, thereby inhibiting the functional activity of 
TNF-α. It was approved for plaque psoriasis by the EMA in September 2005. Infliximab is 
also approved for the treatment of rheumatoid arthritis, adult Crohn’s disease, paediatric 
Crohn’s disease, adult ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis 
and psoriatic arthritis.107
The recommended dose of infliximab for psoriasis is 5 mg/kg iv at day 0 followed by 
additional 5 mg/kg infusions at 2 and 6 weeks after the first infusion, then every 8 weeks 
thereafter. The half-life of infliximab ranges from 8 to 9.5 days. Antibodies to infliximab 
may develop and have been associated with an increased frequency of infusion reactions. 
An association between development of antibodies to infliximab and reduced duration of 
response has also been observed.
The most common adverse events in RCTs were upper respiratory tract infections, 
headache, increased hepatic enzymes and infection.102 Serious adverse events reported 
with infliximab use are mentioned above. In addition, serious infusion reactions and 
hepatobiliary events have occurred with infliximab use.53, 64, 107
Adalimumab
Adalimumab is a human IgG1 monoclonal antibody that binds to human TNF-α and 
neutralizes the biological function of TNF-α by blocking its interaction with the p55 and 
p75 cell surface TNF receptors.53, 108 
Adalimumab was approved for plaque psoriasis by the EMA in December 2007. Other 
therapeutic indications of adalimumab are rheumatoid arthritis, polyarticular juvenile 
idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, adult Crohn’s disease, 
paediatric Crohn’s disease and ulcerative colitis.108 
The recommended dose of Humira for psoriasis is an initial dose of 80 mg sc, followed 
by 40 mg sc given every other week starting one week after the initial dose. The half-life 
is of adalimumab is approximately 2 weeks. Formation of anti-adalimumab antibodies is 
associated with increased clearance and reduced efficacy of adalimumab.82, 108
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The most commonly reported adverse events are infections (such as nasopharyngitis, 
upper respiratory tract infection and sinusitis), injection site reactions, headache and 
musculoskeletal pain.108 Serious adverse events reported with adalimumab use are 
mentioned above. 
Ustekinumab
Ustekinumab is a human IgG1κ monoclonal antibody to the shared p40 protein subunit 
of interleukin (IL)-12 and IL-23.109 Ustekinumab was approved for psoriasis by the EMA 
in January 2009. Recently, ustekinumab was also approved for the treatment of psoriatic 
arthritis.110 Ustekinumab inhibits the activity of IL-12 and IL-23 by preventing these 
cytokines from binding to their IL-12Rβ1 receptor expressed on the surface of immune 
cells.
The recommended dose of ustekinumab for psoriasis is an initial dose of 45 mg sc, followed 
by a 45 mg sc dose 4 weeks later, and then every 12 weeks thereafter. For patients with 
a body weight over 100 kg the initial dose is 90 mg, followed by a 90 mg dose 4 weeks 
later, and then every 12 weeks thereafter. The half-life of ustekinumab is approximately 3 
weeks, ranging from 15 to 32 days. Antibodies to ustekinumab may develop. No apparent 
correlation of antibody development to injection site reactions was seen. Efficacy tended 
to be lower in patients positive for antibodies to ustekinumab.109, 111, 112 
Common adverse events observed with ustekinumab use in RCTs included upper 
respiratory tract infection, nasopharyngitis, arthralgia, cough and headache.64, 109, 111, 112 
Serious infections and malignancies have been observed in the RCTs, but rates were 
low.109, 111, 112
Future therapies
Anti-cytokine therapies currently being tested in clinical trials are targeted at specific 
components of the IL-23/Th17 pathway, such as the p19 protein subunit of IL-23, the 
Th17 cytokine IL-17, the IL-17 receptor and the Th22 cytokine IL-22.113 Secukinumab and 
ixekizumab, new monoclonal anti-IL-17A antibodies have already shown positive results 
in phase II trials.114, 115 Moreover, brodalumab, an anti-interleukin-17-receptor monoclonal 
antibody, significantly improved plaque psoriasis in a phase II study.116
In addition, small molecules (i.e. low molecular-weight organic compounds) 
administered orally and targeting intracellular signaling pathways, like apremilast 
(phosphodiesterase-4 (PDE4) inhibitor)) and tofacitinib (Janus kinase (JAK) inhibitor), are 
currently being tested in clinical trials.117-119 Topical preparations may also be produced 
from these molecules.120 
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Patent expirations of the currently available biologics in the coming years could lead to 
the development of less expensive generic agents, also called ‘biosimilars’. Biosimilars 
could offer cost savings. However, it is difficult to prove that biosimilars are equal to the 
original biologics, due to the complexity of the molecule structures and the manufacturing 
process. Slight differences in the production process may have an important impact on 
the biologic functions of biosimilars. In particular the question about long-term efficacy 
and safety has to be answered. Therefore, the introduction of biosimilars might require 
studies investigating efficacy and safety.121
Psoriasis Area and Severity Index
The Psoriasis Area and Severity Index (PASI) was first described by Frederiksson in 1978.99 
The PASI is a clinical measure of psoriasis severity and is the most commonly used clinical 
measure in psoriasis research.122 
For calculation of the PASI, four body areas are assessed: the head (h), the upper 
extremities (u), the trunk (t) and the lower extremities (l), corresponding to 10%, 20%, 
30% and 40% of the total body surface area, respectively. The skin area affected by 
psoriasis within each body area (Ah, Au, At, and Al) is given a numerical value: 0 = no 
involvement; 1 = 0-<10%; 2 = 10-<30%; 3 = 30-<50%; 4 = 50-<70%; 5 = 70-<90% and 
6 = 90-100%. Within each body area, the severity of three target signs, erythema (E), 
induration (I) and desquamation (D), is assessed on a five-point scale: 0 = none; 1 = mild; 
2 = moderate; 3 = severe; 4 = very severe. The PASI is then calculated using the formula 
0.1(Eh + Ih + Dh)Ah + 0.2(Eu + Iu + Du)Au + 0.3(Et + It + Dt)At + 0.4(El + Il + Dl)Al.
The PASI ranges from 0 (no disease) to 72 (maximum score), with a higher score 
representing greater disease severity. However, in practice only half of the scale is used.
There is no generally accepted definition of mild versus moderate to severe psoriasis.46
According to the ‘rule of tens’, severe psoriasis is defined as body surface area (BSA) 
involved of at least 10 per cent, PASI of at least 10, or Dermatology Life Quality Index 
(DLQI) of at least 10.99, 123 This cut-off point of 10 has been widely adopted in research and 
by healthcare organizations and regulatory authorities from different countries. A PASI of 
at least 10 is often one of the requisites for inclusion in RCTs with biologics.
In the Netherlands, biological therapies are reimbursed for patients with moderate to 
severe plaque psoriasis, defined as a PASI of at least 10 or a PASI ≥ 8 and a Skindex-29 
score ≥ 35 (quality of life index). 
The PASI 75 response, which means at least 75 percent improvement in PASI from baseline, 
is the most commonly used primary efficacy outcome measure in psoriasis research at 
the moment and is accepted as a clinically meaningful improvement of psoriasis.53
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1.3 Registries
Introduction
The efficacy and safety of biological treatments for psoriasis has been established in 
randomized placebo-controlled trials (RCTs) and open-label extension studies. 
RCTs are the gold standard for evaluating the efficacy of new drugs.124 However, 
randomized controlled trials cannot answer all questions about a certain therapy. 
Increasingly, questions in medical research are investigated in observational studies. One 
form of observational studies are cohort studies, with data being recorded in registries.125 
Registries provide complementary information to RCTs about the effectiveness and safety 
of biologics for psoriasis in daily practice.126, 127
Data from RCTs may not reflect the daily practice situation due to strict inclusion and exclusion 
criteria, eligibility criteria that differ from reimbursement criteria, treatment according to 
a predefined protocol and washout periods.89, 128, 129 This limits the generalizability of the 
results, whereas enrolment in registries does reflect daily clinical practice. 
RCTs are often underpowered and of too short duration to detect rare or long-term adverse 
events.124 Open-label extension studies have provided some long-term information, but 
lack a control group. In addition, open-label extension studies are still performed in a 
selected patient group initially included in RCTs, with mostly only responders being allowed 
to enter the open-label extension phase. Observational studies offer the advantage of the 
ability to include larger numbers of patients and are suitable for long-term follow-up. 
Besides monitoring long-term safety, registries can provide information on many aspects 
of clinical effectiveness of biological therapies in daily practice, including the effectiveness 
in the short term and the long term, consecutive biological treatment, nonstandard dosing 
regimens, combination therapy with conventional systemic therapies, transitioning from 
conventional systemic therapies to biologics and the influence of prior exposure to biologics.
Furthermore, registries offer the possibility of studying many other aspects of biological 
treatment, including cost-effectiveness and impact on the quality of life, which is 
important from a societal perspective and for the optimum choice of treatment.
Psoriasis registries
After the registration of biologics for various indications including psoriasis, rheumatologic 
diseases and inflammatory bowel disease, registries were set up in several countries to 
collect long-term safety and effectiveness information on this new generation of drugs. 
In rheumatology, there is a large number of registries covering different indications.130 
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In the Netherlands, the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry was 
founded in 2003 to prospectively evaluate the use of biologics in patients with rheumatoid 
arthritis.131 Patients with psoriasis, however, differ in several aspects from patients with 
rheumatologic diseases or inflammatory bowel disease, such as in the treatments received 
prior to the initiation of biological treatment, types and doses of biologics prescribed, 
body weight and in the nature of the disease itself. Therefore, psoriasis-specific registries 
were established.132
Some psoriasis registries solely collect information on biological therapies, whereas 
others also include patients on classical systemic therapies. The comparator group of 
patients treated with classical systemic therapies aids in attributing causality in adverse 
events detected and in studying the relative effectiveness of biological and conventional 
systemic treatments. In addition, such registries provide long-term information on the 
safety and effectiveness of classical systemic therapies for psoriasis, which have only 
been sparsely investigated until now.132 
In Europe, there are several local and national registries that collect data on systemic 
treatments for psoriasis. These registries differ in certain aspects of study design and 
methodology, funding and voluntarily or compulsory participation.133 
National and international collaboration is present in this field of research. Recently, 
ZonMW has awarded a grant for the establishment of a Dutch national registry to collect 
data on the use of biologics and other systemic treatments for psoriasis. This project is a 
collaboration between the Dutch Society of Dermatology and Venereology (NVDV), the 
Radboudumc and the Academic Medical Center (University of Amsterdam).
In Europe, an international collaborative network of independent registries of patients 
with psoriasis treated with systemic agents, named Psonet, was established.133 Systemic 
therapies can involve both conventional and biological agents or are restricted to 
biological agents. Currently, registries from 13 countries are participating in Psonet. By 
combining data from multiple registries, analyses with greater power can be performed. 
As the role of registries in studying the benefits and harms of medical interventions is 
increasingly being recognized, quality standards regarding various aspects of registries 
have been formulated.134 Furthermore, criteria for reporting observational studies have 
been formulated, named the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) criteria.125 
Continuous Assessment of Psoriasis Treatment Use Registry (CAPTURE)
Right after the registration and reimbursement of etanercept and efalizumab in the 
Netherlands, a registry was set up at the department of Dermatology of the Radboudumc, 
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with the aim to collect effectiveness, safety, quality of life and cost-effectiveness 
information on all patients with psoriasis treated with biologics in daily practice.135 
The first patient was enrolled in February 2005. In 2008, a registry collecting data on 
various aspects of childhood psoriasis was founded. At that time, the registry was named 
‘CAPTURE’, an acronym for Continuous Assessment of Psoriasis Treatment Use Registry. 
The registry concerning biological treatment was named ‘Bio-CAPTURE’ and the registry 
concerning childhood psoriasis was named ‘Child-CAPTURE’.136, 137 
Moreover, in 2010 a registry with a similar design and methodology was set up, collecting 
information on patients with psoriasis treated with methotrexate (MTX-CAPTURE). This 
registry can serve as a comparator for the Bio-CAPTURE registry and will be an important 
source of information on the effectiveness and safety of methotrexate.
Data collected in the Bio-CAPTURE registry include demographics, medical history, 
comorbidities, previous treatments for psoriasis, type of biologic used, doses of biologics 
used including dose adjustments, concomitant therapies, adverse events and parameters 
for effectiveness, quality of life, treatment satisfaction and costs. 
Since 2010, a network consisting of the department of Dermatology of the Radboudumc 
and 8 nonacademic dermatology departments has been established. All participating 
centres contribute to the Bio-CAPTURE registry. Additional centres will be recruited in the 
future. By combining data, analyses can be performed in larger numbers of patients and 
comparisons can be made between academic and nonacademic patients. 
Questions to be answered at the start of the studies included in the present thesis were 
the following: what is the long-term efficacy and safety of biological therapies for psoriasis 
in daily practice? What is the efficacy and safety of consecutive biological treatment 
regimens? What is the efficacy and safety of dose escalation or combination therapy 
in patients with insufficient efficacy? Is there a difference in efficacy between biologic-
naïve and non-naïve patients? What is the clinical relevance of repeated laboratory 
investigations?
At present, the registries are still running and the inclusion of patients is still ongoing. In 
the current thesis, the outcomes from the Bio-CAPTURE registry are described.
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1.4 Outline of the thesis
There are many unanswered questions about the long-term efficacy and safety of biological 
therapies for psoriasis. Observational studies are an important source of information 
for evaluating these questions. This thesis concerns the outcomes of a prospective 
observational study investigating the efficacy and safety of biological treatments for 
psoriasis in daily clinical practice. Data are extracted from the Bio-CAPTURE registry 
(Continuous Assessment of Psoriasis Treatment Use Registry concerning biologics), that 
was founded in 2005.
Main study objective
To prospectively investigate the long-term efficacy and safety of biologics in the treatment 
of patients with moderate to severe psoriasis in daily clinical practice.
Research questions
Part II Long-term efficacy and safety of biologic treatment for psoriasis in daily 
practice
1. What is the long-term efficacy of biologics for psoriasis in daily practice? 
2. Is consecutive treatment with a second biologic therapy effective and safe? Is there an 
influence of biologic-naïvety versus non-naïvety on the efficacy results?
3. What is the efficacy and safety of adalimumab dose escalation or combination therapy 
with methotrexate?
4. What is the influence of different analytical methods on the efficacy results?
5. What is the safety profile of biologic treatment for psoriasis with extended exposure?
Part III Monitoring of biologic treatment
6. Is there a difference in time to first NMSC and the incidence of NMSC between patients 
with psoriasis and patients with rheumatoid arthritis treated with TNF-inhibitors?
7. Is monitoring with regard to laboratory investigations needed in patients with psoriasis 
with extended exposure to etanercept or adalimumab?
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Long-term efficacy of etanercept for psoriasis in daily 
practice
Since the approval and reimbursement of etanercept treatment for psoriasis in Europe, 
this agent has been prescribed in daily practice for the treatment of patients with 
psoriasis. However, daily practice efficacy data on etanercept for psoriasis are limited to 
3 years of treatment.1-3 Although most patients benefit from this therapy, some patients 
discontinue etanercept treatment due to lack of efficacy, loss of efficacy, adverse events 
or other reasons. 
The purpose of our study was to describe the long-term efficacy of etanercept for 
psoriasis in real-world practice, as opposed to the selected patient population and short 
duration of randomized controlled trials (RCTs). Therefore, a prospective patient registry 
was started in 2005, enrolling all patients starting biological treatment for psoriasis in 
the dermatology outpatient department of the Radboud University Nijmegen Medical 
Centre. This analysis involved all consecutive patients who were enrolled in the registry 
at the time of initiation of a (new) biologic therapy between February 2005 and February 
2011.
Efficacy was expressed as the percentage of patients achieving PASI 50, PASI 75 or PASI 90, 
i.e. reductions of at least 50%, 75% and 90%, respectively, in Psoriasis Area and Severity 
Index (PASI) compared with baseline. Where patients received more than one treatment 
episode of etanercept, efficacy was analysed per treatment episode. Restarting etanercept 
treatment after an interruption lasting 6 months or longer constituted a new treatment 
episode. An observed values (as-treated) analysis was performed, which means that all 
available PASI data at predefined time points according to the length of follow-up were 
analysed.4
In this cohort, 152 patients were treated with etanercept during 158 treatment episodes 
(Figure 1). Ninety-five patients were male (62%). The mean ± SD age at the start of 
etanercept treatment was 47.8 ± 11.5 years. From this cohort, 114 patients completed 
1 year of treatment, 76 completed 2 years, 52 completed 3 years, 34 completed 4 years, 
and 16 completed 5 years of therapy. 
In daily practice, two etanercept dosing regimens were used for the first 12 weeks: 25 
mg twice weekly (25 treatment episodes (16%)) or 50 mg twice weekly (133 treatment 
episodes (84%)). In the treatment period thereafter, (temporary) dosage adjustments 
could be made according to the opinion of the treating physician. Patients were allowed 
to use concomitant topical or systemic therapies when indicated. The mean ± SD weekly 
dose of etanercept was 68.3 ± 19.8 mg. 
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Figure 1. Patient disposition. 
*These patients were actively being treated with 
etanercept, but their follow-up did not reach the 
subsequent evaluation time point.
t = 0
158 treatment episodes
15 lack/loss of efficacy
4 adverse event
4 lack/loss of efficacy and adverse event
15 lost to follow-up
1 pregnancy wish
1 deceased
4 follow-up < 1 year*
n = 114 completed
1 year of therapy
10 lack/loss of efficacy
6 adverse event
2 lack/loss of efficacy and adverse event
2 lost to follow-up
1 pregnancy wish
2 deceased
15 follow-up 1-2 years*
n = 76 completed
2 years of therapy
n = 52 completed
3 years of therapy
n = 34 completed
4 years of therapy
n = 16 completed
5 years of therapy
11 lack/loss of efficacy
1 adverse event
3 lost to follow-up
9 follow-up 2-3 years*
7 lack/loss of efficacy
1 adverse event
1 pregnancy wish
9 follow-up 3-4 years*
4 lack/loss of efficacy
1 adverse event
1 lack/loss of efficacy and adverse event
12 follow-up 4-5 years*
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Fifty-one etanercept treatment episodes (32%) were combined with at least one 
concomitant systemic antipsoriatic therapy to prevent a flare of psoriasis when 
transitioning from the systemic treatment to biologic treatment, as add-on therapy during 
biologic treatment because of inadequate response or worsening of psoriasis, or as a 
continuous concomitant therapy. Five etanercept treatment episodes were consecutively 
combined with two different systemic antipsoriatic therapies. Concomitant systemic 
treatments consisted of methotrexate (n = 29), acitretin (n = 14), ciclosporin (n = 10), 
fumarates (n = 2) and mycophenolate mofetil (n = 1). 
Figure 1 shows the disposition of the patients at 1-yearly evaluation time points. Forty-
seven treatment episodes (30%) were discontinued due to loss of efficacy, 13 (8%) due 
to adverse events, 7 (4%) due to a combination of loss of efficacy and adverse events,
3 patients (2%) died and 3 patients (2%) discontinued etanercept treatment because of a 
desire for pregnancy. In addition, 20 patients (13%) were lost to follow-up.
Efficacy results are presented in Figure 2. For one patient, the efficacy of etanercept could 
not be analysed, as this patient died of myocardial infarction 4 days after the start of 
etanercept. At week 12, 103 (65.6%), 37 (23.6%) and eight (5.1%) treatment episodes 
resulted in PASI 50, PASI 75 and PASI 90, respectively. At week 24, these figures were 91 
(67.9%), 51 (38.1%) and 20 (14.9%), respectively. A PASI 75 response was achieved in 41 
(36.6%) treatment episodes at week 48, 29 (40.8%) at week 108, 26 (50.0%) at week 156, 
19 (59.4%) at week 204 and nine (60.0%) at week 264. The PASI 50 and PASI 90 responses 
are presented in Figure 2. 
Figure 2. PASI 50, PASI 75 and PASI 90 response in patients with psoriasis treated with etanercept in daily 
practice, observed values analysis.
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The response rates in this study in patients treated with etanercept in clinical practice 
are lower than in RCTs, a finding which has been described previously.5-9 The eligibility 
criteria in the Netherlands requiring ineffectiveness, intolerance or contraindications to 
classic systemic therapies and ultraviolet (UV) B or psoralen plus UVA (PUVA) therapy 
might account for a more therapy-resistant group of patients treated with biologics in 
daily practice compared with RCTs. Patients in daily practice also have comorbidities and 
comedication, which can negatively influence the efficacy of etanercept. On the other 
hand, the analysis performed in this study is less conservative than the intention-to-treat 
analysis used in RCTs and introduces a bias towards too favourable efficacy outcomes.3
In conclusion, observational research provides data that reflect clinical reality and 
generates additional evidence to RCTs that can be of added value for guidelines. Long-
term efficacy of etanercept for psoriasis in daily practice is substantial, but lower than in 
long-term extension studies of RCTs.10 
Long-term efficacy and safety of biologic treatment for psoriasis in daily practice
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Abstract
Background
Knowledge on the sequential treatment of psoriasis with biologics with regard to 
efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab 
in patients previously treated with etanercept. The relationship between the reasons for 
discontinuation of etanercept and the response to adalimumab is not clear in psoriasis. 
Objectives
To evaluate the efficacy and safety of adalimumab in patients with psoriasis with primary 
failure, secondary failure or intolerance to etanercept in daily practice. 
Methods
Data were extracted from two prospective registries from all patients with psoriasis with 
failure on etanercept, who switched to adalimumab therapy. Thirty patients fulfilled 
these criteria. All patients were naïve to biologics when etanercept was initiated. Primary 
endpoints were the percentage of patients achieving a 50% or 75% improvement of the 
baseline Psoriasis Area and Severity Index (PASI 50 and PASI 75, respectively) at week 12, 
24 and 48. Secondary endpoints were the percentage of patients achieving PASI 90, the 
mean percentage improvement in PASI from baseline and the adverse event rate. 
Results
Compared with the baseline PASI before the start of etanercept, the mean percentage 
improvement in PASI and the PASI 50/75/90 response rates to adalimumab until 
week 48 were comparable to those achieved with etanercept. In the patients failing 
on etanercept, PASI 75 was achieved by 27%, 36% and 54% at week 12, 24 and 48 of 
adalimumab treatment, respectively. The majority of patients showed a beneficial 
response to adalimumab, irrespective of the reason for discontinuation of etanercept. 
Previous treatment with etanercept did not increase the adverse event rate nor change 
the nature of the side effects.
Conclusions
Adalimumab seems to be an effective and safe treatment option for patients with psoriasis 
who failed on etanercept treatment irrespective of the reason for discontinuation.
Long-term efficacy and safety of biologic treatment for psoriasis in daily practice
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Introduction
The introduction of antitumour necrosis factor-α (anti-TNFα) agents has made an 
important contribution to the therapeutic arsenal for patients with moderate to severe 
psoriasis. However, a proportion of patients do not benefit from anti-TNFα treatment. 
Some patients fail to achieve an initial response to an anti-TNFα agent (primary failure), 
others lose efficacy during the course of therapy (secondary failure) or experience adverse 
events (intolerance).1-4 
As the biologics are often prescribed as last treatment options, knowledge about 
consecutive biologic treatments for psoriasis concerning efficacy and safety is very 
important. However, this information and especially long-term information is sparse. 
In some short-term or small studies adalimumab in different dosing regimens has been 
shown to be effective and well tolerated in patients with psoriasis refractory to various 
other biologic treatments and/or other systemic therapies.3, 5-8 Reports on small cohorts 
of patients who successfully switched from etanercept to adalimumab have been 
published.5, 6 The relationship between the reasons for failure on etanercept and the 
response to adalimumab has not been investigated previously.
In the present prospective study we describe the efficacy and safety of 48 weeks of 
adalimumab treatment in 30 patients who failed etanercept treatment in daily practice. 
Patients and methods
Patients
All patients who receive treatment with biologics for psoriasis in the departments of 
Dermatology of the Radboud University Nijmegen Medical Centre and the Academic Medical 
Center (University of Amsterdam) are enrolled in a prospective patient registry, in which 
daily practice efficacy and pharmacovigilance data of these therapies are collected.5, 9-11
Data were extracted on all patients treated with etanercept for an indefinite period of 
time, who subsequently switched to adalimumab because of primary failure or secondary 
failure of etanercept, intolerance to etanercept or other reasons. All patients were naïve 
to biologics when etanercept was initiated. 
All patients fulfilled the reimbursement criteria for treatment with a biologic at the 
time of the start of etanercept therapy, e.g. they had failed to respond to phototherapy, 
methotrexate and ciclosporin in the past, or they had a contraindication to, or were 
intolerant of these treatments. In addition, a Psoriasis Area and Severity Index (PASI)12 of 
at least 10 was required at the time of screening. 
Protocol
Before treatment, a chest X-ray and a purified protein derivative skin test were performed 
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to exclude tuberculosis. A general urine and blood screening was performed in each 
patient. There were no known contraindications as per label.
After 12 weeks of biologic treatment, the guideline of the Dutch Society of Dermatology 
and Venereology and the Dutch reimbursement guideline require the achievement of a 
50% improvement of the baseline PASI (PASI 50). Patients who did not achieve PASI 50 
had to discontinue biologic treatment.
For etanercept, two dosing regimens were used. Twenty-three (77%) patients were 
treated with etanercept 50 mg subcutaneously twice weekly for at least 12 weeks. 
Seven (23%) patients were treated with etanercept 25 mg subcutaneously twice weekly 
for at least 12 weeks. Adalimumab was administered according to the label for at least 
12 weeks. After these 12 weeks, patients were treated according to the opinion of the 
treating dermatologist, including dosage increments or dosage reductions in the case of 
etanercept (dose ranging from 50 mg per week to 100 mg per week) and shortening of 
the treatment interval in the case of adalimumab (40 mg every 10 days or 40 mg per 
week). No adjustments according to body weight were made.
Patients were seen every 12 weeks. Demographic data were documented at the time 
of screening and PASI scores and adverse events were prospectively collected at each 
hospital visit. Interpolated PASI data derived from the two closest visits and extrapolated 
PASI data up to maximal 7 days of extrapolation were used when visits did not occur at 
the indicated time points. 
Patients started adalimumab treatment at different time points before the moment 
of analysis. Therefore the amount of available PASI data from patients treated with 
adalimumab decreases over time according to the length of treatment or the cessation 
of treatment. 
Analysis
All patients who were treated with etanercept followed by adalimumab between 
September 2002 and January 2010 were included for analysis. 
Demographics
Demographic data and patients characteristics were recorded and expressed as numbers 
(percentages) and means (± SD). 
Primary failure, secondary failure and intolerance 
Failure on etanercept was categorized into primary failure, secondary failure and 
intolerance. Primary failure on etanercept was defined as an insufficient response 
(patients not achieving PASI 50) at week 12.3, 6 Secondary failure on etanercept was 
defined as the loss of response in a patient who achieved a PASI 50 response at week 12. 
Intolerance was defined as cessation of treatment caused by side effects. 
Long-term efficacy and safety of biologic treatment for psoriasis in daily practice
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Primary failure on adalimumab was defined as an insufficient response (patients not 
achieving PASI 50) at week 12, relative to the original baseline. 
The response to consecutive treatment with adalimumab was investigated in the total 
group and in the subgroups with primary failure, secondary failure or intolerance to 
etanercept.
Efficacy
Treatment efficacy was analysed at indicated time points, i.e. week 12, 24 and 48 of each 
treatment. Primary endpoints were the percentage of patients achieving at least PASI 50 
and PASI 75. Secondary endpoints were the percentage of patients achieving PASI 90 and 
the mean percentage improvement in PASI from baseline at the indicated time points. 
The response to adalimumab was compared with the response to etanercept in the same 
patients, each patient serving as his or her own control. 
The response to adalimumab was evaluated in comparison with the baseline PASI for 
adalimumab (course baseline) and with the baseline PASI for etanercept (original 
baseline).4, 13, 14 In addition, the mean best PASI obtained during etanercept and 
adalimumab therapy and the mean last PASI obtained with etanercept, irrespective of 
the time point, were calculated.14 
The correlation between the duration of the transition interval and the subsequent 
response to adalimumab was investigated, as well as the correlation between the 
etanercept treatment duration and the response to adalimumab. 
Safety
The adverse event rate was a secondary endpoint. Reported adverse events were 
analysed and categorized in predefined categories. The adverse event rate was expressed 
per patient-year exposed to etanercept and adalimumab, respectively. 
Statistics
McNemar’s test was performed to analyse the differences in the PASI 50 and PASI 75 
response rates at week 12 during etanercept and adalimumab treatment. The Spearman 
correlation coefficient was calculated to analyse correlations. P < 0.05 was considered 
statistically significant. 
Results
Demographics
Nineteen patients from the Radboud University Nijmegen Medical Centre and 11 patients 
from the Academic Medical Center were treated with etanercept as the first biologic 
therapy followed by adalimumab. Nineteen patients (63%) were male and the mean 
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age was 51.5 (± 12.4) years (Table 1). The mean duration of psoriasis was 26.3 (± 11.5)
years. Nine patients (30%) had concomitant psoriatic arthritis and 23 patients (77%) had 
one or more other comorbidities. The mean number of different systemic therapies that 
patients had used before the start of etanercept was 4.2 (± 1.3).
Treatment characteristics
All patients had moderate to severe psoriasis with a mean baseline PASI of 17.7 (± 8.6) 
at the start of etanercept (original baseline) (Table 2). The mean treatment duration 
with etanercept was 2.1 (± 1.3) years. The number of patient-years for etanercept was 
64.2. 
The time between the cessation of etanercept and the introduction of adalimumab varied 
in duration from 0 days to 1.8 years (mean 1.9 ± 5.2 months). One patient continued 
methotrexate therapy throughout the transition period and another patient was treated 
with dithranol. The other patients did not receive any systemic or dithranol therapy 
during the transition period.
Demographics and patient characteristics
Male, n (%) 19 (63.3)
Age (years)
Mean (± SD) 51.5 (12.4)
Range 29-75
Duration of psoriasis (years)
Mean (± SD) 26.3 (11.5)
Range 10-48
Psoriatic arthritis, n (%) 9 (30.0)
Other comorbidities, n (%) 23 (76.7)
BMI (kg/m2), mean (± SD) 29.5 (7.1)
Obesity (BMI > 30), n (%) 14 (46.7)
Diabetes, n (%) 8 (26.7)
Hypertension, n (%) 12 (40.0)
Hyperlipidaemia, n (%) 9 (30.0)
Myocardial infarction, n (%) 2 (6.7)
Cerebrovascular disease, n (%) 1 (3.3)
Previous therapies, n (%)
UVB 29 (96.7)
Psoralen plus UVA 14 (46.7)
Methotrexate 28 (93.3)
Ciclosporin 23 (76.7)
Acitretin 20 (66.7)
Fumarates 13 (43.3)
Table 1. Demographics and patient characteristics (n = 30).
BMI, body mass index; UV, ultraviolet.
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The mean baseline PASI before the initiation of adalimumab (course baseline) was 10.7 
(± 4.0). At the time of analysis, the mean adalimumab treatment duration was 1.1 (± 0.4) 
years. The exposure rate for adalimumab was 33.9 patient-years.
Eleven patients (37%) used concomitant systemic and/or dithranol therapy for their 
psoriasis during etanercept treatment (Table 2). Five patients (17%) received additional 
systemic and/or dithranol treatment during adalimumab treatment. In most patients the 
additional systemic therapies were temporarily applied. 
Taking into account the dosage increases and the treatment interruptions that occurred, 
the mean weekly dose was 73.4 mg for etanercept and 23.0 mg for adalimumab. The 
mean weekly dose of etanercept in the group of 14 obese patients was 71.1 mg and in 
the 16 nonobese patients 75.8 mg. The mean weekly dose of adalimumab in the obese 
patients was 24.0 mg and in the nonobese patients 22.1 mg.
Primary failure, secondary failure and intolerance
Eleven patients were primary nonresponders to etanercept and 14 patients were 
secondary nonresponders (Figure 1). Three patients discontinued etanercept because of 
intolerance to this agent. The two remaining patients did not fail etanercept treatment 
according to the predefined terms, but they were dissatisfied with the effect of etanercept 
in the long term. 
Of the eleven primary nonresponders to etanercept, six were primary responders to 
Etanercept (n = 30) Adalimumab (n = 30)
Baseline PASI
Mean (± SD) 17.7 (8.6) 10.7 (4.0)
Range 5.9 – 39.0 3.0 – 19.4 
Duration of treatment (years)
Mean (± SD) 2.1 (1.3) 1.1 (0.4)
Range 0.2 – 5.7 0.6 – 2.2
Follow-up, patient-years 64.2 33.9
Concomitant therapy*, n
Methotrexate 6 (3 days; 3 weeks; 2 months;
3 months; 8.4 months; 1 year)
2 (6 months; 9.2 months)
Ciclosporin 2 (4.6 months; 3.3 weeks) 0
Acitretin 2 (12 days; 9 months) 0
Fumarates 1 (2 months) 0
UVB 0 1
Dithranol 2 (2.2 months; 5 weeks) 3 (1 month; 7.4 weeks;
4.4 months)
Mean weekly dose (mg) 73.4 23.0
Table 2. Treatment characteristics.
*Duration of concomitant therapy is shown in parentheses. PASI, Psoriasis Area and Severity Index.
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adalimumab and five were primary nonresponders to adalimumab as well (Figure 1).
Eleven out of 14 secondary nonresponders to etanercept were primary responders to 
adalimumab and three patients were primary nonresponders to adalimumab. Of the 
three patients who discontinued etanercept because of intolerance, two were primary 
responders and one patient was a primary nonresponder to adalimumab. The remaining 
two patients who were dissatisfied with the effect of etanercept achieved PASI 50 at week 
12 of adalimumab treatment. 
Four out of 18 patients who were primary responders to etanercept experienced primary 
therapeutic failure on adalimumab (not shown in Figure 1). Fourteen patients achieved 
PASI 50 at week 12 on etanercept as well as adalimumab. 
Relative to the original baseline, nine patients failed to achieve PASI 50 at week 12 with 
adalimumab and were hence defined as primary nonresponders to adalimumab. 
Twenty-eight patients (93%) were still being treated with adalimumab at the moment of 
evaluation. Of the two patients who discontinued adalimumab treatment, one patient 
was a primary nonresponder and the other patient was a secondary nonresponder. 
Seven out of 11 (64%) primary nonresponders to etanercept and five out of nine (56%) 
primary nonresponders to adalimumab were obese. Three out of 5 (60%) primary 
nonresponders to both drugs were obese.
Efficacy
The mean best PASI obtained during etanercept therapy was 5.0 (± 3.6) at a mean 
treatment duration of 1.2 (± 1.0) years (range 30.0 days – 4.0 years) (Figure 2). The mean 
last PASI on etanercept was 10.2 (± 4.1) at a mean treatment duration of 2.1 (± 1.3) years 
(range 2.7 months – 5.5 years). The mean best PASI achieved with adalimumab until the 
moment of evaluation was 4.2 (± 3.8), at a mean treatment duration of 6.0 (± 3.3) months 
(range 30.0 days – 1.0 year). 
When the response to adalimumab is expressed in relation to the course baseline, the 
mean percentage improvement in PASI achieved at week 12, 24, 36 and 48 is less than 
the improvement achieved during etanercept treatment (Figure 3). However, when the 
Figure 1. Results of etanercept and adalimumab treatment in the 30 patients with psoriasis.
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response to adalimumab is represented in relation to the original baseline, there is more 
improvement in PASI during adalimumab therapy than during etanercept therapy. 
During etanercept treatment, 18 patients (60%) achieved PASI 50 at week 12 (Figure 
4). The percentage of patients having a PASI 50 response to adalimumab at week 12 in 
comparison to course baseline and original baseline was 30% (n = 9) and 70% (n = 21), 
respectively. PASI 75 was achieved at week 12 in 13% (n = 4), 13% (n = 4) and 27% (n = 8) 
of patients in the three different categories. 
At week 24, 58% (n = 15), 50% (n = 14) and 61% (n = 17) of patients obtained a PASI 50 
response in the etanercept, adalimumab vs. course baseline and adalimumab vs. original 
baseline categories, respectively (Figure 5). Nineteen percent (n = 5), 7% (n = 2) and 36% 
(n = 10) of patients in the three different categories, respectively, achieved PASI 75. 
At week 48, 79% (n = 19), 54% (n = 7) and 77% (n = 10) of patients in the three different 
categories achieved PASI 50 (Figure 6). Twenty-five percent (n = 6), 23% (n = 3) and 54% 
(n = 7) of patients achieved PASI 75. 
During etanercept therapy, one patient achieved PASI 90 at week 12 and one patient 
achieved PASI 90 at week 24. In comparison to the course baseline, a PASI 90 response 
to adalimumab was obtained by four (13%) and two patients (15%) at week 12 and 48, 
respectively. In comparison to the original baseline, a PASI 90 response to adalimumab 
was achieved by three (10%), two (7%) and two (15%) patients at week 12, 24 and 48, 
respectively. 
The differences in the percentages of patients achieving PASI 50 and PASI 75 at week 12 
of etanercept and adalimumab treatment were not statistically significant. There was no 
correlation between the duration of the transition interval and the subsequent response 
to adalimumab, or between the etanercept treatment duration and the response to 
adalimumab (reduction (%) in PASI at week 12 and 24). 
Figure 2. Values shown are the mean 
(± SD) baseline PASI before the start 
of etanercept (original baseline), the 
mean (± SD) best PASI achieved during 
etanercept therapy, the mean (± SD) 
last PASI on etanercept, the mean
(± SD) baseline PASI before the start of 
adalimumab (course baseline) after a 
transition period and the mean (± SD) 
best PASI achieved with adalimumab until 
the moment of evaluation, irrespective of 
the time point.
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Safety
Etanercept and adalimumab were generally well tolerated. The total rate of adverse 
events reported during etanercept therapy was 3.41 per patient-year compared with 3.18 
adverse events per patient-year during adalimumab treatment (Table 3).
Rates of infections per patient-year were 1.03 for etanercept and 0.91 for adalimumab. 
Upper respiratory tract infections were the adverse events most frequently encountered, 
followed by dermatological conditions, muscle and joint complaints and flu-like symptoms. 
The rate of serious infections seen during etanercept treatment was 0.03 per patient-
year. One patient was admitted with erysipelas and another patient was admitted with 
pneumonia. There have not been any reports of serious infections in the course of 
adalimumab therapy up until the moment of evaluation (Table 4). 
One patient with a medical history of nonmelanoma skin cancer was diagnosed with two 
squamous cell carcinomas during etanercept therapy and three squamous cell carcinomas 
during adalimumab therapy. The first squamous cell carcinoma was diagnosed within a 
few weeks after the start of etanercept. Another patient was diagnosed with two basal 
cell carcinomas during adalimumab therapy, 3 months after the start of this treatment. 
Figure 3. Mean (± SEM) improvement in PASI during etanercept therapy and adalimumab therapy at week 
12, 24, 36 and 48. The response to adalimumab was compared with the baseline PASI before the start of 
adalimumab (course baseline) and the baseline PASI before the start of etanercept (original baseline). 
Note: the number of PASI data for adalimumab does not correspond with the number of patients in follow-
up, as only the 12-week adalimumab follow-up time point was completed by all patients. SEM; standard 
error of the mean.
Etanercept
Adalimumab vs. course baseline
Adalimumab vs. original baseline
Number of PASI data etanercept
Number of PASI data adalimumab
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Discussion
Most patients in our department were treated with etanercept as the first biologic 
therapy, as etanercept was one of the first registered biologics for psoriasis in Europe. 
When etanercept was discontinued because of inefficacy or intolerance, patients were 
mainly treated with adalimumab. Infliximab is reserved for patients with very severe 
psoriasis that warrants a rapid improvement, because of practical reasons and the infusion 
reactions observed with infliximab treatment. The recent registration of ustekinumab for 
the treatment of psoriasis has brought us an alternative treatment option besides the 
TNF-inhibitors, but experience with this new drug is limited at this moment.
In this study we focused on consecutive treatment with etanercept and adalimumab 
in biologic-naïve patients in daily practice and the relationship between reasons for 
discontinuation of etanercept and the response to adalimumab. The identification of 
groups of patients, who may benefit most from a switch to adalimumab when classified 
by reason of discontinuation of etanercept, would be useful to optimize treatment for 
each individual patient. 
The majority of patients showed a beneficial response to adalimumab, irrespective of 
the reason for discontinuation of etanercept. In our patient group, previous treatment 
with etanercept did not increase the adverse event rate nor change the nature of the 
side effects. During the 24-week double-blind, randomized controlled ADEPT trial15 in 
which biologic-naïve patients with psoriatic arthritis were treated with adalimumab 40 
mg every other week, the infection rate was 1.53 per patient-year compared with 0.91 
per patient-year in our patients. Thus, pretreatment with etanercept did not increase the 
infection rate during adalimumab treatment during the studied treatment period. Other 
Figure 4. The percentage of patients achieving PASI 50, PASI 75 and PASI 90 at week 12 in the etanercept, 
adalimumab vs. course baseline and adalimumab vs. original baseline categories. The number of available 
PASI data at week 12 is represented above the bars.
Adalimumab vs. original baselineAdalimumab vs. course baselineEtanercept
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studies support our findings regarding the safety of adalimumab in patients previously 
treated with other biologics.3, 7, 16 A possible disadvantage of switching to adalimumab can 
be the formation of antibodies against adalimumab and an associated decline in efficacy 
in a proportion of patients.17 
The response to adalimumab was calculated in two different ways. Compared with the 
original baseline PASI, the response rates to adalimumab were generally better than 
those achieved with etanercept. On the other hand, when the response to adalimumab 
was compared with the course baseline PASI, the response rates were generally lower. 
This can be explained by the carry-over effect of etanercept, i.e. patients are starting 
Figure 5. The percentage of patients achieving PASI 50, PASI 75 and PASI 90 at week 24 in the etanercept, 
adalimumab vs. course baseline and adalimumab vs. original baseline categories. The number of available 
PASI data at week 24 is represented above the bars.
Figure 6. The percentage of patients achieving PASI 50, PASI 75 and PASI 90 at week 48 in the etanercept, 
adalimumab vs. course baseline and adalimumab vs. original baseline categories. The number of available 
PASI data at week 48 is represented above the bars.
Adalimumab vs. original baselineAdalimumab vs. course baselineEtanercept
Adalimumab vs. original baselineAdalimumab vs. course baselineEtanercept
Long-term efficacy and safety of biologic treatment for psoriasis in daily practice
63
3
Chapter 3
adalimumab treatment from a point of partial response with a lower course baseline PASI 
than the original baseline PASI.14 
The results are also influenced by a phenomenon called ‘regression to the mean’.5, 18-20 
There was less regression to the mean during adalimumab treatment because of the 
lower baseline PASI. To overcome these influences on the PASI response, we prefer the 
fairer comparison with the original baseline.
In addition, the reasons for discontinuation in daily practice are not always straightforward. 
Besides lack or loss of efficacy and adverse events, general dissatisfaction and the 
availability of other biologics may play a role as well.21
With this study we also showed that adalimumab is an effective and well tolerated therapy 
in patients who failed on etanercept. However, the relationship between the reasons for 
failure of etanercept and the response to adalimumab in patients with psoriasis had not 
been investigated in previous studies.
Adverse events Etanercept Adalimumab
Infections 1.03 0.91
Flu-like symptoms 0.23 0.09
Upper respiratory tract infections 0.56 0.56
Skin infections 0.11 0.06
Urinary tract infections 0.04 0
Gastrointestinal infections 0.02 0.03
Lower respiratory tract infections 0.03 0.12
Eye infections 0.03 0.06
(Pre)malignancies 0.03 0.18
Actinic keratosis 0 0.03
Basal cell carcinoma 0 0.06b
Squamous cell carcinoma 0.03a 0.09a
Muscle and joint complaints 0.34 0.35
Dermatological conditions 0.47 0.44
Gastrointestinal complaints 0.14 0.09
Cardiovascular events 0.06 0.03
Ear complaints 0.06 0
Eye complaints 0.06 0
Endocrine diseases 0.03 0.03
Miscellaneous 1.18 1.15
Total 3.41 3.18
Table 3. Incidence of adverse events in patients treated with etanercept followed by adalimumab per 
patient-year. Multiple occurrences of the same adverse event in the same individual were counted 
multiple times.
aOne patient was diagnosed with five squamous cell carcinomas, two during etanercept therapy and three 
during adalimumab therapy. bOne patient was diagnosed with two basal cell carcinomas. Note: the follow-
up for adalimumab was shorter than the follow-up for etanercept.
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In our study, primary failure on etanercept did not preclude the efficacy of adalimumab, 
which is also a TNF-inhibitor. On the contrary, the chance of achieving a primary response 
on adalimumab at week 12 was even greater than the chance of primary failure. The same 
applies to the patients with secondary failure on etanercept, intolerance to etanercept or 
dissatisfaction with the effect of etanercept.
A limitation of this study is the shorter follow-up for adalimumab than for etanercept. 
As a result, we could only identify the primary nonresponders and one secondary 
nonresponder to adalimumab up until the moment of evaluation. In addition, the safety 
of adalimumab after etanercept treatment could be different in the long term.
The lower mean weekly dose of etanercept and the small increase in mean weekly 
dose of adalimumab in the obese patients compared with the nonobese patients could 
possibly explain the relatively high proportion of obese patients among the primary 
nonresponders to each drug and the primary nonresponders to both drugs. However, 
studies with larger numbers of patients are needed to perform subgroup analysis.
Large rheumatoid arthritis studies have shown that the efficacy of a second TNF-inhibitor 
is less than the efficacy of a first TNF-inhibitor.18 This was not found in our study in 
patients with psoriasis. Studies in patients with rheumatoid arthritis also showed that 
the response to a second TNF-inhibitor depends on the reason for discontinuation of the 
first TNF-inhibitor. In general, a second TNF-inhibitor appeared to be more effective in 
Serious adverse events Etanercept Adalimumab
Basal cell carcinoma 0 0.06c
Squamous cell carcinoma 0.03a 0.09a
Erysipelas 0.02 0
Pneumonia 0.02 0
Myocardial infarction 0.03 0
Atrial fibrillation 0.02 0.03
Psoriasis exacerbation 0.06b 0
Cicatricial hernia surgery 0.02 0
Tendon rupture shoulder 0.02 0
Shoulder fracture 0.02 0
Joint complaints, weight loss, malaise 0 0.03
Total 0.22 0.21
Table 4. Incidence of serious adverse events in patients treated with etanercept followed by adalimumab 
per patient-year. Multiple occurrences of the same serious adverse event in the same individual were 
counted multiple times.
aOne patient was diagnosed with five squamous cell carcinomas, two during etanercept therapy and 
three during adalimumab therapy. bOne patient experienced two exacerbations of psoriasis. cOne patient 
was diagnosed with two basal cell carcinomas. Note: the follow-up for adalimumab was shorter than the 
follow-up for etanercept.
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patients with secondary failure rather than primary failure of the first TNF-inhibitor. In 
our study, the percentage of patients with psoriasis achieving PASI 50 at week 12 with 
adalimumab was also higher among the secondary nonresponders than among the 
primary nonresponders.
Studies with larger numbers of patients are needed to investigate the correlation between 
the duration of the transition interval and the subsequent response to adalimumab, as 
well as the correlation between the etanercept treatment duration and the response to 
adalimumab. 
The efficacy of adalimumab in etanercept nonresponders is not clear. Differences in 
molecule structure, pharmacological properties or genetic predisposition of patients 
could be possible explanations. Etanercept failure could possibly be explained by 
decreased bioavailability of the drug or biological adaptation to chronic TNF-α blockade.2 
Differences in the mechanisms of action could explain the efficacy of adalimumab after 
etanercept failure due to biological adaptation. Further research is needed to answer 
these questions. 
The PASI 50/75/90 response rates of adalimumab in comparison to the original baseline at 
the different time points until week 48 were higher than the response rates achieved with 
etanercept, but lower than the response rates found in other daily practice studies and 
randomized clinical trials with adalimumab.3, 6, 7, 16, 22-25 The efficacy results found in other 
daily practice studies are quite similar to those found in randomized controlled clinical 
trials.3, 6, 7, 16 However, these daily practice studies are often limited by small numbers of 
patients and an adalimumab treatment regimen starting with 40 mg weekly instead of 
the registered 40 mg fortnightly dosage. 
Other consecutive treatment regimens have been studied as well. Mazzotta et al. 
demonstrated that etanercept treatment after infliximab and/or efalizumab failure was 
more effective in those patients who had not previously received other biologic therapies 
than in those who had.26 Nevertheless, etanercept was considered to be a good treatment 
option even after failure to respond to other biologic therapies. 
Haitz et al. and Pitarch et al. showed that switching from infliximab to etanercept and vice 
versa is useful, although in the latter case shortening of the treatment interval was required 
to maintain the treatment response.2, 4 No relevant adverse events were observed after 
switching from infliximab to etanercept. Infliximab treatment after etanercept treatment 
was associated with a possible increased incidence of adverse events. 
In conclusion, switching from etanercept to adalimumab in patients with primary failure, 
secondary failure or intolerance to etanercept seems to be an effective and safe treatment 
option in psoriasis. Continuous prospective cohort monitoring is important to gain more 
and long-term efficacy and safety data from these patients in daily practice.
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Abstract
 
Background
Patients and the course of treatment in daily practice are different from randomized 
controlled trials (RCTs).
Objectives
Primary objective: to analyse the percentage of patients achieving PASI 75. Secondary 
objectives: PASI 50, PASI 90, PASI 100 responses, the percentage of patients experiencing 
at least one serious adverse event (SAE) and the response in biologic-naïve vs. non-naïve 
patients.
Methods
Prospectively collected efficacy and safety data of a cohort of psoriasis patients treated 
with adalimumab in daily practice between May 2007 and July 2011 were analysed. 
Efficacy was determined using an intention-to-treat analysis and an as-treated analysis, in 
comparison with the course baseline PASI before the start of adalimumab and the original 
baseline PASI before the start of any biologic therapy. 
Results
Eighty-five patients received adalimumab therapy with a mean treatment duration of 
1.4 (range 0.02 – 3.1) years. Compared with the original baseline PASI, PASI 75 response 
rates at week 12 and 24 were 34% and 38% (ITT). PASI 75 responses were well maintained 
until week 132. 
Only the PASI 75 response rate at week 12 differed significantly between biologic-naïve 
(56%) and non-naïve patients (29%). Sixteen patients (19%) experienced 28 SAEs. Seven 
patients (8%) experienced SAEs considered possibly or probably related to adalimumab.
Conclusions
In this cohort, PASI 75 responses were substantial but lower than in RCTs and other daily 
practice studies. Efficacy was well maintained during more than 2 years of follow-up and 
differed only between biologic-naïve and non-naïve patients at week 12. The incidence of 
SAEs was low but seems higher than observed in RCTs. 
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Introduction
The efficacy and safety of adalimumab for psoriasis has been studied in randomized 
controlled trials (RCTs), one with an extension study up to 3 years of therapy.1-4 These 
studies showed that adalimumab was efficacious and well tolerated in the short-term,2-4 
but also that efficacy was well maintained over more than 3 years of treatment and that 
the long-term benefit-risk profile was favourable with adverse event (AE) rates being 
generally stable over time.1 
However, RCTs were conducted in selected patients fulfilling strict inclusion and exclusion 
criteria. In addition, the course of therapy in RCTs is predefined with strict continuation 
and discontinuation criteria. Therefore, the results of RCTs cannot simply be extrapolated 
to daily practice. Moreover, one of the phase III trials of adalimumab for psoriasis 
excluded patients who previously failed a TNF-antagonist and therefore did not provide 
information about the efficacy and safety of adalimumab in these patients.4 Prospective 
observational cohort studies provide complementary information about the efficacy and 
safety of biologics for psoriasis in daily practice and in the long term. However, there are 
few reports on the management of unselected patients in day-to-day practice.
Published daily practice studies are limited to a maximum of 46 patients and a maximum 
mean treatment duration of 61.5 weeks.5, 6 Moreover, most daily practice studies 
performed an ‘as-treated analysis’,5-8 which makes comparisons with RCTs difficult, as 
those performed an intention-to-treat analysis.2-4 
The purpose of this study was to analyse the efficacy and safety of adalimumab for 
psoriasis in daily practice in a larger number of patients with a longer follow-up and to 
compare response rates in biologic-naïve patients with patients who had previously been 
exposed to biologic agents and therefore possibly comprise a more therapy-resistant 
group.
Patients and methods
Patients
In February 2005, the department of Dermatology of the Radboud University Nijmegen 
Medical Centre started a prospective registry, containing efficacy and safety data of all 
consecutive patients treated with biologics for psoriasis in daily practice.9 For the current 
analysis, data were extracted from all patients treated with adalimumab. 
In the Netherlands, biologics were approved and reimbursed for patients with moderate 
to severe plaque psoriasis who had not responded to phototherapy, methotrexate and 
ciclosporin, or who had contraindications to, or did not tolerate these therapies. In 2010, 
the reimbursement criteria were changed into moderate to severe plaque psoriasis with 
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nonresponse, contraindications or intolerance to phototherapy and methotrexate ór 
ciclosporin. Furthermore, a Psoriasis Area and Severity Index (PASI)10 of at least 10 or a 
PASI ≥ 8 and a Skindex-29 score ≥ 35 (quality of life index)11 was required.
Methods
Patients were seen at screening, week 6 and 12 of adalimumab therapy and subsequently 
every 12 weeks. At screening, demographic data and information about the medical 
history, previous medication use for psoriasis and current medication use for psoriasis 
and other indications were recorded. 
PASI scores were calculated at each visit. Patients were asked to report all AEs since the 
last visit and to report changes in comorbidity and concomitant medication. When visits 
did not occur at the exact time points, PASI scores were interpolated to the most nearby 
time point, allowing 7 days of extrapolation. 
The primary objective was to analyse the percentage of patients achieving PASI 75. 
Secondary objectives were the percentage of patients achieving PASI 50, PASI 90 and PASI 
100, the percentage of patients experiencing at least one serious adverse event (SAE) and 
the response in biologic-naïve patients compared with biologic-exposed patients.
Patients started adalimumab with a loading dose of 80 mg subcutaneously, followed 
by 40 mg every other week starting 1 week after the initial dose. In case of insufficient 
efficacy, the dose could be increased to 40 mg weekly or a topical or conventional 
systemic antipsoriatic therapy could be added. The decision to change the therapeutic 
regimen was based on clinical judgment of the treating dermatologist. The mean weekly 
dose of adalimumab was calculated.
As it is known that the method of analysis applied is of great importance for the efficacy 
results,12 efficacy was analysed using two methods: (i) observed values of continuing 
patients only (as-treated analysis), and (ii) intention-to-treat (ITT) analysis with the last 
available PASI carried forward (LOCF) in case of missing data due to discontinuation of 
adalimumab or insufficient follow-up. 
The response to adalimumab was evaluated in comparison with the baseline PASI before 
the start of adalimumab (course baseline) and with the first available baseline PASI before 
the start of any biologic therapy and enrolment in the registry (original baseline). This was 
done because patients switching to adalimumab after a previous biologic sometimes can 
be partial responders to the previous treatment, and therefore start with a lower course 
baseline PASI than the original baseline PASI.13, 14 
The total group of patients was subdivided in patients who were biologic-naïve (defined 
as patients who had not previously been treated with a biologic agent (TNF-inhibitor 
or a biologic agent with another mechanism of action (efalizumab, alefacept and/or 
ustekinumab, partly in the context of clinical trials))) at the time of adalimumab initiation 
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and patients who had previously been treated with at least one biologic agent. PASI 
50/75/90 response rates in comparison with the original baseline until week 48 were 
calculated and compared between the groups.
Serious adverse events were defined as life-threatening events, events requiring 
(prolongation of) hospitalization, congenital anomalies/birth defects, events resulting 
in persistent or significant disability/incapacity or death and important medical events 
according to medical and scientific judgment, consistent with the EMEA definition.15 
Statistics
Descriptive statistics were used to represent study results as percentages, means
(± standard deviation (SD)) and medians (range). The chi-square test or Fisher’s exact 
test were used to compare responses in biologic-naïve and biologic-exposed patients. An 
independent samples t-test was performed to compare means. P < 0.05 was considered 
statistically significant. 
Results
Patients
Between May 2007 and July 2011, 85 patients were treated with adalimumab during 120 
patient-years of follow-up. The mean treatment duration was 1.4 (± 0.8) years and the 
median treatment duration was 1.4 (range 0.02 – 3.1) years. Forty-eight patients were 
male (56%) and the mean age at the start of adalimumab treatment was 48.8 (± 12.4)
years. The mean duration of psoriasis was 23.0 (± 11.3) years (Table 1). Twenty-five 
patients (29%) had psoriatic arthritis. The mean weekly dose of adalimumab was 24.0 mg.
Sixteen patients (19%) were biologic-naïve at the start of adalimumab therapy. Sixty-nine 
patients (81%) had previously been treated with biologics in daily practice or a clinical 
trial. Sixty-six patients out of these 69 patients (96%) had previously been treated with 
at least one TNF-α blocking agent. Previous biologic therapies are presented in Table 1. 
The number of different previous biologics that patients had used varied between 0 and 
4. Thirty-eight patients out of 85 (45%) had only received etanercept therapy and fifteen 
patients (18%) had been treated with etanercept and efalizumab, as these were the first 
registered biologics for psoriasis in Europe. The other 16 patients (19%) had been treated 
with varying consecutive biologics. 
At least one concomitant systemic antipsoriatic therapy was used in 25 patients (29%), 
as bridging therapy or added therapy to improve efficacy. These comprised methotrexate
(n = 17), acitretin (n = 3), ciclosporin (n = 6) and fumarates (n = 1). 
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Treatment status
Fifty-four patients (64%) completed one year of adalimumab therapy, 25 patients 
(29%) completed two years and one patient (1%) completed three years (Figure 1). 
Sixteen treatment episodes (19%) were discontinued due to insufficient efficacy, two 
(2%) due to AEs, four (5%) due to a combination of insufficient efficacy and AEs, one 
patient (1%) died (unrelated to adalimumab therapy) and seven patients (8%) were 
lost to follow-up.
Efficacy
Figure 2 and 3 present the ITT analysis with the PASI response compared with the original 
baseline PASI and the course baseline PASI, respectively. Figure 4 and 5 present the as-
treated analysis with the PASI response in relation to the original baseline PASI and the 
course baseline, respectively. 
Intention-to-treat analysis
When the response to adalimumab was expressed in relation to the original baseline, 
PASI 75 was obtained by 34% (n = 29) and 38% (n = 32) of patients at week 12 and 24 
(Figure 2). At week 48, 96 and 132, PASI 75 response rates were 40% (n = 34), 38% (n = 32)
and 36% (n = 31), respectively. 
At both week 12 and 24, PASI 50 was achieved in 65% of patients (n = 55). Eleven per 
cent (n = 9) and 14% (n = 12) of patients attained PASI 90 at these time points. From week 
36 until 132, PASI 50 response rates varied between 66% and 68% and PASI 90 response 
Patient characteristics n = 85
Male gender, n (%) 48 (56)
Age (years), mean ± SD 48.8 (12.4)
Duration of psoriasis (years), mean ± SD 23.0 (11.3)
Psoriatic arthritis, n (%) 25 (29)
Original baseline PASI, mean ± SDa 15.1 (7.9)
Course baseline PASI, mean ± SDb 10.9 (5.6)
Previous biologic therapies, n (%)
Etanercept 62 (73)
Efalizumab 21 (25)
Alefacept 8 (9)
Infliximab 6 (7)
Ustekinumab 1 (1)
Table 1. Patient characteristics.
aOriginal baseline PASI, first available baseline PASI before the start of biologic treatment and enrolment in 
the registry. bCourse baseline PASI, baseline PASI before the start of adalimumab. 
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rates were 13% to 19%. None of the patients achieved PASI 100 at week 12. At week 24, 
four patients (5%) achieved PASI 100 and from week 36 until 132, this applied to three 
patients (4%). 
In relation to the course baseline, 27% (n = 23) and 26% (n = 22) of patients achieved PASI 75
at week 12 and 24 (Figure 3). At week 48, 96 and 132, these figures were 26% (n = 22),
26% (n = 22) and 25% (n = 21), respectively. PASI 50 response rates at week 12 and 24 
were 46% (n = 39) and 49% (n = 42). PASI 90 response rates at these time points were 
8% (n = 7) and 9% (n = 8). From week 36 until week 132, PASI 50 response rates varied 
between 52% and 55% and PASI 90 response rates varied between 8% and 13%. PASI 100 
response rates are described above.
Figure 1. Patient disposition. 
*These patients were actively being treated 
with adalimumab and included in the efficacy 
analysis until the last available visit.
n = 85 started
adalimumab therapy
10 lack/loss of efficacy
1 adverse event
2 lack/loss of efficacy and adverse event
3 lost to follow-up
1 deceased
14 follow-up < 1 year*
n = 54 completed
1 year of therapy
6 lack/loss of efficacy
1 adverse event
2 lack/loss of efficacy and adverse event
3 lost to follow-up
17 follow-up 1-2 years*
n = 25 completed
2 years of therapy
n = 1 completed
3 years of therapy
1 lost to follow-up
23 follow-up > 2 years*
Efficacy analysis until week 132
Safety analysis until a maximum of 
3.1 years of follow-up
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As shown in Figures 2-3, the long-term efficacy of adalimumab was relatively stable over 
time with the ITT analysis.
As-treated analysis
In relation to the original baseline, PASI 75 response rates at week 12 and 24 were 35% 
(n = 29) and 45% (n = 32) (Figure 4). At week 48, 96 and 132, PASI 75 response rates were 
57% (n = 30), 44% (n = 8) and 50% (n = 3), respectively. 
At week 12 and 24, PASI 50 was achieved in 65% (n = 55) and 69% of patients (n = 49). 
PASI 50 response rates at week 48, 96 and 132 were 83% (n = 44), 94% (n = 17) and 83% 
(n = 5), respectively. 
PASI 90 response rates at week 12 and 24 were 11% (n = 9) and 17% (n = 12). At week 
48, 96 and 132, a PASI 90 response was obtained by 21% (n = 11), 22% (n = 4) and 0% of 
patients, respectively. 
None of the patients achieved PASI 100 at week 12. At week 24 and 48, complete clearance 
of psoriasis was seen in 6% (n = 4) and 4% (n = 2) of the patients. From week 96 until week 
132, none of the patients obtained PASI 100. 
In relation to the course baseline, 27% of patients (n = 23) achieved PASI 75 at week 12, 
31% (n = 22) at week 24, 38% (n = 20) at week 48, 44% (n = 8) at week 96 and 50% (n = 3) 
at week 132 (Figure 5). 
PASI 50 response rates at week 12 and 24 were 46% (n = 39) and 56% (n = 40). PASI 50 
response rates at week 48, week 96 and week 132 were 72% (n = 38), 72% (n = 13) and 
50% (n = 3), respectively. At week 12 and 24, PASI 90 was achieved by 8% (n = 7) and 11% 
Figure 2. PASI 50/75/90/100 response rates in patients with psoriasis treated with adalimumab in 
comparison with the original baseline, ITT analysis with LOCF.
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(n = 8) of patients. PASI 90 response rates at week 48, week 96 and week 132 were 15% 
(n = 8), 22% (n = 4) and 0%, respectively. PASI 100 response rates are described above. 
As shown in Figures 4-5, efficacy continued to improve through weeks 60-96, with 
fluctuating efficacy afterwards, using an as-treated analysis. 
Response rates in biologic-naïve and non-naïve patients
The mean original baseline PASI in the biologic-naïve patients (n = 16) was 13.0 (± 7.5). In 
the non-naïve patients (n = 69), the original baseline PASI was 15.6 (± 7.9). This difference 
was not statistically significant. 
Compared with the original baseline PASI, 56% of biologic-naïve patients achieved PASI 75
at week 12 (ITT analysis with LOCF) (Figure 6). In the non-naïve patients, this was 29%. 
This difference was statistically significant (p = 0.04). PASI 75 response rates were not 
significantly different at week 24-48. PASI 50 and PASI 90 responses were not significantly 
different between the groups at any time point.
The mean course baseline PASI in the biologic-naïve patients corresponds with the mean 
original baseline PASI (13.0 (± 7.5)). In the biologic-exposed patients (n = 69), this was 
10.4 (± 5.1). This difference was also not statistically significant. 
Serious adverse events
Sixteen patients (19%) experienced 28 SAEs (0.23 events per patient-year) (Table 2). Eight 
out of 28 SAEs (29%) were considered possibly or probably related, which concerned 7 
out of 85 patients (8%). 
One patient was diagnosed with two basal cell carcinomas after 3 months of adalimumab 
Figure 3. PASI 50/75/90/100 response rates in patients with psoriasis treated with adalimumab in 
comparison with the course baseline, ITT analysis with LOCF.
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therapy, which were considered unlikely related to adalimumab therapy due to the rapid 
occurrence and the extensive history of previous immunosuppressive therapies. 
Two patients developed a serious infection, comprising a Legionella pneumonia and 
hospital-acquired pneumonia (possibly related). 
One patient experienced a gastric perforation occurring after 4 months, which was 
considered possibly related. Another patient died from internal bleeding after 9 months, 
which was considered unrelated because of a history of alcoholic liver cirrhosis and 
oesophageal variceal bleeding. 
A patient with psoriatic arthritis developed joint complaints, malaise and weight loss 
after 2.5 months. We considered these complaints to be probably related to immune 
complex formation of anti-adalimumab antibodies (AAAs) (53.000 AE/mL) and 
adalimumab (trough level < 0.002 μg/mL). Adalimumab antibodies were measured using 
a radioimmunoassay and adalimumab trough concentrations were measured by enzyme-
linked immunosorbent assay (ELISA), as described previously.16, 17 
Another patient with plaque psoriasis developed palmoplantar pustulosis and generalized 
pustular psoriasis after 4.5 months. Histology showed pustular psoriasis or a combination 
with toxicodermia. Adalimumab was discontinued and acitretin was started. Three weeks 
later the patients developed suberythrodermia. This patient responded very well to 
successive treatment with etanercept. We considered this to be probably related. 
Four patients experienced 9 hospitalizations for exacerbations of psoriasis. Two of these 
patients tested positive for AAAs, which might have contributed to the exacerbation. 
Figure 4. PASI 50/75/90/100 response rates in patients with psoriasis treated with adalimumab in 
comparison with the original baseline, as-treated analysis.
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Possible explanations for the exacerbations in the other patients were psychological 
distress, discontinuation of concomitant ciclosporin therapy, interruption of therapy 
because of influenza and a compliance problem.
Other SAEs, which were considered probably unrelated, are presented in Table 2. 
Discussion
The efficacy and safety of adalimumab for psoriasis has been investigated in RCTs, one 
with an extension study up to 3 years of treatment.1-4 Prospective observational cohort 
studies provide complementary information about the efficacy and safety in daily practice 
and in the long term. 
In this daily practice study, PASI 75 response rates on adalimumab compared with the 
original baseline PASI until week 132 were lower than in RCTs and other daily practice 
studies. PASI 75 at week 12 was achieved by 68% of patients in the REVEAL study, 
compared with 34% in this study (both ITT analysis).3 At week 24, these results were 70% 
and 38%, respectively. In the daily practice study of Warren et al., PASI 75 at week 16 
was achieved by 64% of patients, compared with 35% at week 12 in this study (both as-
treated analysis). At week 24, these results were 65% and 45%, respectively. 
A few explanations can be given for this observation. Firstly, this study concerned patients 
treated in a university hospital fulfilling strict reimbursement criteria, with treatment 
failure on conventional systemic therapies and in the majority of patients (81%) also on 
biologics. Therefore, the patients in this study could be more therapy-resistant.
Figure 5. PASI 50/75/90/100 response rates in patients with psoriasis treated with adalimumab in 
comparison with the course baseline, as-treated analysis.
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Secondly, the course baseline PASI in this study was considerably lower than in RCTs and 
other daily practice studies.2-8, 18 This can be explained by lengthy washout periods applied 
in RCTs and also in the study of Papoutsaki et al.,18 whereas in our department, most 
patients started adalimumab treatment from a point of partial response due to the effect 
of previous (biologic) therapies or switched to adalimumab due to AEs during the previous 
biologic therapy but with low disease activity.14 However, this situation reflects daily 
clinical practice, as most dermatologists apply short intervals between discontinuation of 
the previous biologic and the start of a new biologic, sometimes accompanied by the use 
of overlapping traditional systemic therapies.
A result of the lower course baseline PASI is that there is less regression to the mean 
and that a smaller absolute reduction in PASI is needed to achieve PASI 75.19 However, 
a residual PASI of between 5 and 6 at week 36-84 was observed in this study and has 
also been described in studies on etanercept for psoriasis.9, 20 Due to this remaining PASI 
and limitations of the PASI itself in limited psoriasis,21 PASI 75 is difficult to attain starting 
from a low baseline PASI. We prefer the fairer comparison with the original baseline PASI, 
which has also been applied in other studies.13, 14, 22, 23
Other explanations for the lower efficacy of adalimumab in daily practice compared 
with RCTs could be comorbidity and concomitant medication, intercurrent infections or 
interruptions of therapy due to infections or elective surgery in daily practice. Higher efficacy 
in other daily practice studies could also be explained by adalimumab administration at a 
dosage of 40 mg weekly, instead of the registered 40 mg fortnightly dosage.7, 18 
Figure 6. PASI 75 response in biologic-naïve and non-naïve patients in comparison with the original 
baseline PASI*, ITT analysis with LOCF. *Original baseline PASI corresponds with course baseline PASI in 
biologic-naïve patients.
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In this study, two methods of analysis were used. The as-treated analysis introduces 
a positive bias, as patients who continue treatment for a long time are usually good 
responders.1 The more conservative results of the ITT analysis may approximate the true 
efficacy of adalimumab, although efficacy may be a little overestimated, as it is known 
that efficacy does not remain constant in all patients. Both methods are important to be 
able to compare results from different studies.
Serum adalimumab concentrations and AAAs were not determined on a regular basis 
in patients with insufficient efficacy. AAA formation could have been the cause of 
exacerbations of psoriasis in two patients who tested positive for AAAs. The effect of AAA 
formation on the efficacy of adalimumab for psoriasis needs further investigation.16 
At week 12, the percentage of biologic-naïve patients achieving PASI 75 was significantly 
higher than the percentage of non-naïve patients. However, PASI 75 response rates at 
week 24-48 and PASI 50/90 responses did not differ.
Gniadecki et al. showed that the drug survival of infliximab, etanercept and adalimumab 
for psoriasis, which is an indicator of treatment success, was higher in anti-TNFα-naïve 
Serious adverse event Number of 
events
Number of 
patients (%)
Basal cell carcinoma 1* 1 (1)
Legionella pneumonia 1 1 (1)
Hospital-acquired pneumonia 1 1 (1)
Exacerbation of psoriasis with hospitalization 9 4 (5)
Palmoplantar pustulosis and pustular psoriasis 1 1 (1)
Suberythrodermia 1 1 (1)
Lymphoedema 1 1 (1)
Pulmonary embolism 1 1 (1)
Nefrolithiasis 1 1 (1)
Ablation therapy for atrial fibrillation 1 1 (1)
Hysterectomy for menorrhagia 1 1 (1)
Abdominal aortic aneurysm surgery 1 1 (1)
Traumatic wrist fracture 1 1 (1)
Malaise, joint complaints, weight loss 1 1 (1)
Knee surgery for osteoarthritis 2 1 (1)
Gastric perforation 1 1 (1)
Liver cirrhosis 1 1 (1)
Oesophageal variceal haemorrhage 1 1 (1)
Death 1 1 (1)
Table 2. Serious adverse events (SAEs) in patients with psoriasis treated with adalimumab.
*One patient was diagnosed with 2 basal cell carcinomas at the same time.
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patients compared with patients who previously failed anti-TNFα therapy.24 However, 
Ortonne et al. found only modestly reduced efficacy responses to adalimumab in patients 
with prior anti-TNFα exposure compared with anti-TNFα-naïve patients.25 Clemmensen 
et al. found no difference in the efficacy of ustekinumab in anti-TNFα-naïve patients 
compared with anti-TNFα unresponsive patients.26 Additional studies with larger numbers 
of patients are needed to address the question whether biologic-naïve patients are better 
responders than non-naïve patients. 
Sixteen patients (19%) experienced 28 SAEs. Only 8 out of 28 SAEs (29%) were considered 
possibly or probably related and this concerned only 7 out of 85 patients (8%). The 
incidence of SAEs observed in this daily practice study (0.23 events per patient-year) is 
higher than reported in the REVEAL randomized controlled trial (0.06 events per patient-
year).3 However, the treatment duration with adalimumab in the REVEAL study (52 weeks) 
was shorter than in this study, which can be important in a setting where an adverse event 
requires prolonged exposure to adalimumab to become clinically detectable, for instance 
in case of malignancies.27 In addition, the mean weekly dose of adalimumab in this study 
was higher than in the REVEAL study, as in the latter study the dose of adalimumab could 
not be escalated.
The number of patients and events in this study is too small to draw firm conclusions 
about safety, but the results point to future directions. Studies with larger numbers of 
patients have shown that SAE rates are stable over time.1, 28 
In conclusion, in this cohort PASI 75 response rates were substantial but lower than in RCTs 
and other daily practice studies. Efficacy was well maintained over more than 2 years of 
follow-up and did only differ between biologic-naïve and non-naïve patients at 12 weeks 
of treatment, but not during prolonged treatment. The incidence of therapy-related SAEs 
was low.
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Effectiveness of adalimumab dose escalation, 
combination therapy of adalimumab with 
methotrexate, or both in patients with psoriasis in 
daily practice
88
Abstract
Background
To increase effectiveness of standard adalimumab treatment 40 mg every other week 
(EOW) for patients with psoriasis, dose escalation to 40 mg every week or addition of 
methotrexate (MTX) are possible strategies.
Methods
Daily practice data on adalimumab treatment were extracted from a prospective 
observational cohort. We analysed all patients with insufficient efficacy of adalimumab 
EOW who received 1) adalimumab dose escalation, 2) addition of MTX to adalimumab 
EOW, or 3) both. Effectiveness was analysed after 12 and 24 weeks using PASI 50, PASI 75, 
and differences in mean PASI.
Results
Forty-seven treatment episodes (TE) of adalimumab dose escalation, 11 of MTX addition 
and six combinations were analysed. After a first episode of adalimumab dose escalation, 
25% and 34% resulted in PASI 50 after 12 and 24 weeks, respectively. Addition of MTX to 
adalimumab EOW, resulted in PASI 50 in 9%  of TE after 12 weeks and 18% of TE after 24 
weeks. No therapy-related serious adverse events were reported.
Conclusions
Twenty-five percent of first TE with adalimumab dose escalation induced a PASI 50 
response after 12 weeks and 34% after 24 weeks. Addition of MTX to adalimumab EOW 
resulted in PASI 50 in 9% after 12 weeks and 18% after 24 weeks. Defining patient groups 
that will benefit from these interventions is important.
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Introduction
Treating patients with moderate to severe psoriasis with biologics is a major step forward 
for patients with recalcitrant disease. In a subgroup of these patients, the normal dosage 
schedule (40 mg every other week) does not induce a sufficient response.1 Modification 
strategies include dose escalation (reducing dose interval or increasing dose) or adding 
another systemic therapy.2,3 Before switching to another systemic agent, it is recommended 
to first use these strategies mentioned.2 In case a patient uses the TNF-antagonist 
adalimumab (Humira®), dose escalation (a decrease of dose interval from 2 weeks
to 1 week) is frequently applied for suboptimal responders in clinical practice. In an 
open-label study, Leonardi et al. found a substantial improvement in clinical outcome in 
a quarter of psoriasis patients undergoing dose escalation.4 In rheumatoid arthritis, there 
was no significant improvement in clinical outcome after dose escalation of adalimumab.5
Another option is to add methotrexate (MTX), which has been combined in previous 
studies with TNF-antagonists in patients with rheumatoid arthritis and psoriatic 
arthritis.6-9 Combination with MTX is known to improve the clinical response and decrease 
the formation of antibodies against adalimumab in patients with rheumatoid arthritis.10-12 
However, for psoriatic arthritis, the addition of MTX to adalimumab has not been shown 
to enhance improvement of joint symptoms.7,9 The combination of MTX and the TNF-
antagonist etanercept has been proven to be successful in the treatment of moderate-
to-severe psoriasis.13,14 However, data on the effects of addition of MTX in patients who 
do not respond to adalimumab monotherapy in daily practice are scarce. In a recent case 
study, including 32 patients treated with MTX concomitant with adalimumab (early or late 
in the course of treatment), the majority of patients had a good or very good response.15 
In that case series, varying adalimumab dose schedules were described and the response 
was not analysed at fixed time points. 
In the present study, we analysed all patients who started with adalimumab 
monotherapy per label (40 mg every other week) and needed treatment adjustment. 
All analyses commenced at the starting point of intervention. We included all patients 
with 1) adalimumab dose escalation (40 mg every week), 2) addition of (low-dose) MTX 
to adalimumab 40 mg every other week (EOW), or 3) the combination of adalimumab 
dose escalation and addition of MTX. All data were collected in an academic hospital in 
the Netherlands in a daily practice setting. 
The objective of this study was to establish the effectiveness of these treatment strategies 
using the change in PASI after 12 and 24 weeks expressed as PASI 50, PASI 75, and the 
difference in mean PASI between time points (ΔPASI). In addition, the safety of these 
interventions in daily practice was described.
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Methods
Since 2005, daily practice data of all patients starting a biologic agent are collected 
prospectively at the department of Dermatology of the Radboud University Nijmegen 
Medical Centre. In general, patients were eligible for adalimumab treatment if they had 
failed to respond to phototherapy, MTX and/or ciclosporin in the past, or if they had a 
contraindication to or were intolerant for these treatment modalities. Patients needed to 
have a Psoriasis Area and Severity Index (PASI) of at least 10. Patients visited the clinic 6 
and 12 weeks after starting a biologic agent, and every 3 months thereafter.
For this study, we selected all patients with an insufficient response to 40 mg adalimumab 
every other week and requiring adalimumab dose escalation to 40 mg per week and/or 
addition of MTX. The decision whether a response to standard adalimumab dosing was 
considered ‘insufficient’ was made by the treating physician to his/her own discretion. 
The choice between pharmacological interventions (adalimumab dose escalation and/
or MTX addition) was also made by the treating physician. Data were analysed from the 
start of adalimumab treatment until discontinuation or the last date of data inclusion 
(July 13, 2012).
Effectiveness of the interventions was analysed in treatment episodes (TE). A treatment 
episode was defined as a continuous episode of a single intervention (adalimumab dose 
escalation or MTX addition). If a patient received more than one episode of the same 
intervention, the interventions were regarded as different TEs when interrupted for at 
least 6 weeks. In case a patient underwent two different interventions (adalimumab dose 
escalation and MTX addition), these interventions were considered as one combined 
TE when there was overlap in time, or as different TEs if there was no overlap in time. 
These combined episodes were analysed separately from the other treatment episodes 
described above. The PASI measurements were related to the interventions in a graph, to 
visualize the effects of the intervention.
Patients undergoing two TEs of adalimumab dose escalation were described separately 
as well. This separation was made because patients undergoing a second TE were 
probably good initial responders to adalimumab dose escalation. Hypothetically, they 
could respond differently compared with patients naïve for this intervention and/or the 
baseline PASI could be lower due to the ongoing effects of the first episode. 
Descriptive statistics were summarized for the total cohort. Clinical characteristics were 
summarized for the TE with first and second adalimumab dose escalation separately, 
MTX addition, or the combination of both. The analysis of third and fourth time 
adalimumab dose escalation was not described separately due to the low number of 
episodes. Effectiveness was expressed as PASI 50 (reduction of PASI of 50%) and PASI 75
(reduction of PASI of 75%). Mean PASI scores with standard error of the mean (SEM) 
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from baseline of treatment intervention until week 6, 12 and 24 were calculated (data 
are presented as mean PASI ± SEM). Differences in mean PASI (mean PASI at start of TE 
minus mean PASI at end of TE) at fixed time points were represented as ΔPASI. The PASI 
at different time points compared with the moment of intervention was analysed with 
a paired t-test. 
PASI courses were analysed using both an ‘as-treated’ analysis and an ‘intention-to-treat’ 
analysis with ‘last observation carried forward’ (ITT with LOCF). Analyses were performed 
on all available data per TE, but TEs were not allowed to overlap. In an ‘as-treated’ 
analysis, the focus is on the actual results for the remaining patients in the study at the 
time of analysis. To include ongoing effects after discontinuation of the intervention and 
to prevent for selection bias, ITT with LOCF is a good method.16 When PASI measurements 
were not available at the date of initiation of the treatment intervention, the PASI 
before or shortly (max. 2 weeks) after introduction of the treatment intervention, which 
represented the moment of initiation of the intervention best, was used.
Figure 1. Diagram of included patients and treatment episodes.
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Serious adverse events (SAEs) were recorded and the relation of the pharmacological 
intervention with the SAE was determined. Statistical analyses were done with PASW 
18.0 (Chicago).
Results
From the prospective database, 112 patients were identified who used adalimumab in 
the past or were still actively treated. Forty-five patients (40.2%) underwent one or more 
treatment adjustments of interest, consisting of 47 TE of adalimumab dose escalation, 
11 TE of addition of MTX to adalimumab 40 mg EOW, and 6 TE of adalimumab dose 
escalation combined with addition of MTX (Figure 1).
Patient characteristics
As show in Table 1, the mean age at the moment of inclusion (± SD) of all 45 patients was 
49.1 ± 13.6 years. Twenty-five patients were male (55.6%). Twelve patients (26.7%) were 
diagnosed with psoriatic arthritis. The mean body mass index (BMI) was 29.9 ± 6.3 kg/m2.
Thirty-seven patients were (previous) smokers (82.2%) and 30 patients (66.7%) were 
alcohol users. 
The median psoriasis duration was 20.9 [4.3-53.6] years at the time of starting adalimumab 
treatment in our hospital. A total of 66.9 patient-years (years actively treated with 
adalimumab) were analysed. 
All patients (n = 45)
Male gender, n (%) 25 (55.6)
Age at inclusion (years), mean ± SD 49.1 ± 13.6
Duration of psoriasis (years), median [range]a 20.9 [4.3 - 53.6]
Total patient-years in follow-up (years on adalimumab) 66.9
Episodes of ADA dose escalation, n 53
Episodes of MTX addition, n 17
Known diagnosis of psoriatic arthritis, n (%) 12 (26.7)b
Smoking (yes), n (%) 37 (82.2)c
Alcohol (yes), n (%) 30 (66.7)c
BMI (kg/m2), mean ± SD 29.9 ± 6.3
Table 1. Demographic and clinical characteristics of the patients treated with adalimumab EW, addition of 
methotrexate to adalimumab EOW, or the combination of MTX and adalimumab EW.
aOf 44 valid data. bFour cases unknown. cOne case unknown. ADA, adalimumab; EOW, every other week; 
EW, every week; MTX, methotrexate.
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Adalimumab dose escalation: all TE
A total of 47 TE of adalimumab dose escalation were identified and analysed, excluding 
combinations with MTX, which were analysed separately. Thirty-two, eleven, three and 
one dose escalations were given as a first, second, third and fourth TE, respectively 
(Figure 1).
Of all dose escalations (47 TE), the median treatment duration was 2.7 [0.4-27.4] months 
(Table 2). The mean PASI (± SEM) before dose escalation was 10.0 ± 0.9. Using an ‘as-
treated’ approach, the course of the mean PASI was 9.3 ± 0.9, 7.7 ± 1.1 and 5.1 ± 1.0 
after 6, 12 and 24 weeks, respectively (Table 3). After 12 weeks, 32% of TE resulted in 
PASI 50 and 3% in PASI 75. After 24 weeks, 47% of TE resulted in PASI 50 and 18% in
PASI 75 (Figure 2).
Figure 3 shows the PASI course using an ITT with LOCF approach. PASI 50 was achieved 
for 26% and PASI 75 for 2% of TE after 12 weeks. After 24 weeks, PASI 50 was achieved for 
36% and PASI 75 for 11% of TE.
Separate analysis of first and second TE of adalimumab dose escalation
Thirty-two dose escalation TE were administered as a first course of dose escalation and 
11 dose escalation TE were administered as a second course of dose escalation. Three 
All TE First 
episode of 
ADA dose 
escalationb
Second 
episode of 
ADA dose 
escalationb
Addition 
of
MTX
Combined episodes
(ADA dose
escalation and 
addition of MTX)
Number of TE 70 32 11 11 6
Duration of adalimumab dose 
escalation per TE (months)a
2.7
[0.4-27.4]
2.7
[0.5-24.3]
1.6
[0.4-27.4]
NA 4.6 ± 4.1
Total patient-years of adalimumab 
usea
66.9 NA NA NA NA
Total patient-years of adalimumab 
dose escalationa
21.1 12.5 4.9 NA 2.3
Adalimumab cumulative 
escalation dose per TE (mg)
474.3
[74.3-4771.4]
477.1
[80.0-4228.6]
285.7
[74.3-4771.4]
NA 795.3 ± 710.9
Duration of MTX use per TE 
(months)a
3.0
[0.5-16.9]
NA NA 3.0
[1.0-15.1]
5.2 ± 6.3
Total patient-years of MTX usea 6.15 NA NA 3.55 2.61
MTX cumulative dose per TE (mg) 94.7
[11.0-748.2]
NA NA 105.7
[11.0-748.2]
92.2
[19.9-625.0]
Weekly dose of MTX per TE (mg) 10.0
[2.5-14.1]
NA NA 9.5 ± 3.2 9.8
[5.6-10.0]
Table 2. Clinical characteristics per pharmacological intervention.
aMedian duration of intervention until discontinuation of adalimumab or July 13 2012 (last date of data 
inclusion). bA separate analysis of the third and fourth episodes was omitted due to an insufficient number 
of TE. Mean ± SD or median [range]. ADA, adalimumab; MTX, methotrexate; NA, not applicable.
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and one patients received a third or fourth course of adalimumab dose escalation, 
respectively (Figure 1).
The 32 first time dose escalations had a median duration of 2.7 [0.5-24.3] months 
(Table 2). As shown in Table 3, the last mean (± SEM) PASI before intervention was 10.6 
± 1.2. The mean PASI was 9.7 ± 1.3, 8.7 ± 1.7 and 5.3 ± 1.6 after 6, 12 and 24 weeks, 
respectively, using an as-treated analysis. Figure 4 shows the PASI course using an ITT 
with LOCF approach. After 12 weeks, PASI 50 was achieved in 25% of TE. PASI 75 was 
not achieved at that time (ΔPASI all first TE: 1.6, ΔPASI of responders: 8.8). After 24 
weeks, 34% of TE achieved PASI 50 and 9% PASI 75 (ΔPASI all first TE: 2.5, ΔPASI of 
Figure 2. Efficacy of adalimumab dose escalation, all treatment episodes (as-treated analysis).
Figure 3. Efficacy of adalimumab dose escalation, all treatment episodes (ITT with LOCF).
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responders: 8.9). The mean PASI of the whole group had significantly decreased after 
24 weeks (p = 0.03), but not after 12 weeks (p = 0.14). The number needed to treat 
(NNT) to identify one responder (PASI 50) after 12 weeks in patients naïve for dose 
escalation was 4.
The 11 second time dose escalations lasted 1.6 [0.4-27.4] months (Table 2). The mean 
PASI was 8.2 ± 1.3 shortly before commencing the second-time dose escalation and
8.1 ± 1.7, 5.5 ± 1.4 and 4.2 ± 0.8 after 6, 12 and 24 weeks, respectively (as-treated analysis) 
(Table 3). 
Figure 5 shows the PASI course of the first and second episode using an ITT with LOCF 
analysis. The second episodes started with a slightly lower mean PASI (8.2) compared with 
the first episode (mean PASI 10.6). This could be due to the fact that most patients who 
received a second episode, had a good response on their first TE with dose escalation. 
Consequently, these responses could still be positively influencing the baseline PASI of the 
second episode. Also, the ΔPASI of the first episode was higher compared with the second 
episode (4.4 vs. 2.5) after 24 weeks. Note that this could be due to the lower baseline PASI 
of the latter as well. The achieved mean PASI after 24 weeks was comparable for these 
episodes (mean PASI 5.0 vs. 5.6).
Addition of MTX without adalimumab dose escalation
Eleven TE of MTX addition combined with normal adalimumab dosing were analysed 
(six combined TE of adalimumab dose escalation and MTX addition were analysed 
separately). A mean weekly dose of 9.5 ± 3.2 mg MTX per TE was used with a median 
duration of 3.0 [1.0-15.1] months (Table 2). The last PASI (± SEM) before addition of MTX 
was 9.8 ± 1.9. The mean PASI was 9.4 ± 2.2, 7.9 ± 3.2 and 11.4 ± 9.1 after 6, 12 and 24 
Figure 4. Efficacy of adalimumab dose escalation, first episode (ITT with LOCF).
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weeks, respectively, using an ‘as-treated’ approach (Table 3).
Using an ITT with LOCF approach, PASI 50 and PASI 75 was achieved for 9% of TE after 
12 weeks (ΔPASI of all patients: 1.2, ΔPASI of responders: 5.9). After 24 weeks, PASI 50
was achieved for 18% and a PASI 75 for 9% of TE (ΔPASI of all patients: 1.1, ΔPASI of 
responders: 7.1). There was no significant difference in mean PASI for the whole group 
after 12, nor after 24 weeks (Figure 6, Table 4).
Table 3. Mean PASI after 6, 12 and 24 weeks of intervention (adalimumab dose escalation or MTX addition 
to adalimumab 40 mg EOW), as-treated analysis.
Pharmacological intervention Baselinea Week 6  Week 12 Week 24 
Adalimumab dose escalation
Number (n) of patients with increase of adalimumab 
frequency (1st, 2nd, 3rd and 4th episodes)b
47 45 34 17
PASI ± SEM 10.0 ± 0.9 9.3 ± 0.9 7.7 ± 1.1 5.1 ± 1.0
Number (n) of patients with increase of adalimumab 
frequency, first episode onlyb
32 30 21 10
PASI ± SEM 10.6 ± 1.2 9.7 ± 1.3 8.7 ± 1.7 5.3 ± 1.6
Number (n) of patients with increase of adalimumab 
frequency, second episode onlyb
11 11 9 5
PASI ± SEM 8.2 ± 1.3 8.1 ± 1.7 5.5 ± 1.4 4.2 ± 0.8
Methotrexate addition (to adalimumab 40 mg EOW)
Number (n) of patients with MTX addition 11 10 7 3
PASI ± SEM 9.8 ± 1.9 9.4 ± 2.2 7.9 ± 3.2 11.4 ± 9.1
aThe last PASI measured before or shortly after the pharmacological intervention. bA separate analysis of 
the third and fourth episodes was omitted due to an insufficient number of TE. PASI, Psoriasis Area and 
Severity Index.
Table 4. PASI response of patients with a first episode of adalimumab dose escalation or MTX addition to 
adalimumab 40 mg EOW after 12 and 24 weeks, ITT with LOCF analysis.
Adalimumab dose escalation 
(first episode) (n = 32)
MTX addition
(n = 11)
PASI 50a at week 12, n (%) 8 (25) 1 (9)
PASI 75a at week 12, n (%) 0 (0) 1 (9)
ΔPASIa at week 12, all patients 1.6 (p = 0.14) 1.2 (p = 0.3)
ΔPASIa at week 12, respondersb 8.8 5.9
PASI 50a at week 24, n (%) 11 (34) 2 (18)
PASI 75a at week 24, n (%) 3 (9) 1 (9)
ΔPASIa at week 24, all patients 2.5 (p = 0.03) 1.1 (p = 0.05)
ΔPASIa at week 24, respondersb 8.9 7.1
aPASI at the moment of initiation of the intervention was used for comparison. bPatients with PASI 50 
response. PASI, Psoriasis Area and Severity Index.
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Adalimumab dose escalation combined with methotrexate
Six patients received adalimumab dose escalation and addition of methotrexate with 
significant overlap in time. Since all six patients received only one combined TE each, we 
refer to ‘patients’ instead of ‘TE’ in this section. Adalimumab dose escalation was given 
with a mean cumulative dose of 795.3 ± 710.9 mg per TE for a mean duration of 4.6 ± 4.1 
months (Table 2). MTX was given with a median weekly dose of 9.8 [5.6-10.0] mg per TE 
with a mean duration of 5.2 ± 6.3 months.
Figure 7 shows the PASI course for these six patients. The black arrow represents the 
introduction of MTX in patient 1. All other patients received adalimumab dose escalation 
and MTX introduction simultaneously (week 0 in Figure 7). As can be seen in Figure 7, 
patients 3, 4 and 5 show an initial improvement in PASI. The deterioration of the PASI 
in patient 2 is stabilized after the introduction of MTX and adalimumab dose escalation. 
Patients 1 and 6 show a (further) increase in PASI.
Serious adverse events
Two serious adverse events were recorded after adalimumab dose escalation. One patient 
died due to bleeding of oesophageal varices, which was considered probably unrelated to 
adalimumab treatment. This patient suffered from liver cirrhosis and oesophageal varices 
with bleeding as a complication of cirrhosis. Another patient experienced an exacerbation 
of psoriasis, 13 months after adalimumab dose escalation. He was still using adalimumab 
in an escalated dose when he was admitted to the hospital. This event was considered 
to be probably unrelated, since he had been using an escalated dose of adalimumab for 
months. No SAEs were reported after the addition of MTX.
Figure 5. PASI course of 11 patients after introduction of adalimumab dose escalation as a first and second 
TE (ITT with LOCF).
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Discussion
In this prospective observational cohort study, we described the effect of dose escalation 
of adalimumab and combination therapy of MTX with adalimumab. Twenty-five percent 
of first TE with adalimumab dose escalation resulted in a PASI 50 response after 12 
weeks and 34% after 24 weeks. In TE with adalimumab in a standard dose, addition of 
methotrexate resulted in a PASI 50 response in 9% after 12 weeks and 18% after 24 weeks.
All first adalimumab dose escalations resulted in a ΔPASI of 1.6 after 12 weeks. The 
ΔPASI of responders to a first TE was 8.8 after 12 weeks. When second, third and fourth 
adalimumab treatment episodes were taken into account, the percentage of PASI 50 
responders increased to 36% after 24 weeks.
The addition of MTX to adalimumab EOW induced a PASI 50 response in 9% of TE after 12 
weeks. The ΔPASI of the whole group was 1.2 after 12 weeks; the responders achieved a 
ΔPASI of 5.9 after 12 weeks. These results indicate that a subgroup of patients benefited 
from these treatment strategies, but that the ΔPASI was hampered by the influence of 
nonresponders. The combination of both strategies showed mixed results.
Second episodes of adalimumab dose escalation were analysed separately as well. The 
mean PASI in the second episode group was slightly lower at start of the second TE 
compared with the first. This could be due to the fact that most patients who received a 
second episode had a good response on their first TE with dose escalation. Consequently, 
these responses could still be positively influencing the baseline PASI of the second 
episode. The ΔPASI of the first episode was higher compared with the second episode 
Figure 6. Efficacy of methotrexate addition to adalimumab 40 mg EOW, all treatment episodes (ITT with LOCF).
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(4.4 vs. 2.5) after 24 weeks. Note that this could also be due to the lower baseline PASI 
of the latter. The achieved mean PASI after 24 weeks was comparable for these episodes 
(mean PASI 5.0 vs. 5.6). In some patients, the normal dosage schedule (40 mg every other 
week) does not induce a sufficient response.
Both pharmacological interventions (and the combination of both) were well tolerated 
in this study. Two SAEs were reported after adalimumab dose escalation and were 
considered ‘probably unrelated’. No SAEs were reported shortly after the introduction of 
MTX. Although both pharmacological interventions seemed safe in this relatively small 
group, attention for safety in treatment with these agents is still needed.
The REVEAL study showed that 71% responded, which means that 29% of the patients 
did not achieve a PASI 75 response after 16 weeks of adalimumab treatment in a standard 
dose.1 Compared with a study of Leonardi et al., the present study is in line with the 
percentage of people benefiting from adalimumab dose escalation for psoriasis in a 
randomized controlled trial.4 A difference is that Leonardi et al. showed that 25% achieved 
Figure 7. PASI course of 6 patients with a combined TE (adalimumab dose escalation and MTX addition).
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PASI 75 compared with PASI 50 for 25% in this daily practice study.4 Although PASI 50 is 
lower than PASI 75, it is considered a clinical meaningful response.
It has been described before that the effects of TNF-antagonists in patients with 
rheumatoid arthritis in daily practice studies are usually smaller than in RCTs.17 It is 
plausible that this phenomenon is seen in psoriasis research as well. Another important 
issue is that in most RCTs, the PASI change is analysed using the first PASI at the start of 
biological treatment as a comparator. In this study, the PASI at the start of the intervention 
is chosen as a comparator, which leads to lower responder percentages. In our opinion, 
the PASI before intervention is more appropriate since at the moment of intervention, a 
significant change in PASI (PASI 50 or PASI 75) is desired.
A factor that could influence the response to a biologic is the previous treatment with 
other biologics. In the literature, the response to a second biologic was lower in some 
studies in RA. To date, there has been no convincing evidence that treating a patient with 
a second biologic is less effective than the first in dermatology.
In this study, we showed that four patients had to be treated with adalimumab dose 
escalation to identify one responder (defined as at least a PASI 50) (NNT = 4). This NNT 
must be carefully weighed against the costs that dose escalation of adalimumab entail. 
However, a decision must be made for every individual patient since other issues are 
important as well for successful treatment, such as long-term maintenance. It is important 
to use the full potential of a treatment before switching to another, as switching reduces 
the number of available treatment options.
This study has some limitations that need to be kept in mind. Firstly, analysing more 
treatment episodes in a single patient gives rise to the problem that effects can be carried 
forward to the next episode. It must be taken into account that a lower PASI at the start 
of the next episode hampers the netto effect (ΔPASI). Secondly, interpreting efficacy data 
is highly dependent on the method of analysis.16 An as-treated analysis and intention-
to-treat with last observation carried forward analysis were therefore both used, with 
emphasis on the latter. ITT with LOCF carries forward the ongoing effects of ceased 
interventions and therefore provides a better reflection of the real effects as both success 
and failure are frequently characterized by ending the intervention. Thirdly, it must also 
be noted that our patients treated with additional MTX received a relatively low dose 
of MTX and in some cases only for short episodes. Long-term MTX addition in a higher 
dose could lead to better results and therefore could be interesting for further studies. In 
addition, the study is based on a limited number of patients.
Adalimumab dose escalation and/or addition of methotrexate were good strategies for 
increasing efficacy in a subgroup of patients with an insufficient response to adalimumab 
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40 mg every other week. For safety and cost issues, it may be important to escalate the 
dose for a limited period of time. If a patient responds well, the dose can be de-escalated 
again. As can be seen in this study, these patients can start a dose re-escalation for a 
second period. In this daily practice study, it was not possible to define characteristics of 
(non)responders. Previously it was shown that secondary nonresponders, patients with 
a body weight of ≤102 kg and a disease duration <8.3 years were most likely to benefit 
from adalimumab dose escalation.4 Defining subgroups of patients who will respond to 
the various treatment strategies in daily practice is a challenge for future studies.
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Abstract
Background
A problem encountered when analysing long-term efficacy is that the number of patients 
in follow-up decreases with time for different reasons. The method used to account for 
missing observations for the therapy under analysis has a great influence on the inference 
of efficacy.
Objectives
To describe the long-term efficacy of etanercept for psoriasis in daily practice using 
3 analytical approaches. 
Methods
Prospective data from a cohort of patients with psoriasis treated with etanercept for at 
least 24 weeks were analysed using 3 analytical approaches: as-treated analysis, intention-
to-treat analysis (ITT) with last observation carried forward (LOCF) and intention-to-treat 
analysis with modified nonresponder imputation (modified NRI). 
Results
One hundred thirty-one patients were treated with etanercept during 134 treatment 
episodes with a mean treatment duration of 2.7 years. The maximum follow-up was 6.0 
years. The methodological approach chosen had a great influence. Psoriasis Area and 
Severity Index (PASI) 75 response rates varied from 60% in the as-treated approach to 
34% in LOCF and to 29% in modified NRI at week 264. 
Limitations 
All analytical methods applied have limitations. Other outcome measures could be used 
to overcome the bias introduced by each method of analysis, such as drug survival.
Conclusions
The methodological approach chosen to analyse long-term efficacy data has a great 
influence on the inferences that may be drawn regarding the degree of efficacy. Therefore 
we support the use of different methods to present long-term efficacy data.
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Introduction
The efficacy and safety of etanercept for psoriasis have been studied in randomized 
controlled trials with open-label extension studies for up to 4 years of treatment.1-3 
Open-label extension studies have shown some loss of efficacy of etanercept after week 
48-52.2,3 However, the results from randomized controlled trials (RCTs) may not reflect 
the daily clinical practice situation, as patients included in RCTs are highly selected and 
treated according to a predefined treatment schedule. There are few reports on the 
management of unselected patients in day-to-day practice, especially in the long term. 
This study provides complementary information to RCTs about the efficacy and safety of 
etanercept for psoriasis in daily practice up to 300 weeks of treatment.
Observational cohort studies can be analysed according to the intention-to-treat (ITT) 
principle and the as-treated principle. The intention-to-treat principle was originally 
designed for the analysis of RCTs. In an intention-to-treat analysis, all patients are 
analysed according to the initial treatment intent following randomization, irrespective 
of the treatment actually received. This is different from an as-treated analysis, in which 
the analysis is based on the treatment that patients actually received. 
A problem encountered when analysing long-term efficacy data is that the number of 
patients with available efficacy data for the therapy under analysis decreases with time. 
In observational studies, inclusion of patients is continuously ongoing. At the time of 
analysis a data lock is performed, including patients with a short follow-up for the therapy 
under analysis. Furthermore, in some patients, biologic therapy is discontinued because 
of insufficient efficacy or intolerance. In that case, efficacy data for the therapy analysed 
are not available anymore and can only be measured when patients are on another 
therapy or no therapy. In addition, in case of loss of follow-up, outcome measures cannot 
be measured anymore. 
In an ITT analysis, none of the patients are excluded from the analysis. This is different 
from an as-treated analysis, in which patients with insufficient follow-up for the therapy 
under analysis are excluded from the analysis. In order to include patients with missing 
efficacy data for the therapy under analysis in the ITT analysis, the last observation 
available for the therapy analysed can be extrapolated, which is also applied in the RCTs 
with etanercept for psoriasis. This involves making assumptions about the outcomes, 
which can be done with the last observation carried forward (LOCF) method or the 
(modified) nonresponder imputation ((modified) NRI) method. 
The method used has a great influence on the inference of efficacy.4, 5 The ITT analysis with 
(modified) nonresponder imputation approach may give a too negative view of the efficacy 
of etanercept. On the other hand, the as-treated analysis introduces a bias towards a too 
positive outcome. The ITT analysis with LOCF approach produces intermediate results. 
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The primary objective of this study was to describe the long-term efficacy of etanercept 
therapy for psoriasis in daily practice and to compare 3 analytical approaches. Efficacy 
was expressed as the percentage of patients reaching a reduction of the Psoriasis Area 
and Severity Index (PASI)6 of 50% (PASI 50), 75% (PASI 75) or 90% (PASI 90). Results are 
described as follows: as-treated analysis, LOCF, and modified NRI.4 
Patients and methods
Patients
This prospective cohort study involved all consecutive patients with psoriasis treated with 
etanercept between February 2005 and February 2011 for at least 24 weeks. Efficacy 
data were extracted from a prospective patient registry, containing data from all patients 
starting biological treatment for psoriasis in the Dermatology outpatient department 
of the Radboud University Nijmegen Medical Centre.7 In the Netherlands, biological 
treatment was approved for the treatment of patients with psoriasis who had not 
responded to phototherapy, methotrexate and ciclosporin, or who had contraindications 
to, or did not tolerate these therapies. Furthermore, a PASI6 of at least 10 was required.
The study protocol was presented to the institutional review board (IRB). A formal IRB 
procedure was considered unnecessary by the board because of the noninterventional 
character of the study.
Methods
Efficacy and safety evaluations were scheduled at baseline, week 6 of treatment, week 12, 
and subsequently every 12 weeks. At baseline, demographic information and information 
about the medical history, previous medication use for psoriasis and concomitant 
medication was collected. PASI scores were collected at baseline and at each subsequent 
visit, as well as information on concomitant medication use and adverse events.
The long-term efficacy of etanercept was investigated in patients with a follow-up of at 
least 24 weeks. The primary objective of this study was to analyse the percentage of 
patients achieving a 50%, 75% or 90% reduction in PASI (PASI 50/75/90) at multiple time 
points.
Treatments were analysed as separate treatment episodes. A new treatment episode was 
started when patients started a new biologic therapy or when the same biologic was 
restarted after an interruption lasting 6 months or longer.
In this daily practice study, hospital visits did not always take place at the scheduled 
time points (week 6, week 12, and subsequently every 12 weeks). In that case, PASI 
scores at the scheduled time points were obtained with interpolation, using the PASI 
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score at the hospital visit closest before the scheduled time point and the PASI score at 
the hospital visit closest after the scheduled time point. This was done using the linear 
function y = ax + b, in which a is the slope of the curve representing the course of the 
PASI score between the two hospital visits closest to the scheduled time point and b is 
the PASI score measured at the hospital visit closest before the scheduled time point. 
Extrapolation of PASI scores obtained before a scheduled time point was allowed up to 
maximal 7 days of extrapolation, using the same linear function.
The long-term efficacy of etanercept was analysed in 3 ways. The following approaches 
were used: (1) analysis of continuing patients only (as-treated analysis), (2) ITT analysis 
with imputation of missing PASI data for etanercept therapy over the remainder of the 300 
weeks using LOCF and (3) ITT analysis with imputation of missing PASI data for etanercept 
therapy using the modified nonresponder imputation approach (modified NRI).2, 4
The LOCF method carries forward the last available PASI score until the last evaluation 
time point. With the nonresponder imputation method, patients with missing PASI scores 
for etanercept therapy at predefined evaluation time points are assumed not to have 
achieved binary efficacy endpoints (PASI 50/75/90).2 In this study, a less conservative 
modification of the nonresponder imputation approach as described by Papoutsaki et al.4 
was used, as the inclusion of patients in this observational cohort study is continuously 
ongoing; nonresponder imputation for patients who were still taking etanercept at the 
time of analysis but did not reach subsequent evaluation time points was considered 
inappropriate. 
The modified NRI method consists of analysing patients as nonresponders for the
PASI 50/75/90 calculation in case the patient discontinued etanercept due to loss 
of efficacy or a combination of loss of efficacy and adverse events, whereas the last 
available PASI was carried forward in case a patient discontinued etanercept treatment 
due to adverse events only or other reasons. In case the patient was lost to follow-up or 
in case the patient was still taking etanercept but the length of follow-up did not reach 
the subsequent evaluation time points, the last available PASI was carried forward as 
well.2, 4 
 
In this ongoing registry, patients started etanercept treatment at different time points 
before the moment of analysis. Therefore in the ‘as-treated analysis’ the number of 
available PASI data of patients treated with etanercept decreases over time according to 
the length of follow-up or the cessation of treatment. In the intention-to-treat analysis 
with imputation using the LOCF approach or the modified NRI approach the number of 
patients in follow-up remains constant, as a result of the methods used to account for 
missing PASI scores for etanercept therapy. 
Patients were treated according to the opinion of the treating physician, including dose and 
interval changes of etanercept therapy and the addition of topical or systemic therapies.
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Statistics
Descriptive statistics were used to represent study results as percentages, means
(± standard deviation (SD)) and medians (range). 
Results
Patients
The cohort consisted of 131 patients treated with etanercept during 134 treatment 
episodes lasting for 24 weeks or longer. The number of patient-years of follow-up was 362. 
Eighty-one patients were male (62%), the mean age at the start of etanercept treatment 
was 47.5 (± 11.4) years, and the mean duration of psoriasis was 22.4 (± 10.6) years (Table 1).
The mean body mass index (BMI) was 28.7 (± 5.6) kg/m2 and 40 patients (31%) suffered 
from psoriatic arthritis. The mean duration of an etanercept treatment episode was 2.7 
(± 1.6) years. The median duration was 2.4 years (range 0.5 – 6.0 years).
The number of different systemic therapies (including biologics applied in our hospital, 
other hospitals, and in clinical trials) that patients had used before the start of an 
etanercept treatment episode in daily practice and enrolment in the registry varied 
between 2 and 8; the mean number was 4.8 (± 1.4). Forty-three patients (33%) had been 
treated with at least one biologic before the start of etanercept in daily practice and 
enrolment in the registry. This mainly concerned biologic treatment in the context of 
clinical trials. 
Forty-two etanercept treatment episodes (31%) were combined with at least one 
concomitant systemic antipsoriatic therapy as bridge therapy when transitioning to 
biologic treatment, as rescue therapy during the course of biologic treatment because of 
unsatisfactory efficacy or as a continuous concomitant therapy. Five etanercept treatment 
episodes were consecutively combined with 2 different systemic antipsoriatic therapies. 
Twenty-four etanercept treatment episodes were combined with methotrexate, 11 with 
acitretin, 9 with ciclosporin, 2 with fumarates and 1 with mycophenolate mofetil. 
The median time between the start of etanercept and the start of a concomitant systemic 
therapy as add-on therapy was 27 weeks (range 1 – 202 weeks). The mean weekly dose 
of etanercept was 64.1 (± 14.0) mg.
Treatment status
From this cohort, 114 patients completed one year of treatment, 76 completed two 
years, 52 patients completed three years, 34 patients completed four years, and 16 
patients completed five years of therapy (Figure 1). These patients were actively being 
treated with etanercept at the time of analysis. Thirty-seven treatment episodes (28%) 
were discontinued due to loss of efficacy, 12 (9%) due to adverse events, 3 (2%) due to 
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a combination of loss of efficacy and adverse events, 2 patients (1%) died and 2 female 
patients (1%) discontinued etanercept therapy because of a pregnancy wish. In addition, 
15 patients (11%) were lost to follow-up.
Efficacy
As-treated analysis
Results from the as-treated analysis are presented in Figures 2-4. At week 24, 67.9% (n = 91),
38.1% (n = 51) and 14.9% (n = 20) of treatment episodes resulted in PASI 50, PASI 75 
and PASI 90, respectively. Efficacy continued to improve through week 288. A PASI 75 
response was obtained in 36.6% of treatment episodes (n = 41) at week 48, 40.8% (n = 29)
at week 108, 50.0% (n = 26) at week 156, 59.4% (n = 19) at week 204 and 60% (n = 9) at 
week 264. The PASI 50 and PASI 90 response rates are presented in Figures 2 and 4. 
Patient characteristics n = 131
Male gender, n (%) 81 (62%)
Age (years)
Mean ± SD 47.5 (11.4)
Median (range) 47.9 (21.7-77.3)
Duration of psoriasis (years)
Mean ± SD 22.4 (10.6)
Median (range) 20.8 (1.9-46.2)
Body mass index (kg/m2)
Mean ± SD 28.7 (5.6)
Median (range) 28.1 (15.9-54.1)
Psoriatic arthritis, n (%) 40 (31)
Previous classical systemic therapies, n (%)
Ultraviolet (UV) B 116 (89)
Psoralen plus UVA 91 (69)
Methotrexate 127 (97)
Ciclosporin 97 (74)
Acitretin 81 (62)
Fumarates 58 (44)
Azathioprine 2 (2)
Previous biologic therapies, n (%)
Etanercept 16 (12)
Efalizumab 15 (11)
Alefacept 11 (8)
Onercept 7 (5)
Adalimumab 3 (2)
Infliximab 2 (2)
Table 1. Patient characteristics.
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Figure 1. Patient disposition. 
*These patients were actively being treated with 
etanercept at the time of analysis and included in the 
efficacy analysis until the last available visit.
t = 0
134 treatment episodes
5 lack/loss of efficacy
3 adverse event
10 lost to follow-up
2 follow-up < 1 year*
n = 114 completed
1 year of therapy
10 lack/loss of efficacy
6 adverse event
2 lack/loss of efficacy and adverse event
2 lost to follow-up
1 pregnancy wish
2 deceased
15 follow-up 1-2 years*
n = 76 completed
2 years of therapy
n = 52 completed
3 years of therapy
n = 34 completed
4 years of therapy
n = 16 completed
5 years of therapy
11 lack/loss of efficacy
1 adverse event
3 lost to follow-up
9 follow-up 2-3 years*
7 lack/loss of efficacy
1 adverse event
1 pregnancy wish
9 follow-up 3-4 years*
4 lack/loss of efficacy
1 adverse event
1 lack/loss of efficacy and adverse event
12 follow-up 4-5 years*
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Last observation carried forward (LOCF)
Efficacy results at week 24 were the same as in the as-treated analysis. Data from the 
LOCF analysis show almost constant efficacy over time, although there is some loss of 
efficacy. A PASI 75 response was obtained in 35.1% of treatment episodes (n = 47) at
week 48, 35.1% (n = 47) at week 108, 38.1% (n = 51) at week 156, 37.3% (n = 50) at 
week 204 and 34.3% (n = 46) at week 264. The PASI 50 and PASI 90 response rates are 
presented in Figures 2 and 4. 
Modified nonresponder imputation (modified NRI)
Efficacy results at week 24 were the same as in the as-treated analysis. This approach 
shows declining efficacy. A PASI 75 response was obtained in 34.3% of treatment episodes 
(n = 46) at week 48, 32.8% (n = 44) at week 108, 34.3% (n = 46) at week 156, 32.8% (n = 44)
at week 204 and 29.1% (n = 39) at week 264. The PASI 50 and PASI 90 response rates are 
presented in Figures 2 and 4. 
Discussion
As shown in this study, the methodological approach chosen to analyse long-term efficacy 
has a great influence on the efficacy results. As an example, the PASI 75 response rate 
varied from 60% in the as-treated approach to 34% in LOCF and 29% in modified NRI 
at week 264. This means that efficacy doubled when the as-treated approach was used 
instead of modified NRI. Therefore, when comparing efficacy data from different studies, 
it is important to consider the analysis method used. 
With the as-treated approach, a selection bias is introduced, as patients who are treated 
for a long time are usually the patients who respond well to a certain therapy.2 As reflected 
Figure 2. PASI 50 response by analysis method.
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in this study, the most frequent reason for discontinuing etanercept treatment was loss 
of efficacy or a combination of loss of efficacy and adverse events. This information is left 
out of consideration in the as-treated analysis.4 
In the short-term RCTs with etanercept for psoriasis, a modified ITT analysis with missing 
efficacy data imputed using LOCF was used as the primary efficacy analysis.8-11 The 
problem with using LOCF for analysing long-term efficacy results is that efficacy data 
may be carried forward for a very long time and that this analysis method assumes that 
efficacy will remain constant, consistent with the last known value.4 
The LOCF method is a single imputation method. Besides single imputation methods, 
multiple imputation methods exist, which may be more accurate. Instead of filling in a 
single value for each missing value, multiple imputation replaces each missing value with 
a set of plausible values that represent the uncertainty about the right value to impute.12 
The most conservative approach is NRI, in which patients with missing efficacy data for a 
specific therapy at predefined evaluation time points are assumed not to have achieved 
binary efficacy endpoints (PASI 50/75/90), irrespective of the reason of missing data and 
the actual PASI improvement.2 
Applying NRI in an observational cohort study is problematic, as the inclusion of patients 
in such studies is continuously ongoing. At the time of analysis, a data lock is performed, 
including patients with a short follow-up period. Applying NRI for patients who were still 
treated with etanercept at the time of analysis but did not reach subsequent evaluation 
time points was considered inappropriate. Therefore, in this study, a less conservative 
modification of the NRI approach, as described by Papoutsaki et al.4 was used. The 
advantage of the modified NRI approach is that reasons for missing PASI scores for 
etanercept therapy are taken into account.
All 3 analysis methods introduce a bias; therefore the true efficacy of etanercept is 
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Figure 3. PASI 75 response by analysis method.
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unknown. A way to overcome this problem is to change the outcome measure. A possible 
outcome measure could be represented by the amount of time patients remain on a 
specific treatment, which is also referred to as ‘drug survival’. Drug survival is a surrogate 
measure of treatment success, as it depends on the efficacy of the drug. However, 
drug survival is also dependent on tolerance, general satisfaction with the treatment, 
and patients who are lost to follow-up.13 An alternative outcome measure could be 
represented by the number of patients with psoriasis in remission at specific time points. 
However, there are no biomarkers for remission of psoriasis available at this moment. 
The PASI 50/75/90 response rates at week 12 and 24 in this study in patients treated with 
etanercept in daily practice are lower than that reported in the RCTs.8-11 The difference in 
efficacy between RCTs and daily practice could be explained by multiple factors. Patients 
in daily practice are possibly more therapy-resistant or show less efficacy of treatment 
because of comorbidity, concomitant medication, intercurrent infections, or interruptions 
of therapy due to infections or elective surgery. On the other hand, patients in daily 
practice can use concomitant topical or systemic therapies for psoriasis, which may have 
biased the efficacy results of etanercept towards a more favourable outcome. Because of 
the variability in concomitant topical and systemic therapies used and the variability in 
dosages used, this source of bias was not addressed.
In conclusion, the methodological approach chosen to analyse long-term efficacy has a 
great influence on the efficacy results. Therefore we support the use of all 3 methods to 
present long-term efficacy and the use and development of other outcome measures.
Figure 4. PASI 90 response by analysis method. Efficacy results for the LOCF approach and modified NRI 
approach are equal. 
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Abstract
Background
The cumulative exposition to biologics is increasing with prolonged treatment with a 
certain biologic or consecutive biological treatment. However, long-term safety data are 
limited available.
Objectives
The aim of this study was to prospectively evaluate the 5-year safety of biological 
treatment for psoriasis in daily practice.
Methods
A cohort of 173 psoriasis patients on biologics was prospectively followed for 5 years. 
All adverse events reported were documented and analysed. Primary endpoint was 
the percentage of patients reporting at least one serious adverse event. The rate of 
malignancies, serious infections and serious cardiovascular events was compared with the 
general population incidence rate. The nature and rate of dermatological adverse events 
was compared with a group of prospectively followed rheumatoid arthritis patients on 
TNF-α blocking therapy.
Results
Between February 2005 and April 2010, 173 patients were enrolled in the registry and 
went through a total number of 263 treatment episodes. The total number of patient-
years of follow-up in the registry was 409. The number of patient-years was the highest 
for etanercept. Forty-nine patients (28%) reported 88 serious adverse events. Only one 
serious adverse event was certainly causally related to the biologic and 21 events (24% of 
SAEs) were considered possibly related. The incidence of malignancies, serious infections 
and serious cardiovascular events was comparable with the population incidence rate, 
except for skin malignancies. The incidence of skin malignancies was significantly higher 
than the general population incidence rate. The nature and rate of dermatological adverse 
events differed from the rheumatoid arthritis cohort.
Conclusions
In this cohort, the safety of biological therapies for psoriasis was favourable with a low 
incidence of therapy-related serious adverse events.
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Introduction
The safety of biological treatment for psoriasis is an important issue. Concerns exist about 
a possible increased risk of cancer, including nonmelanoma skin cancer and lymphomas 
in psoriasis patients treated with TNF-inhibitors.1 A potential risk for the development of 
other malignancies cannot be excluded based on the current knowledge either.2 Other 
important safety aspects are the development of or worsening of pre-existing heart 
failure and demyelinating diseases and drug-induced lupus for the TNF-α blockers and 
infections for the biologics in general.2, 3 
The cumulative exposition to biologics is increasing with prolonged treatment with a 
certain biologic or consecutive biological treatment, but long-term safety data are limited 
available. Moreover, these patients often already have an increased risk of malignancies 
due to previous UV phototherapy, particularly PUVA and/or the use of immunosuppressive 
drugs.1 Dermatological conditions have been shown to be a significant and clinically 
important problem in rheumatoid arthritis patients receiving TNF-α blocking therapy.4 
We now present 5-year safety data of biological treatment for psoriasis in daily practice 
with a focus on serious adverse events (SAEs). 
Methods
Patients
All consecutive patients starting biological treatment for psoriasis in the Dermatology 
outpatient clinic of the Radboud University Nijmegen Medical Centre are enrolled in a 
registry, in which efficacy and pharmacovigilance data are collected.5-7 In the Netherlands, 
biological treatment is approved for the treatment of psoriasis patients who have not 
responded to phototherapy, methotrexate and ciclosporin, or who have contraindications 
to, or do not tolerate these therapies. Furthermore, a PASI8 of at least 10 is required. 
Protocol
Screening procedures included a chest X-ray, Mantoux test, urine screening, routine 
chemistry and haematology, antinuclear antibodies (ANA), hepatitis serology and a 
serum pregnancy test if applicable. A general blood screening was repeated every 12 
weeks during therapy (Table 1).
Patients were treated according to the opinion of the dermatologist, including dose 
and interval changes and the addition of topical or systemic therapies. Women of 
childbearing potential were strongly recommended to use adequate contraception to 
prevent pregnancy.
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Outpatient clinic visits were planned every 4 to 6 weeks during the first 12 weeks of 
treatment, every 6 weeks until week 24 and every 12 weeks afterwards. Demographic 
data, the medical history and previous (antipsoriatic) medication use were recorded at 
the time of screening. Adverse events were prospectively collected at each hospital visit. 
Analysis
Reported adverse events and comorbidities were categorized in line with the ICD-10.9 
Primary endpoint was the percentage of patients reporting at least one SAE. The SAE rate 
was compared with the general population incidence rate from a Dutch general practice 
registry (CMR).10, 11 The CMR collects data concerning all morbidity that patients present to 
the involved general practitioners, including diagnoses made by specialists after referral.
Adverse events were defined as serious in case of life-threatening events, events requiring 
(prolongation of) inpatient hospitalization, congenital anomalies and events resulting in 
persistent or significant disability/incapacity or death.12 
The nature and rate of dermatological adverse events was compared with an article about 
a group of prospectively followed rheumatoid arthritis (RA) patients on TNF-α blockers 
from the same hospital, who were followed in the same way as the present cohort.4 
Adverse events were analysed per patient as well as per treatment episode. A new 
treatment episode was started when patients started a new biologic therapy or when the 
same biologic was restarted after an interruption lasting more than 6 months. The number 
of patients having at least one adverse event in a predefined category was represented. 
Patient characteristics were expressed as numbers (percentages) and means (± standard 
deviation (SD)). 
Chemistry Haematology Additional
Creatinine Haemoglobin Antinuclear antibodies*
C-reactive protein (CRP) Haematocrit Hepatitis B/C serology*
Direct bilirubin White blood cell count Serum pregnancy test*
Total bilirubin White blood cell differentiation
Alkaline phosphatase (ALP) Platelet count
Alanine aminotransferase (ALT)
у-Glutamyl transferase (GGT)
Cholesterol*
Triglycerides*
Urinalysis*
*These laboratory tests were only performed at screening. The other tests were performed at screening 
and every 12 weeks during therapy.
Table 1. Laboratory investigations.
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Statistics
Relative rates, defined as the ratio of the observed to the expected number of serious 
adverse events, were calculated. The expected number of serious adverse events was 
calculated by multiplying the gender- and 10-year-age-group incidence rates in the CMR 
by the patient-year distribution of the psoriasis cohort. We calculated the 95% confidence 
interval for each relative rate on the assumption of a Poisson distribution of the number 
of observed cases. 
Results
Patients
Between February 2005 and April 2010, 173 patients were enrolled in the registry and 
went through a total number of 263 treatment episodes. Sixty-three percent of patients 
were male and the mean age was 50.6 (± 12.1) years (Table 2). The mean psoriasis disease 
duration was 26.0 ± 12.8 years. 
The number of different biologics applied per patient, including pre-enrolment biological 
treatment (e.g. biological treatment in other hospitals and biologics applied in clinical 
trials) and postenrolment biological treatment (e.g. biological treatment in our university 
hospital), varied between one and five (Table 2).
Patient characteristics n = 173
Male gender, n (%) 109 (63.0)
Age (years), mean ± SD 50.6 ± 12.1
Duration of psoriasis (years), mean ± SD 26.0 ± 12.8
Psoriatic arthritis, n (%) 51 (29)
Total duration of exposition to biologicsa
Mean ± SD (years) 2.7 ± 1.6
Median (years) (range) 2.7 (4 days – 7.4 years)
Duration of registry follow-up
Mean ± SD (years) 2.3 ± 1.6
Median (years) (range) 2.3 (4 days – 5.2 years)
Number of different biologicsb, n (%)
One 88 (50.9)
Two 53 (30.6)
Three 24 (13.9)
Four 7 (4.0)
Five 1 (0.6)
aData on the total duration of exposition to biologics (consisting of pre-enrolment and postenrolment 
biological treatment) were available for 170 patients (98%). bConsisting of pre-enrolment and 
postenrolment biological treatment.
Table 2. Patient characteristics.
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Comorbidities  n = 173
 n (%)
Diseases of the blood and blood-forming organs, total*  8 (5)
Diseases of the circulatory system, total  74 (43)
Cardiac arrhythmia  6 (3)
Cerebrovascular disease  10 (6)
Diseases of veins, lymphatic vessels and lymph nodes  18 (10)
Hypertension  55 (32)
Ischaemic heart disease  12 (7)
Diseases of the digestive system, total  58 (34) 
Appendectomy  13 (8)
Disorders of gallbladder, biliary tract and pancreas  13 (8)
Fatty liver  8 (5)
Liver fibrosis  8 (5)
Hernia  16 (9)
Diseases of the ear and mastoid process, total  9 (5)
Diseases of the eye and adnexa, total  12 (7)
Diseases of the genitourinary system, total  37 (21)
Urolithiasis  6 (3)
Diseases of the musculoskeletal system, total  57 (33)
Osteoarthritis  7 (4)
Gout  7 (4)
Meniscus derangement  9 (5)
Shoulder lesion  5 (3)
Surgery, NOS  25 (14)
Diseases of the nervous system, total  28 (16)
Epilepsy  10 (6)
Herniated nucleus pulposus  10 (6)
Nerve, nerve root and plexus disorders  9 (5)
Diseases of the respiratory system, total  3 (19)
Chronic lower respiratory diseases  13 (8)
Diseases of the upper respiratory tract  19 (11)
Diseases of the skin and subcutaneous tissue, total  25 (14)
Hidradenitis suppurativa  5 (3)
Endocrine, nutritional and metabolic diseases, total  45 (26)
Diabetes mellitus  22 (13)
Hypercholesterolaemia  25 (14)
Hypothyroidism  6 (3)
Certain infectious and parasitic diseases, total  33 (19)
Viral hepatitis  10 (6)
Mental and behavioural disorders, total  22 (13)
Depressive disorder  7 (4)
Neoplasms, total  20 (12)
Benign neoplasms  9 (5)
Malignant neoplasms  15 (9)
Other  66 (38)
*Including certain disorders involving the immune mechanism. NOS, not otherwise specified.
Table 3. Comorbidities in the cohort of 173 psoriasis patients treated with biologics up until the moment 
of evaluation. Only comorbidities occurring in ≥ 5 patients are represented.
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Concomitant systemic antipsoriatic treatment consisted of methotrexate (n = 37), 
acitretin (n = 12), ciclosporin (n = 13), fumarates (n = 2) and mycophenolate mofetil (n = 1).
One hundred and sixty-four patients reported 755 comorbidities (Table 3). Common 
comorbidities were hypertension (n = 55 (32%)), hypercholesterolaemia (n = 25 (14%)) 
and diabetes mellitus (n = 22 (13%)). 
Pre-enrolment biological treatment 
Biologics applied in the pre-enrolment period were etanercept, adalimumab, infliximab, 
ustekinumab, efalizumab, alefacept and onercept. Alefacept and onercept were 
exclusively applied before enrolment. The mean total duration of exposition to biologics 
(i.e. pre-enrolment and postenrolment biological treatment) was 2.7 ± 1.6 years
(median 2.7 years (range 4 days - 7.4 years)) (Table 2). 
Postenrolment biological treatment
The registry contains data of etanercept, adalimumab, efalizumab, infliximab and 
ustekinumab treatment episodes (Table 4). Single biological treatment regimens applied 
from the moment of enrolment consisted of etanercept (n = 94), adalimumab (n = 13), 
efalizumab (n = 3), infliximab (n = 3) and ustekinumab (n = 2). Twenty-four patients (14%) 
were treated with etanercept followed by adalimumab. The other 34 patients (20%) 
were treated with variable consecutive biological treatment regimens. In 79 patients 
(46%), etanercept was the only biologic ever applied. For 22 patients (13%), etanercept 
and subsequently adalimumab were the only biologics they had ever received. The mean 
duration of registry follow-up was 2.3 ± 1.6 years (median 2.3 years (range 4 days - 5.2 years)) 
(Table 2). The total number of patient-years in the registry was 409. Dosing information 
is provided in Table 4. 
Biological No. of 
treatment 
episodes
No. of 
patients
Treatment episode duration (years) Patient-
years
Dose (mg)
Mean ± SD Median (range)
Etanercept 159 150 2.0 ± 1.5 1.7 (0.01 – 5.2) 319.8 67.6a
Adalimumab 59 59 0.9 ± 0.5 0.9 (0.02 – 1.9) 55.4 25.5a
Efalizumab 28 27 0.9 ± 0.9 0.5 (0.08 – 3.4) 24.8 Per label
Infliximab 9 7 0.6 ± 0.5 0.5 (0.04 – 1.6) 5.3 Per labelb
Ustekinumab 8 8 0.5 ± 0.4 0.4 (0.14 – 1.1) 4.0 Per labelc
aMean weekly dose. bOne patient was initially treated with 3 mg/kg infliximab. cUstekinumab was applied 
per label in all but two patients. In one patient shortening of the treatment interval to 8 weeks and in 
another patient shortening of the treatment interval as well as a dosage increment to 90 mg was necessary.
Table 4. Treatment characteristics.
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Safety
A total of 169 patients reported 1530 adverse events (Table 5). Common adverse events 
(reported by 20% of patients or more) were upper respiratory tract infections, skin 
infections, pruritus, joint complaints, flu-like symptoms, gastrointestinal complaints, 
headache and fatigue. 
Serious adverse events
Forty-nine patients (28%) reported 88 SAEs (Table 6). Twenty-one events (24% of SAEs) 
Adverse events  n = 173 
 n (%)
(Pre)malignancies, total 18 (10)
Actinic keratosis 11 (6)
Basal cell carcinoma 4 (2)
Squamous cell carcinoma 4 (2)
Cervix carcinoma in situ 1 (1)
Metastatic colon cancer* 1 (1)
Bowen disease 1 (1)
Breast cancer 1 (1)
Oesophageal carcinoma 1(1)
Cardiovascular diseases/complaints, total 22 (13)
Skin diseases/complaints, total 103 (60)
Endocrine diseases/complaints, total 8 (5)
Gastro-intestinal diseases/complaints, total 52 (30)
Infections, total 133 (77)
Upper respiratory tract infections 98 (57)
Lower respiratory tract infections 15 (9)
Gastrointestinal infections 16 (9)
Genital infections 2 (1)
Influenza/influenza-like symptoms 65 (38)
Skin infections 34 (20)
Latent tuberculosis 1 (1)
Urinary tract infections 16 (9)
Diseases/complaints of the musculoskeletal system, total 79 (46)
Diseases/complaints of the nervous system, total 48 (28)
Diseases/complaints of the genitourinary system, total 14 (8)
Eye diseases/complaints, total 29 (17)
Ear diseases/complaints, total 13 (8)
Mental diseases/complaints, total 13 (8)
Pulmonary diseases/complaints, total 25 (14)
Other, total 125 (72)
*Poorly differentiated metastatic cancer, possibly originated in the colon.
Table 5. Numbers and percentages of psoriasis patients treated with biologics with at least one adverse 
event in a category.
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Serious adverse events No. of 
patients
Treatment
Malignancies
Basal cell carcinoma 4 ETN (n = 3), ADA (n = 1)
Squamous cell carcinoma 4 ETN (n = 3), EFZ (n = 1)
Breast cancer 1 ETN
Oesophageal carcinoma 1 ETN
Metastatic colon cancera 1 ETN
Infections
Erysipelas 1 ETN
Pneumonia 1 ETN
Asthmatic bronchitis exacerbationb 1 ETN
Cardiovascular events
Myocardial infarction 2 ETN
Angina pectoris 2 ETN
Congestive cardiomyopathy 1 ETN
Atrial fibrillation 2 ETN
Perimesencephalic haemorrhage 1 ETN
Gastro-intestinal diseases/complaints
Cholecystectomy (cholecystitis) 1 ETN
Hernia cicatricialis surgery 1 ETN
Hernia inguinalis surgery 1 ETN
Liver cirrhosis 1 ADA
Stomach complaints 1 ETN
Peri-anal fistula 1 ETN
Oesophageal varices bleeding 1 ADA
Diseases/complaints of the musculoskeletal system
Arthritis 1 EFL
Shoulder enthesopathy 1 ETN
Traumatic bone fracture 3 ETN (n = 2), ADA (n = 1)
Joint complaints 1 EFL
Diseases of the genitourinary system
Cystocele surgery 1 ETN
Nefrolithiasis 1 ADA
Hysterectomy (polyps) 1 ETN
Exacerbation of psoriasis 17 ETN (n = 13), ADA (n = 3), 
EFL (n = 5), INF (n = 2)c
Other
Leg abscess 1 ETN
Infusion reaction 1 INF
Knee surgery 3 ETN
Spontaneous abortion 1 ETN
Child born with patent ductus arteriosus 1 ETN
Malaise, joint complaints, weight loss 1 ADA
Death 4 ETN (n = 3), ADA (n = 1)
Total 49
aPoorly differentiated metastatic cancer, possibly originated in the colon. bTriggered by an airway 
infection. cThree patients experienced psoriasis exacerbations during different biological therapies. ADA, 
adalimumab; EFL, efalizumab; ETN, etanercept; INF, infliximab.
Table 6. Numbers of psoriasis patients treated with biologics with at least one serious adverse event in a 
category.
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were considered possibly related and one event (infusion reaction) was certainly causally 
related to the biologic. 
Four patients died during biological treatment. Two patients died from a sudden cardiac 
arrest after 12 and 15 months of etanercept treatment, respectively. One of these patients 
had a history of hypertension and stroke and the other patient suffered from chronic 
obstructive pulmonary disease. The third patient was diagnosed with alcoholic liver 
cirrhosis and died from an internal bleeding after 9 months of adalimumab treatment. 
In our opinion, a causal relation between the biological treatment and these deaths was 
unlikely. In the fourth patient, a myocardial infarction was revealed at autopsy after 4 days 
of etanercept treatment, which made a relation possible.
Malignancy No. of 
malignancies 
in category
Rx Time to 
event 
(months)
Relevant pretreatment Relevant 
medical 
history
BCC
Patient 1 5 ETN 2, 2, 4, 
30, 33
UVB 138 J/cm2, PUVA 1982
J/cm2, CsA 1.5 yr, azathioprine 
0.5 yr, MTX
-
Patient 2a 2 ETN 5 UVB, PUVA > 30 months,
MTX 3 yr
SCC, multiple 
BCCs
Patient 3 1 ETNb 3 CsA, PUVA (low dose), MTX -
Patient 4 2 ADA 3 CsAc, MTX, UVB 7 treatments, 
PUVA (high dose), ETN
4 months
-
SCC
Patient 1d 3 ETN 4 UVB 2 treatments, PUVA, 
CsAc, MTX
-
Patient 2a 1 ETN 6 UVB, PUVA > 30 months, 
MTX 3 yr
SCC, multiple 
BCCs
Patient 3 1 ETN 17 UVB 6 months, PUVA > 330 J, 
CsA 1.9 yr, MTX
-
Patient 4 5 EFL 27 PUVA (high dose), UVB, CsA, 
MTX, alefacept
-
Breast cancer 1 ETN 30 CsA 2.5 yr, MTX 1.5 yr -
Oesophageal 
carcinomad
1 ETN 10 CsAc, MTX -
Metastatic 
colon cancere
1 ETN 35 CsA 6.5 yr, azathioprine
4 months, EFL 1 yr, MTX
-
aThis patient was diagnosed with 2 BCCs and one SCC. b1.5 months concomitant CsA. c< 3 months. dThis 
patient was diagnosed with 3 SCCs and an oesophageal carcinoma. ePoorly differentiated metastatic 
cancer, possibly originated in the colon. ADA, adalimumab; BCC, basal cell carcinoma; CsA, ciclosporin 
A; EFL, efalizumab; ETN, etanercept; MTX, methotrexate; Rx, treatment; SCC, squamous cell carcinoma 
of the skin.
Table 7. Malignancies.
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Malignancies
Eleven malignancies were found in 9 patients (Table 7). A 48-year-old man was diagnosed 
with three squamous cell carcinomas (SCCs) of the skin and an oesophageal carcinoma 
during etanercept therapy. Another patient had 2 basal cell carcinomas (BCCs) and one 
SCC of the skin within half a year after the start of etanercept. All patients with skin 
malignancies had an extensive history of UVB and/or PUVA exposure and were previously 
treated with immunosuppressive drugs, including a biologic in two cases. In all patients 
with skin malignancies but three patients with BCCs, the biologic was discontinued. 
Moreover, a 66-year-old female patient on etanercept was diagnosed with an invasive 
ductal carcinoma of the breast. Recently, a 76-year-old male patient on etanercept was 
diagnosed with a poorly differentiated metastatic cancer, possibly originated in the colon. 
Biological treatment was discontinued in the patient with the oesophageal carcinoma, 
but continued in the patient with breast cancer and the patient with metastatic cancer, 
because of the significant negative impact of withdrawal of the biologic on their quality of 
life and only after informed consent of the patient and approval of the treating oncologist.
The incidence of breast cancer, oesophageal carcinoma and colon carcinoma in our 
cohort was not increased compared with the rate expected from the CMR (Table 8). The 
observed rate of skin malignancies was higher than in the CMR.
Expecteda Observedb RR (95% CI)c
Malignancies
Breast cancer 0.4 1 2.7 (0.1 – 15.1)
Upper digestive tract 0.2 1 4.3 (0.1 – 23.8)
Lower digestive tract 0.4 1 2.4 (0.1 – 13.3)
Basal cell carcinoma  0.8d 10 12.2 (5.9 – 22.5)
Squamous cell carcinoma 0.1 10 81.4 (39.0 – 149.8)
Infections
Erysipelas 2.2 1 0.5 (0.1 – 2.6)
Pneumonia 4.5 1 0.2 (0.1 – 1.2)
Asthmatic bronchitis exacerbation 4.0 1 0.2 (0.1 – 1.4)
Cardiovascular 
Myocardial infarction 1.3 2 1.5 (0.2 – 5.6)
Cerebrovascular accident 1.3 1 0.8 (0.1 – 4.2)
Heart failure 0.7 1 1.4 (0.1 – 7.7)
Angina pectoris 1.3 2 1.6 (0.2 – 5.6)
Atrial fibrillation 1.2 2 1.7 (0.2 – 6.1)
aExpected number of events based on the general population incidence rate (CMR). bObserved number of 
events in the psoriasis cohort. cRR (95% CI), relative rate (95% confidence interval). dExpected number of 
skin malignancies other than SCC and melanoma (almost always BCCs). 
Table 8. Expected and observed numbers of malignancies, serious infections and serious cardiovascular 
events per 409 patient-years in the cohort of 173 psoriasis patients. 
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Biological treatment in patients with previous malignancies
A patient with a history of breast cancer more than 10 years before the start of biological 
treatment was treated with alefacept, etanercept and adalimumab for a total duration 
of 5.7 years. Another patient diagnosed with breast cancer more than 8 years before 
the start of etanercept was treated with this agent for 3 months. Again another patient 
with a history of a bladder carcinoma more than 9 years before the start of etanercept 
was treated with etanercept followed by adalimumab for a total period of 2.7 years. No 
recurrences of solid tumours were seen. 
A 65-year-old female patient with a history of a SCC of the skin and multiple BCCs 11 years 
and 3 years before the initiation of etanercept, respectively, was diagnosed with another 
SCC of the skin and 2 BCCs during etanercept treatment (Table 7). We did not see any 
recurrences or new skin malignancies in two other patients with a history of BCCs and 
one patient with a history of a SCC of the skin. 
Infections
A total of 412 infections were reported in 133 patients (Table 5). Upper respiratory 
tract infections, influenza/influenza-like symptoms and skin infections occurred most 
frequently. 
Serious infections concerned an exacerbation of asthmatic bronchitis (triggered by an 
airway infection) (n = 1), erysipelas (n = 1) and pneumonia (n = 1) (Table 6). The rate 
of serious infections was comparable with the CMR. In one patient, latent tuberculosis 
was detected during treatment. Etanercept was discontinued and isoniazid was started. 
Five patients were prophylactically treated with isoniazid, because of suspected latent 
or old healed tuberculosis. A chronic hepatitis B carrier was treated with etanercept and 
antiretroviral therapy for 0.8 years. No reactivation of hepatitis B occurred during the 
study period. 
Cardiovascular events
Twenty-nine cardiovascular events were recorded in 22 patients. A 64-year-old male 
patient with a history of myocardial infarction was diagnosed with heart failure due to 
congestive cardiomyopathy after 3.5 years of etanercept treatment (Table 6). Another 
53-year-old male patient with a history of a cerebrovascular accident was admitted with 
myocardial infarction after 2.9 years of etanercept treatment and another 61-year-old 
female patient died from a myocardial infarction after 4 days of etanercept treatment. 
Another 61-year-old male patient had a perimesencephalic haemorrhage after 10 
months of etanercept treatment. Two patients required a PTCA procedure for angina 
pectoris after 3 months and 1.3 years of etanercept treatment, respectively. All but one of 
abovementioned patients had cardiovascular risk factors. A relation with the etanercept 
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use was considered unlikely, except for the perimesencephalic haemorrhage and the 
early cases of angina pectoris and myocardial infarction, which were considered possibly 
related. The rate of serious cardiovascular events was comparable with the CMR.
Dermatological event No. of 
events (%)
No. of 
patients (%)
Biologic Time to event (months)
Median Range
Pruritus 70 (21.7) 55 (44.7) ETN 47, A 14, 
EFZ 8, I 1
3.0 0.0 – 46.5
Skin infection 58 (18.0) 38 (30.9) ETN 45, EFZ 5, A 3, 
I 4, U 1
9.9 0.1 – 54.2
Injection site reaction 29 (9.0) 27 (22.0) ETN 26, A 2, EFZ 1 0.5 0.0 – 32.2
Benign skin tumour 23 (7.1) 21 (17.1) ETN 19, EFZ 3, A 1 17.8 0.7 – 54.2
Malignant skin tumour 20 (6.2) 7 (5.7) ETN 13, EFZ 5, A 2 4.6 1.1 – 33.1
Premalignant skin tumour 15 (4.7) 12 (9.8) ETN 11, EFZ 3, A 1 7.2 1.2 – 38.0
Eczema 11 (3.4) 10 (8.1) ETN 8, A 2, U 1 9.4 0.8 – 38.8
Hair loss 9 (2.8) 9 (7.3) ETN 5, EFZ 2, A 1, U 1 4.8 1.1 – 40.9
Morphological change in 
psoriasis
8 (2.5) 8 (6.5) ETN 7, EFZ 1 10.9 1.6 – 32.2
Xerosis cutis 7 (2.2) 7 (5.7) ETN 3, A 4 15.3 0.5 – 48.2 
Leg ulcer 5 (1.6) 5 (4.1) ETN 4, A 1 18.3 3.7 – 41.5
Prurigo 4 (1.2) 4 (3.3) ETN 3, A 1 26.0 0.5 – 51.7
Acneiform dermatosis 4 (1.2) 3 (2.4) ETN 3, I 1 5.2 0.5 – 28.9
Drug eruption 5 (1.6) 5 (4.1) ETN 3, A 1, EFZ 1 0.9 0.0 – 8.8
Seborrheic dermatitis 2 (0.6) 2 (1.6) A 2 2.8; 4.8 -
Stasis dermatitis 2 (0.6) 2 (1.6) ETN 2 0.2; 26.4 -
CVI/varices 2 (0.6) 2 (1.6) ETN 1, EFZ 1 2.0; 19.5 -
Porokeratosis 2 (0.6) 2 (1.6) ETN 1, A 1 5.7; 56.0 -
Worsening of hidradenitis 
suppurativa
2 (0.6) 2 (1.6) ETN 2 7.0; 36.9 -
Photodermatosis 1 (0.3) 1 (0.8) ETN 7.7 -
Grover disease 1 (0.3) 1 (0.8) ETN 2.1 -
Vitiligo 1 (0.3) 1 (0.8) ETN 23.0 -
Interstitial granulomatous 
dermatitis
1 (0.3) 1 (0.8) A 17.2 -
Lichenoid dermatitis 1 (0.3) 1 (0.8) ETN 1.4 -
Alopecia areata 1 (0.3) 1 (0.8) ETN 17.4 -
Dyshidrosis lamellosa sicca 1 (0.3) 1 (0.8) EFZ 33.9 -
Other 37 (11.5) 27 (22.0) 5.6 0.1 – 47.2
Total 322 (100) 123 (100) 5.7 0.0 – 56.0
A, adalimumab; ETN, etanercept; EFZ, efalizumab; I, infliximab; U, ustekinumab.
Table 9. Number of dermatological events in a category and percentages of patients with at least one 
adverse event in a category.
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Dermatological conditions
A total of 123 patients reported 322 dermatological events (Table 9). Common 
dermatological events were pruritus (n = 55) and skin infections (n = 38), consisting of 18 
bacterial, 17 fungal, 14 viral and 9 nonspecified infections. Injection site reactions occurred 
frequently during the first 6 months of biological treatment. Eczema diagnosis comprised 
allergic contact dermatitis (n = 1), asteatotic eczema (n = 1), irritant contact dermatitis (n = 2),
nonspecified cases of eczema (n = 5) and hand eczema (n = 1). Forty-eight dermatological 
events were classified as serious, comprising skin malignancies, exacerbations of psoriasis 
and one case of erysipelas. Seventeen patients required 27 hospital admissions because 
of an exacerbation of their psoriasis due to abrupt discontinuation of other systemic 
antipsoriatic treatments at the start of biological treatment, interruptions because of 
infections or suboptimal efficacy or loss of efficacy of the biologic. 
In two patients on etanercept, a worsening of their concomitant hidradenitis suppurativa 
was seen. Eight patients experienced a morphological change in psoriasis, e.g. 
inverse psoriasis (n = 3), pustular psoriasis (n = 3), palmoplantar pustulosis (n = 1) and 
suberythrodermia (n = 1). One hundred and twenty-three dermatological events were 
considered possibly related, comprising among others, 58 skin infections and 36 reports 
of pruritus. Two drug eruptions were considered probably related and 29 reports of 
injection site reactions were considered certainly related. 
Musculoskeletal events
Seventy-nine patients (46%) reported at least one musculoskeletal adverse event.
Serious musculoskeletal events comprised arthritis (n = 1), tendon rupture (n = 1), 
traumatic bone fractures (n = 3) and one case of nonspecified joint complaints (Table 6).
All were considered unlikely causally related. Fifty-one patients of the total group of 
patients (29%) had psoriatic arthritis. Of the patients who reported musculoskeletal 
adverse events, 26 (33%) had psoriatic arthritis.
Other adverse events
Pregnancy: Three healthy children were born to a parent taking etanercept. In two cases, 
the father was taking etanercept and in the other case the mother was taking etanercept 
at the time of conception. In the latter patient, etanercept was discontinued after 4 weeks 
of pregnancy. One male patient had a child born with a patent ductus arteriosus during 
etanercept treatment (Table 6). The child recovered completely. 
Uveitis: One patient developed bilateral uveitis after 3.8 years of etanercept use. 
Etanercept was unlikely causally involved. 
Laboratory: Significant changes in laboratory measurements were occasionally seen, but 
were often transient or pre-existent or could be explained by concomitant medication 
or comorbidity. Laboratory abnormalities did not lead to permanent withdrawal of 
biological treatment. 
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Discussion
In this study, we investigated the safety of biologic therapy for psoriasis applied in real-
world practice for 5 years. The number of patient-years of follow-up was the highest 
for etanercept (319 patient-years), as this was one of the first biologics registered for 
the treatment of psoriasis (Table 4). To provide a complete overview, efalizumab was 
described as well, although the marketing authorization has been withdrawn. 
The assessment of the relationship between an adverse event and the biologic was based 
on the investigator’s judgment, taking into account the time relationship and the patient’s 
comorbidity and/or comedication. This cohort of 173 psoriasis patients had an extensive 
medical history, with a mean number of 4.4 comorbidities per patient. Fifty-five patients 
(32%) received concomitant systemic antipsoriatic treatment. Additional morbidity 
caused by biological treatment can have a further negative impact on the quality of life 
of patients with psoriasis. 
The mild adverse events were of the same nature as described in our previous articles and 
other studies and hardly ever outweighed the benefits of continuing the biologic.2, 3, 5-7
The incidence of upper respiratory tract infections and flu-like symptoms was much 
higher in our cohort compared with the CMR. This will at least in part be the result of 
surveillance bias, as our cohort was followed more closely than the general population. 
In addition, the expected number of serious adverse events in our cohort was calculated 
using 10-year-age-group incidence rates from the CMR, which may have caused under- or 
overestimation of the expected rate for sharp age-related diseases in case of clustering at 
the top or the bottom of the 10-year-age-groups in our cohort. 
The incidence of SAEs was comparable with the CMR, except for skin malignancies. Apart 
from exposition to biologics, the significantly higher number of skin malignancies in 
the psoriasis cohort could also be explained by previous exposure to UV phototherapy 
and immunosuppressive drugs, a higher awareness for skin malignancies among 
dermatologists than among general practitioners and by the fact that some patients in 
our cohort had several skin tumours, which were all registered as separate incident cases 
for comparison with the CMR. 
With respect to skin malignancies in rheumatoid arthritis patients treated with TNF-
antagonists, data are inconsistent. Some studies have found an increased risk of 
nonmelanoma skin cancer as well.13-15 As these patients have not previously been treated 
with phototherapy, TNF-antagonists might play a role in this. 
Two Swedish studies found an increased risk of SCCs of the skin in patients hospitalized 
for psoriasis compared with the general population.16, 17 The relative rate of SCCs of the 
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skin in the present study was higher than that in the Swedish studies. However, in these 
studies only the first SCC in a patient was registered, in contrast to the present study and 
the CMR where all SCCs were registered. Selection bias might influence the incidence of 
malignancies during biologic therapy in a positive way, as past malignancies are a relative 
contraindication for biologic therapy.18
Nine malignancies were diagnosed within the first 10 months of biological treatment. 
This period of time is probably too short for the biologic to play a role in the pathogenesis 
of the tumour, although the drug could have accelerated the process of malignant 
degeneration.18 
The oesophageal carcinoma concerned an adenocarcinoma in a Barrett oesophagus and 
was therefore probably not related to biological treatment but to reflux disease. 
Malignancies are a relative contraindication for a TNF-antagonist and ustekinumab.2, 3 We 
did not see any recurrences of malignancies in patients with previous malignancies.
Infections were mainly mild. Only three serious infections occurred. Guidelines recommend 
to avoid biologics in chronic hepatitis B carriers because of the risk of reactivation.2, 3 No 
reactivation of hepatitis B occurred in a chronic hepatitis B carrier during 0.8 years of 
monitored etanercept treatment in combination with antiretroviral therapy. 
A relation between the majority of serious cardiovascular events and the biologic was 
considered unlikely in view of the medical history, the presence of cardiovascular risk 
factors and the time relationship. The incidence of serious cardiovascular events was 
comparable with the CMR, but the prevalence of cardiovascular risk factors in our 
cohort was high compared with the CMR. Attention should be paid to these pre-existent 
cardiovascular risk factors. 
The most common dermatological adverse event encountered in our cohort was pruritus, 
which was hardly ever reported by the RA patients. Skin infections were frequently seen 
in both our cohort as well as the RA cohort. Eczema was the second most common event 
in the RA cohort, but was less frequently seen in our cohort. A possible explanation given 
for eczema occurring in RA patients on anti-TNFα therapy was a shift of the Th1/Th2 
balance towards a Th2-dominated immune response.4 Why this occurs to a much lesser 
extent in psoriasis needs further investigation. 
Paradoxical events were seen in the form of worsening of hidradenitis suppurativa, uveitis 
and morphological changes or exacerbations of psoriasis. Paradoxical events have been 
described before.2 This phenomenon needs further investigation. 
A child with a patent ductus arteriosus was born from a father taking etanercept, which 
we considered probably unrelated to the biologic. This congenital anomaly has been 
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described earlier but as part of a probable VACTERL association in a mother taking 
adalimumab.19 As pregnancy safety data are still sparse, female patients should still be 
strongly advised to prevent pregnancy during biological treatment.2 
In conclusion, in this cohort the safety of biological therapy for psoriasis was favourable 
with a low incidence of therapy-related SAEs. This especially holds for etanercept. 
Continuing long-term follow-up in registries and reporting of rare adverse events by 
physicians (inter)nationally is very important to substantiate data further and to detect 
adverse events for which cumulative exposition may play a role.
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Abstract
Background
Concerns exist about a risk of NMSC in psoriasis patients and rheumatoid arthritis (RA) 
patients treated with TNF-inhibitors. However, current data also show that in some 
psoriasis patients, NMSC is diagnosed relatively short after the start of TNF-inhibitors, 
which suggests that these NMSC can be explained by previous therapies like phototherapy 
instead of by TNF-inhibitor therapy. We hypothesized that if NMSC during TNF-inhibitor 
therapy can be attributed to phototherapy, the time until first NMSC will be shorter and 
the incidence of NMSC will be higher in psoriasis compared with RA.
Objective
To investigate whether there was a difference in time until first NMSC and the incidence 
of NMSC between psoriasis and RA patients on TNF-inhibitors. 
Methods
Time until first NMSC and the rate of NMSC were compared between psoriasis and RA 
patients from the same region treated with TNF-inhibitors and followed-up for at least 
one year in prospective cohort studies, by using Cox regression and Poisson regression. 
Both analyses were corrected for confounders (age, gender, disease duration, prior NMSC 
and duration of anti-TNFα and other systemic therapies). 
Results
The NMSC risk was significantly higher in the psoriasis group (fully adjusted HR 6.0
(1.6 – 22.4 95%CI)) with a shorter time until first NMSC in psoriasis compared with RA. By 
Poisson regression, psoriasis patients had a 5.5 (2.2 – 13.4 95%CI) higher rate of NMSC.
Conclusion
The risk of developing NMSC was significantly higher in psoriasis compared with RA with 
a shorter time until first NMSC in psoriasis. This indicates that disease related factors like 
phototherapy may be an important contributing factor to NMSC diagnosed in psoriasis 
patients treated with TNF-inhibitors.
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Introduction
Concerns exist about a possible increased risk of malignancies, including nonmelanoma 
skin cancer (NMSC), in psoriasis and RA patients treated with TNF-inhibitors.1-3 However, 
current data also show that in some psoriasis patients, NMSC is diagnosed relatively 
short after the start of TNF-inhibitor therapy2, 4-9, which suggests that these NMSC can be 
explained by previous therapies like phototherapy instead of by TNF-inhibitor therapy.
To investigate the influence of phototherapy, the occurrence of NMSC in a group of 
psoriasis patients treated with TNF-inhibitors would ideally be compared with a group of 
psoriasis patients who have received TNF-inhibitor therapy and other immunosuppressive 
therapies, but no phototherapy. However, as TNF-inhibitors can only be prescribed to 
patients who failed on phototherapy in most countries, such a group of patients is not 
available. Therefore, a comparison with a group of RA patients who were treated with TNF-
inhibitors therapy and other immunosuppressive therapies but no prior phototherapy, 
provides valuable information.
Patients with psoriasis or RA have all been treated with immunosuppressive therapies like 
methotrexate, ciclosporin, prednisone and azathioprine before the start of TNF-inhibitor 
therapy. Corrections can be carried out for differences in previous treatments and 
demographic characteristics. This means that after statistical corrections, an important 
difference between the psoriasis and the RA group, is the fact that the psoriasis patients 
have received phototherapy (UVB and/or PUVA) whereas the RA patients have not 
received phototherapy.
Our hypothesis was that, if the occurrence of NMSC is attributable to phototherapy in 
psoriasis patients, the time from start of anti-TNFα treatment to first NMSC is expected to 
be shorter and the incidence of NMSC is expected to be higher in psoriasis compared with 
RA. Therefore the objective of this study was to investigate whether there is a difference 
in time to first NMSC and the incidence of NMSC between psoriasis patients and RA 
patients treated with TNF-inhibitors. 
Methods
Patients
First, all available patients with plaque psoriasis initiated on etanercept, adalimumab and/
or infliximab at the department of Dermatology of the Radboud university medical centre 
(Radboudumc) and the department of Dermatology of the Academic Medical Centre 
(AMC) of the University of Amsterdam between February 2005 and November 2011 with 
a follow-up of at least one year after the start of anti-TNFα therapy and enrolled in their 
respective registries, were selected.10, 11 
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Second, a group of RA patients initiated on the same TNF-inhibitors at the department of 
Rheumatic Diseases of the Radboudumc with a follow-up of at least one year between 
2001 and November 2011 was selected. The number of available RA patients was higher 
than the number of available psoriasis patients, but all RA patients were selected for 
analysis (instead of a random selection). As the number of NMSC in the RA population 
was expected to be lower than in the psoriasis cohort, selecting all available RA patients 
would gain sufficient power.
Patients were not always treated with TNF-inhibitors for at least one year, due to possible 
interruptions of therapy. Effects of etanercept, adalimumab and infliximab were analysed, 
as these agents are prescribed for psoriasis as well as RA. Exposure to TNF-inhibitors 
in other contexts (participation in trials or treatment in nonacademic hospitals) before 
enrolment in the registries was taken into account as well.
The protocol of the prospective study performed at the department of Dermatology 
and Rheumatic Diseases of the Radboudumc was presented to the institutional review 
board (IRB). A formal IRB procedure and obtaining informed consent was considered 
unnecessary by the board because of the noninterventional character of the studies. 
The prospective study performed at the AMC was approved by the IRB of the AMC and 
patients registered in this database gave informed consent for registration. 
Available data
Data were extracted from three prospective registries in which psoriasis or RA patients 
starting biological therapy in daily practice are enrolled.10-12 All three registries covered 
the same time period and contained prospectively collected data about patient 
characteristics, exposure to biologic therapies and prior (systemic) therapies, concomitant 
therapies, adverse events and effectiveness. The psoriasis and RA patients were expected 
to be comparable with regard to the degree of sun exposure as all 3 registries cover parts 
of the Netherlands.
Information about NMSC and histology data were obtained from PALGA, the Dutch 
national histo- and cytopathology database and verified with data from the registries and 
(electronic) patient records.13 This study focused on the most common types of NMSC, 
i.e. basal cell carcinoma (BCC) and SCC of the skin. Keratoacanthomas were considered as 
SCCs. Only primary skin tumours were included for analysis.
Statistical analysis
The primary analysis was a Cox proportional hazard regression analysis with time until 
occurrence of first NMSC after the start of anti-TNFα therapy as dependent variable and 
‘disease’ (psoriasis or RA) as independent variable. For patients who were not diagnosed 
with NMSC after the start of anti-TNFα therapy, follow-up ended at November 2011 or 
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the date of loss of follow up or death, whichever was first (censoring date). As anti-TNFα 
therapy may continue to influence the risk of NMSC after its cessation, follow-up time in 
patients who discontinued anti-TNFα treatment before November 2011 was included in 
the analysis until November 2011 or another censoring date, if applicable. This is further 
named the ‘ever exposed to anti-TNF analysis’ and was considered the main analysis of 
this study. In the Cox regression analysis, only the first NMSC diagnosed after the start 
of TNF-inhibitor therapy contributes to the results. Time until first NMSC is presented by 
Kaplan-Meier survival curves.
The secondary analysis is a Poisson regression analysis with the rate of NMSC (number 
of events of NMSC divided by observation time in patient-years) as dependent variable 
and ‘disease’ as independent variable. This analysis was done to support the results of 
the Cox regression analysis. A rate ratio (RR) was calculated by dividing the rate of NMSC 
in the psoriasis group by the rate of NMSC in the RA group. For this analysis, observation 
time started at the time of initiation of the first anti-TNFα agent and ended at November 
2011 or another censoring date, if applicable. In the Poisson regression analysis, all 
NMSC diagnosed after the start of TNF-inhibitor therapy contribute to the results. This 
Poisson regression model was built using the Generalized Linear Models procedure with 
a binominal distribution and a logit link function.
It was foreseen that the psoriasis and RA patients would differ at important prognostic 
factors for getting NMSC, like for instance a difference in ciclosporin use. Both analyses 
were corrected for those possible confounders: age, gender, disease duration (as an 
intermediate variable for severity of the disease), history of NMSC before the start of 
anti-TNFα therapy, cumulative duration of anti-TNFα therapy, cumulative duration of 
MTX, ciclosporin, prednisone and azathioprine therapy and the cumulative duration 
of treatment with biologics with a mechanism of action other than TNF-α blockade. 
Correction for immunosuppressive therapies was applied for those therapies which have 
in some studies been shown to increase the risk of developing NMSC.14-20
As our hypothesis was based on the assumption of equal duration of exposition to anti-
TNFα therapy and because follow-up time was longer than the duration of exposition to 
anti-TNFα therapy in the ‘ever exposed to anti-TNF analysis’, ‘cumulative duration of anti-
TNFα therapy’ was included in this analysis independent of the presence of a significant 
difference in the univariate analysis. The other candidate confounding variables were 
tested univariately between the psoriasis and RA groups with the unpaired student’s 
t-test, Mann-Whitney U test, chi-square test or Fisher’s exact test. Variables with a 
p-value < 0.1 were all included in the multivariate analysis. The number of UVB and PUVA 
treatments per patient was calculated. In case only the start date and stop date of UVB or 
PUVA were known, UVB and PUVA were expected to be applied 3 times a week.
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In addition to the ‘ever exposed to anti-TNF analysis’, a sensitivity analysis was done 
to support the results of the main ‘ever exposed to anti-TNF analysis’, analyzing time 
until occurrence of first NMSC (Cox regression) and rates of NMSC (Poisson regression) 
between the start date of the first anti-TNFα agent and the discontinuation date of the last 
anti-TNFα agent (‘on drug analysis’). For patients who were not diagnosed with NMSC, 
follow-up ended at the discontinuation date of the last anti-TNFα agent, November 2011 
if the patient was still on anti-TNFα therapy or another censoring date, whichever was 
first. Patients were included for analysis when the time between the start date of the 
first anti-TNFα agent and the discontinuation date of the last anti-TNFα agent or another 
censoring date comprised at least one year. In the ‘on drug analysis’, cumulative duration 
of anti-TNFα therapy was not included as a confounder. All analyses as described above 
were repeated for the ‘on drug analysis’. Analyses were done using PASW statistics 18®.
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Psoriasis
n = 280
Rheumatoid arthritis
n = 448
p-value
Male gender, n (%) 181 (65) 144 (32) < 0.001
Age, years, mean ± SD 46.8 ± 11.9 56.3 ± (12.9) < 0.001
Disease duration, years, median (range) 19.7 (1.1 – 64.4) 9.7 (0 – 51.3) < 0.001
Psoriatic arthritis, n (%) 77 (28) 0 (0) N.A.
NMSC prior to anti-TNFα therapy, n (%) 6 (2.1) 5 (1.1) 0.4
Phototherapy (unspecified), % (n)a 99% (275/279)c UNK N.A.
UVB, % (n)a 92% (254/276)d UNK N.A.
PUVA, % (n)a 58% (160/275)e UNK N.A.
Methotrexate use, n (%)a 270 (96) 439 (98) 0.2
Duration of methotrexate use, years, median 
(range)b
1.3 (0 – 27.3) 4.4 (0 – 28.6) < 0.001
Ciclosporin use, n (%)a 217 (78) 23 (5) < 0.001
Duration of ciclosporin use, years, median 
(range)b
0.5 (0 – 10.2) 0 (0 – 2.1) < 0.001
Prednisone use, n (%)a 25 (9) 270 (60) < 0.001
Duration of prednisone use, years, median 
(range)b
0 (0 – 2.7) 0.5 (0 – 33.4) < 0.001
Azathioprine use, n (%)a 3 (1) 160 (36) < 0.001
Duration of azathioprine use, years, median 
(range)b
0 (0 – 0.6) 0 (0 – 30.4) < 0.001
Duration of anti-TNFα therapyb, years, 
median (range)
3.7 (0.2 – 8.1) 4.1 (0.1 – 14.9) 0.3
Duration of non anti-TNFα biological 
therapyb, years, median (range)
0 (0 – 3.7) 0 (0 – 4.3) 0.009
aNumber and percentages represent patients ever exposed to the respective therapy. bDuration of use 
until date of first diagnosis of NMSC, November 2011 or the date of loss of follow-up or death (‘ever 
exposed to anti-TNF analysis’). N.A.; not applicable. UNK; unknown. c1 missing, d4 missing,e5 missing,
Table 1. Demographics and treatment characteristics.
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As NMSC prior to the start of TNF-inhibitor therapy was a strong predicting factor for 
being diagnosed with NMSC after the start of TNF-inhibitor therapy, a second sensitivity 
analysis excluding patients with prior NMSC was performed.
Results
Patients
Demographics and treatment characteristics
Two hundred and eighty psoriasis patients and 448 RA patients were included in the ‘ever 
exposed to anti-TNF analysis’ (Table 1). One patient with psoriasis was excluded because 
of insufficient information about the treatment history.
The median follow-up of the psoriasis patients in the ‘ever exposed to anti-TNF analysis’ 
was 4.8 (range 1.0 – 9.3) years. In the RA patients, this was 6.6 (range 1.0 – 14.9) years. The 
median follow-up in the ‘on drug analysis’ was 4.5 (range 1.0 – 9.3) years in de psoriasis 
group and 5.3 (range 1.0 – 14.9) years in the RA group. In the psoriasis cohort, 27 patients 
(9.6%) were lost to follow-up. In the RA group, this concerned 14 patients (3.1%).
The median exposition (censored) to anti-TNFα therapy in the psoriasis group was 3.7 
(range 0.2 – 8.1) years. In the RA group, this was 4.1 (range 0.1 – 14.9) years. 
The two groups differed significantly at important demographic characteristics, but 
were representative of a group of psoriasis patients or RA treated with biologic agents
(Table 1).12, 21 The psoriasis group contained a significantly higher proportion of males. In 
the psoriasis group, the mean age and disease duration at the start of anti-TNFα therapy 
was significantly lower, respectively longer. Ninety-nine percent of the psoriasis patients 
Figure 1. Time until first NMSC in all psoriasis and 
RA patients.
Figure 2. Time until first NMSC in psoriasis and RA 
patients with an event.
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had been treated with phototherapy (UVB and/or PUVA). For the RA patients, information 
about phototherapy was lacking. However, when only considering psoriasis as an indication 
for phototherapy, the percentage of RA patients that had been treated with phototherapy 
was expected to be low, as only 5.6% of the RA patients had a history of psoriasis. Twenty-
eight percent of the psoriasis patients had psoriatic arthritis and none had a concomitant 
diagnosis of RA. For 154 psoriasis patients, the number of UVB treatments was known and 
for 76 psoriasis patients, the number of PUVA treatments was known. In these patients, 
the median number of UVB treatments (censored) was 75 (range 2 – 490) and the median 
number of PUVA treatments (censored) was 65 (range 4 – 936).
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Patient NMSC Total duration of anti-TNFα, 
(unadjusted, months)a
N° of NMSC during 
anti-TNFαb
N° of NMSC after
anti-TNFαc
1 SCC ETNg (101) 1 0
2 SCC
BCC
ETN (12) 3
2
1
3
3 BCC ETN, ADAj (17) 2 0
4 BCC ETN, ADA (80) 1 0
5 SCC ETN (39) 1 1
6 BCC ETN (70) 5 0
7 BCC ETN (63) 1 0
8 SCC ETN, ADA (81) 1 0
9 BCC ETN (67) 1 0
10 BCC ETN (73) 1 0
11 SCC ETN, ADA (76) 14 0
Table 2. Patients with psoriasis diagnosed with NMSC after the initiation of TNF-inhibitor therapy. 
aDuration of therapy expressed as time (months) between the date of initiation of the first TNF-inhibitor 
and the date of discontinuation of the last TNF-inhibitor. bNMSC diagnosed between the date of initiation 
of the first TNF-inhibitor and the date of discontinuation of the last TNF-inhibitor. cNMSC diagnosed after 
the cessation of TNF-inhibitor therapy until November 2011 or the date of loss of follow up or death, 
whichever was first. dTime (months) between the date of initiation of TNF-inhibitor therapy and NMSC 
diagnosis. eDuration of treatment until the date of the first diagnosis of NMSC. fSkin cancer history before 
the initiation of TNF-inhibitor therapy. gETN; etanercept, hMTX; methotrexate, iCsA; ciclosporin A, jADA; 
adalimumab; kAZA; azathioprine. lKA; keratoacanthoma.
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The proportion of RA patients that had ever used prednisone or azathioprine was 
significantly higher and the duration of these therapies (censored) was significantly longer 
than in the psoriasis group (Table 1). In contrast, the proportion of patients that had ever 
used ciclosporin and the duration of ciclosporin therapy (censored) were significantly 
higher respectively longer in the psoriasis group. The dose of ciclosporin in the psoriasis 
patients was been between 2.5 and 3 mg per kg per day, according to Dutch guidelines. 
The proportion of patients that had used methotrexate did not differ significantly. The 
duration of methotrexate therapy (censored) was significantly longer in the RA group.
In the psoriasis group, 249 patients (89%) were treated with etanercept, 132 with 
adalimumab (47%) and 10 with infliximab (4%). In the RA group, 228 patients (51%) were 
treated with etanercept, 226 (50%) with adalimumab and 188 (42%) with infliximab.
Skin malignancies
Ever exposed to anti-TNF analysis
In the group of psoriasis patients, 11 patients (3.9%) were diagnosed with at least one 
NMSC after the start of TNF-inhibitor therapy (Table 2). In the group of RA patients, this 
concerned 12 patients (2.7%) (Table 3). The total number of NMSC was 38 (16 BCCs and 
22 SCCs) in the psoriasis group and 27 (20 BCCs and 7 SCCs) in the RA group. One case of 
Time to event (months) 
during anti-TNFαd
Time to event (months) 
after anti-TNFαd
Treatments, duration 
(censored, years)e
Skin cancer historyf
94 N.A. UVB (0.5), MTXh (1.4), 
CsAi (0.01), ETN (3.1)
-
2, 6, 10
5, 5
16
14, 14, 16
UVB, PUVA (>2.5), MTX (3), 
ETN (0.2) 
4 BCC
2 KAl
7, 7 N.A. UVB 7 courses, MTX (5.6), 
CsA (0.6), ETN (0.4), ADA (0.2)
-
78 N.A. UVB 213 J, PUVA 2 courses, 
MTX (0.4), ETN (3.7), ADA (2.6)
-
38 51 UVB (0.5), PUVA (>0.9), MTX 
(5.6), CsA (1.9), ETN (1.4)
-
2, 2, 4, 30, 33 N.A. UVB 138 J/cm2, PUVA 1982
J/cm2, MTX, CsA (1.5),
AZAl (0.5), ETN (0.2)
-
3 N.A. PUVA, MTX (0.3), CsA (0.4), 
ETN (0.3)
-
17 N.A. UVB, MTX (1.2), CsA (0.4), 
alefacept (0.2), ETN (0.7)
-
45 N.A. UVB >74 J/cm2, PUVA, MTX 
(5.8), CsA (0.1), ETN (3.5)
-
21 N.A. UVB, PUVA, MTX (1),
ETN (1.6)
-
19, 31, 31, 40, 45, 49, 
50, 50, 50, 59, 69, 69, 
74, 74
N.A. UVB, PUVA 12 courses,
MTX (5.3), CsA (10.2),
ETN (1.4)
5 BCC, 4 SCC, 1 KAl,, 
1 melanoma in situ
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BCC in the psoriasis group showed locally transition to a basosquamous carcinoma, which 
was considered as a BCC. No forms of NMSC other than BCC and SCC were diagnosed.
In the psoriasis group, six patients (2.1%) had a history of NMSC before the start of anti-
TNFα therapy (Table 1). In the RA group, this concerned 5 patients (1.1%). Of the 11 
psoriasis patients who were diagnosed with NMSC after the start of anti-TNFα therapy, 
36% (4/11) received this diagnosis within the first year after the start of anti-TNFα therapy 
and 18% (2/11) had a history of NMSC before the start of TNF-inhibitor therapy. In the RA 
group, 17% (2/12) received a NMSC diagnosis within the first year and 17% (2/12) had a 
history of NMSC.
Apart from an SCC, patient 1 from the psoriasis group was also diagnosed with a superficial 
Chapter 8
Table 3. Patients with RA diagnosed with NMSC after the initiation of TNF-inhibitor therapy. 
aDuration of therapy expressed as time (months) between the date of initiation of the first TNF-inhibitor 
and the date of discontinuation of the last TNF-inhibitor. bNMSC diagnosed between the date of initiation 
of the first TNF-inhibitor and the date of discontinuation of the last TNF-inhibitor. cNMSC diagnosed after 
the cessation of TNF-inhibitor therapy until November 2011 or the date of loss of follow up or death, 
whichever was first. dTime (months) between the date of initiation of TNF-inhibitor therapy and NMSC 
diagnosis. eDuration of treatment until the date of the first diagnosis of NMSC. fSkin cancer history before 
the initiation of TNF-inhibitor therapy. gINF; infliximab, hMTX; methotrexate, iCsA; ciclosporin A, jAZA; 
azathioprine, kETN; etanercept, lADA; adalimumab.
Patient NMSC Total duration of anti-TNFα, 
(unadjusted, months)a
N° of NMSC during 
anti-TNFαb
N°of NMSC after
anti-TNFαc
1 BCC INFg (6) 0 3
2 BCC INF, ETNk, ADAl (113) 1 0
3 SCC
BCC
ETN (107) 6
1
0
0
4 BCC ADA (10) 0 3
5 BCC ADA (69) 1 0
6 SCC ADA (16) 0 1
7 BCC  INF, ETN, (11) 0 1
8 BCC INF (16) 0 2
9 BCC ETN, ADA (49) 0 1
10 BCC INF, ETN, ADA (94) 1 0
11 BCC INF (96) 1 0
12 BCC ETN (12) 5 0
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spreading melanoma (Breslow thickness 0.3 mm, Clark level 3) after 101 months of TNF-
inhibitor therapy.
The BCC:SCC ratio in the psoriasis group was 0.7:1 (16:22). In the RA group, this was 
2.9:1 (20:7). After excluding patient 11 of the psoriasis group who had multiple SCCs, the 
BCC:SCC ratio was 2:1 (16:8).
Cox regression analysis
Figure 1 and Figure 2 show the time until first NMSC after the start of anti-TNFα therapy 
in all patients and in patients with an event only, respectively. The estimated mean time 
until first NMSC in all patients was 8.8 years in the psoriasis group and 12.9 years in the 
RA group. In patients with an event only, the median time until event was 1.6 years in the 
psoriasis patients and 3.7 years in the RA patients. The unadjusted hazard ratio (HR) of 
developing NMSC in the psoriasis group compared with the RA group was 2.0 (0.9 – 4.7 
95%CI) (raw model, Table 4). The fully adjusted HR was 6.0 (1.6 – 22.4 95%CI) (corrected 
model). Correction for the duration of azathioprine therapy was not possible due to the 
low number of psoriasis patients that had used azathioprine.
The sensitivity analysis with exclusion of patients with NMSC prior to the start of TNF-
inhibitor therapy showed  an unadjusted HR of 2.1 (0.8 – 5.4 95%CI) and an adjusted HR 
of 13.4 (2.9 – 63.0 95%CI).
Time to event (months) 
during anti-TNFαd
Time to event (months) 
after anti-TNFαd
Treatments, duration (censored, 
years)e
Skin cancer 
historyf
N.A. 21, 53, 126 MTXi (2.2), CsAi (1), prednisone (8), 
AZAk (2), INF (0.5)
3 BCCs
28 N.A. MTX (4.3), prednisone (5), INF (2.3) -
5, 32, 58, 67, 70, 82
45
N.A.
N.A.
MTX (2.3), prednisone (9), AZA (6), 
ETN (0.4)
-
N.A. 31, 31, 56 MTX (0.7), prednisone (13),
AZA (1), ADA (0.9)
-
64 N.A. MTX (0.1), prednisone (17),
AZA (5), ADA (5.3)
-
N.A. 86 MTX (11.3), prednisone (10),
ADA (1.1)
-
N.A. 66 MTX (1.8), prednisone (6), AZA (1), 
INF (0.6), ETN (0.3), rituximab (0.2)
-
N.A. 59, 61 MTX (28.6), prednisone (22),
AZA (5), INF (1.3), abatacept (0.7)
-
N.A. 49 MTX (1.6), ETN (2.0), ADA (0.5) -
44 N.A. MTX (4.0), prednisone (2), AZA (1), 
INF (0.7), ETN (2.8), 
6 BCCs
71 N.A. MTX (10.8), prednisone (1),
AZA (9), INF (6.0)
-
3, 3, 3, 3, 3 N.A. MTX (0.1), prednisone (0.1),
ETN (0.2)
-
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Poisson regression analysis
In the psoriasis patients a total number of 38 NMSC was reported in 1306 patient-
years, resulting in an event rate of 2.9 (2.1-4.0 95%CI) per 100 patient-years; in the RA 
patients the event rate was 0.9 (0.6-1.3 95%CI) per 100 patient-years (27 events in 2863 
patient-years). By Poisson regression, this resulted in an unadjusted rate ratio of 4.1 (2.3-
7.0 95%CI). Corrected for confounders, by Poisson regression, psoriasis patients had a 
5.5 (2.2 – 13.4 95%CI) higher rate of NMSC compared with RA patients. The model fit 
statistics showed that the Poisson model fitted the data well.
The sensitivity analysis with exclusion of patients with NMSC prior to the start of TNF-
inhibitor therapy showed an unadjusted rate ratio of 2.1 (1.0 – 4.1 95%CI) and an adjusted 
rate ratio of 7.0 (2.3 – 21.5 95%CI).
On drug analysis
For this analysis, 397 RA patients and 279 psoriasis patients could be included. In the 
‘on drug’ analysis, 11 psoriasis patients (3.9%) and 6 RA patients (1.5%) were diagnosed 
with NMSC (Table 2-3). The total number of NMSC was 33 (13 BCCs and 20 SCCs) in the 
psoriasis group and 16 (10 BCCs and 6 SCCs) in the RA group.
Cox regression analysis
The estimated mean time until first NMSC in all patients was 8.7 years in the psoriasis 
group and 12.9 years in the RA group. In patients with an event only the median time until 
event was 1.6 years in the psoriasis patients and 7.8 years in the RA patients.
The unadjusted HR of developing NMSC in the psoriasis group compared with the RA 
group was 6.8 (2.1-22.1 95%CI) (raw model, see Table 5) and the fully adjusted HR was 7.5 
(1.7-33.6 95%CI) (corrected model).
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Table 4. Results of the Cox regression analysis (‘ever exposed to anti-TNF analysis’).
Variable B HR (exp B) 95% CI
Raw model 
Diagnosis 0.689 1.992 0.853-4.656
Corrected model 
Diagnosis 1.788 5.977 1.596-22.385
Age 0.053 1.054 1.011-1.099
Gender 0.381 1.464 0.586-3.660
Disease duration 0.010 1.010 0.997-1.023
NMSC prior to anti-TNFα therapy 1.843 6.316 1.698-23.499
Duration of anti-TNFα therapy -0.013 0.988 0.982-0.993
Duration of non anti-TNFα biological therapy -1.324 0.266 0.037-1.907
Duration of ciclosporin therapy 0.029 1.030 0.794-1.336
Duration of prednisone therapy 0.034 1.035 0.956-1.120
Duration of methotrexate therapy -0.058 0.944 0.862-1.034
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Poisson regression analysis
In the psoriasis patients a total number of 33 NMSC was reported in 1240 patient-years, 
resulting in an event rate of 2.7 (1.8-3.7 95%CI) per 100 patient-years; in the RA patients 
the event rate was 0.7 (0.4-1.2 95%CI) per 100 patient-years (16 events in 2193 patient-
years). By Poisson regression, this resulted in an unadjusted rate ratio of 5.9 (2.8-12.3 
95%CI). Corrected for confounders, by Poisson regression, psoriasis patients had a 3.0 
(1.1 – 8.4 95%CI) higher rate of NMSC compared with RA patients. The model fit statistics 
showed that the Poisson model fitted the data well.
Discussion
In this study, it was hypothesized that, if the occurrence of NMSC is attributable to 
phototherapy in psoriasis patients, the time from start of anti-TNFα treatment to first 
NMSC is expected to be shorter and the incidence of NMSC is expected to be higher 
in psoriasis patients compared with RA patients. We can confirm this hypothesis by 
our results. In the ‘ever exposed to anti-TNF analysis’, which was the main analysis of 
this study, the adjusted hazard ratio of developing NMSC was significantly higher in the 
psoriasis group with a shorter time until first NMSC (HR 6.0 (1.6 – 22.4 95%CI)), after 
correction for differences in previous treatments and demographic characteristics. In 
addition, the total event rate was 5.5 (2.2 – 13.4 95%CI) times higher in the psoriasis 
group.
Two other findings support these results. Firstly, the proportion of patients diagnosed 
with NMSC within the first year after the start of anti-TNFα therapy was higher in 
psoriasis (36%) compared with RA (17%), which supports pointing towards phototherapy 
Table 5. Results of the Cox regression analysis (‘on drug analysis’).
Variable B HR (exp B) 95% CI
Raw model 
Diagnosis 1.910 6.752 2.064-22.094
Corrected model 
Diagnosis 2.021 7.544 1.692-33.633
Age 0.091 1.095 1.041-1.151
Gender 0.803 2.233 0.736-6.776
Disease duration 0.013 1.013 0.993-1.033
NMSC prior to anti-TNFα therapy 2.561 12.943 2.696-62.138
Duration of non anti-TNFα biological therapy -4.197 0.015 0.000-48.898
Duration of ciclosporin therapy 0.072 1.074 0.810-1.426
Duration of prednisone therapy 0.005 1.005 0.895-1.129
Duration of methotrexate therapy -0.126 0.882 0.768-1.012
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as a contributing factor. Secondly, the low BCC:SCC ratio found in the psoriasis group 
in this study also supports our hypothesis. In the general population, BCC:SCC ratios of 
4:1 are reported.22-24 As it is known that the incidence of SCC may be more affected by 
phototherapy than BCC, the low BCC:SCC ratio found in this study supports an influence 
of phototherapy.
To support the abovementioned results, a sensitivity analysis was performed (‘on drug 
analysis’). In this analysis, the time until first NMSC was also significantly shorter (HR 7.5 
(1.7-33.6 95%CI) and the rate of NMSC was also significantly higher in de psoriasis group 
(rate ratio 3.0 (1.1 – 8.4 95%CI)) compared with the RA group. To our knowledge, this 
was the first observational study comparing the occurrence of NMSC in psoriasis patients 
with RA patients. Other studies comprised meta-analyses of RCTs with relatively short 
treatment durations or open label extension studies lacking a control group or comparing 
NMSC rates with expected NMSC rates in the general population.4-9, 25 
The difference in the incidence of NMSC found could, apart from phototherapy, be 
influenced by differences in patient characteristics and previous immunosuppressive 
treatments. However, differences in patient characteristics and the use of ciclosporin, 
methotrexate and prednisone were corrected for in the Cox proportional hazard and 
Poisson regression analyses.
NMSC prior to the start of TNF-inhibitor therapy was shown to be a strong predicting 
factor for being diagnosed with NMSC after the start of TNF-inhibitor therapy. We 
corrected for this confounder (history of NMSC before the start of anti-TNFα therapy) in 
the Cox proportional hazard regression analysis and the Poisson regression analysis. In 
addition, a sensitivity analysis excluding patients with prior NMSC was performed which 
showed similar results.
This study has some limitations. Firstly, the absolute number of NMSC was small. 
However, despite the small number of NMSC, statistically significant differences between 
the psoriasis and the RA group were detected. In addition, the fact that the number of 
NMSC was small, is reassuring with respect to the risk of NMSC associated with treatment 
with TNF-antagonists.
Secondly, correction for important risk factors for developing NMSC such as skin type and 
sun exposure was not possible, as skin type information was only available for a part of 
the psoriasis patients and not for the RA patients. Information on sun exposure was not 
available. However, as both groups cover the Netherlands and the same time period, the 
degree of sun exposure and skin cancer trends were expected to be the same for both 
groups. Nevertheless, psoriasis patients could have higher recreational sun exposure as 
this often improves their psoriasis.
Thirdly, detection bias may have played a role in the psoriasis group due to more regular 
skin assessments by dermatologists. In addition, the actual number of NMSC may have 
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been higher due to treatment of in particular superficial BCCs without taking a biopsy. 
However, as both groups were treated in academic hospitals where is common practice 
to take a biopsy before initiating treatment, this influence is expected to be small. 
Furthermore, the follow-up was shorter in the psoriasis patients compared with the RA 
patients. This could be a bias in a setting where NMSC takes time to become clinically 
detectable.26
In addition, acitretin treatment in combination with immunosuppressive treatments in 
renal transplant recipients may be protecting against NMSC.27, 28 In psoriasis, concomitant 
acitretin may have the same effect. In this study, 150 psoriasis patients (54%) had 
ever used acitretin but only 16 patients (5.7%) used acitretin concomitantly with TNF-
inhibitors. The influence of acitretin is therefore expected to be small.
Another limitation is the fact that 28% of the patients also had psoriatic arthritis, which 
theoretically should be analysed as a separate group with its own NMSC risk. 
In addition, the difference in the incidence of NMSC found, could be influenced by the 
specific disease. Ideally, the current psoriasis group would have been compared with 
a group of psoriasis patients who had received anti-TNFα therapy and conventional 
systemic antipsoriatic therapies but no phototherapy. However, as TNF-inhibitors can 
only be prescribed to patients who failed to respond to phototherapy in the largest part 
of the world, this group of patients is not available.
In conclusion, the risk of developing NMSC was significantly higher in the psoriasis group 
compared with the RA group with a shorter time until first NMSC. This indicates that 
disease related factors like phototherapy may be an important contributing factor to 
NMSC diagnosed in psoriasis patients treated with TNF-inhibitors.
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Relevance of laboratory investigations in monitoring 
patients with psoriasis on etanercept or adalimumab
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Abstract
Background
Guidelines concerning biological treatment of patients with psoriasis recommend 
different pretreatment and monitoring laboratory panels in variable frequencies to 
monitor treatment. 
Objectives
To investigate the relevance of laboratory investigations in monitoring patients with 
psoriasis on etanercept or adalimumab.
Methods
A prospective cohort study over 5 years was conducted in all consecutive patients with 
psoriasis on etanercept or adalimumab. All laboratory investigations performed for 
monitoring treatment were analysed. Laboratory abnormalities were graded according 
to the Common Terminology Criteria for Adverse Events v4.03. The primary endpoint 
was the percentage of patients with a grade 3 or grade 4 laboratory abnormality. The 
secondary endpoints were defined as: (i) significant changes in laboratory parameters 
during etanercept or adalimumab treatment and (ii) the percentage of patients having 
a laboratory abnormality requiring discontinuation of etanercept or adalimumab 
treatment.
Results
Laboratory parameters were available for 162 patients treated with etanercept and/
or adalimumab. The number of treatment episodes was 155 for etanercept and 58 for 
adalimumab. Follow-up was 316 patient-years for etanercept and 54 patient-years for 
adalimumab. Thirty-eight of 146 patients treated with etanercept (26%) had one or more 
grade 3 and/or grade 4 laboratory abnormalities. For adalimumab, this was 8 of 58 (14%). 
These were predominantly considered unrelated to biologic therapy.
For both biologics, significant changes were observed in mean laboratory parameters 
during treatment compared with pretreatment as well as significant trends. However, 
mean values during treatment remained within normal ranges. Laboratory abnormalities 
did not lead to permanent discontinuation of biologic treatment in any patient.
Conclusions
In this cohort, the incidence of biologic therapy-related serious laboratory abnormalities 
was low. Our findings do not support a need for routine laboratory testing in patients 
with psoriasis on etanercept or adalimumab beyond the laboratory testing required for 
concomitant therapies or comorbidities.
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Introduction
Patients with psoriasis treated with biologics are monitored routinely with laboratory 
investigations according to existing guidelines.1-8 Several laboratory investigations 
including analysis of clinical chemistry (liver and kidney function tests) and haematology 
(full blood cell counts), urinalysis, hepatitis B/C and human immunodeficiency virus (HIV) 
serology, analysis of autoantibodies and a pregnancy test are recommended before the 
initiation of treatment. During biologic treatment, laboratory investigations are repeated 
periodically with variable panels and frequencies.1-8 Most guidelines advise laboratory 
investigations at pretreatment, after the start of therapy at 4-12 weeks and at 3-6-monthly 
intervals thereafter.7, 8 
However, the clinical relevance of these laboratory investigations remains to be 
determined. Moreover, a venipuncture is an invasive procedure for the patient and 
this procedure and the laboratory investigations involve health-care costs. Therefore, 
the objectives of this study were to investigate (i) how frequently serious abnormal 
laboratory parameters were observed during etanercept or adalimumab treatment, 
(ii) significant changes in laboratory parameters during etanercept or adalimumab 
treatment and (iii) the percentage of patients having a laboratory abnormality requiring 
discontinuation of etanercept or adalimumab treatment. In addition, we investigated the 
relationship between serious abnormal laboratory parameters and the use of etanercept 
or adalimumab.
To meet the objectives, all laboratory investigations of a prospective cohort consisting 
of all consecutive patients with psoriasis treated with etanercept and/or adalimumab 
between February 2005 and April 2010 were analysed.
Patients and methods
Patients
All consecutive patients starting biological treatment for psoriasis in the Dermatology 
outpatient clinic of the Radboud University Nijmegen Medical Centre are enrolled in a 
prospective patient registry, in which daily practice efficacy and pharmacovigilance data, 
including laboratory investigations, are collected. In the Netherlands, biological treatment 
was approved for the treatment of patients with psoriasis who had not responded to 
phototherapy, methotrexate and ciclosporin, or who had contraindications to or did not 
tolerate these therapies. Furthermore, a Psoriasis Area and Severity Index (PASI) of at 
least 10 was required.9 
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Laboratory investigations
At pretreatment, laboratory investigations included routine clinical chemistry and 
haematology analyses, determination of antinuclear antibodies (ANA), hepatitis B and 
C serology, a serum pregnancy test if applicable and a urinanalysis. General laboratory 
investigations were repeated at week 6 and 12, every 12 weeks afterwards and at other 
occasions when indicated (Table 1). Additional laboratory analyses were performed 
according to clinical signs and concomitant medication. All laboratory investigations were 
performed at the department of Laboratory Medicine or Medical Microbiology of the 
Radboud University Nijmegen Medical Centre.
Methods
Treatments were analysed as separate treatment episodes. A treatment episode was 
defined as a new course of biological treatment or a restart after an interruption of at 
least 6 months. In patients who were treated with both etanercept and adalimumab, 
laboratory investigations were analysed separately. In cases where patients had more 
than one treatment episode with the same biologic, laboratory investigations were 
analysed per treatment episode of that biologic.
For categorizing laboratory abnormalities, the Common Terminology Criteria for Adverse 
Events version 4.03 (CTCAE v4.03) of the National Cancer Institute of the U.S.A. were used 
(Table 2).10 Where the CTCAE criteria did not provide a classification, a grading scale was 
designed at our own discretion, as described in Table 2. 
The primary endpoint was the percentage of patients having a grade 3 or grade 4 
laboratory abnormality. The secondary endpoints were defined as 1) significant changes 
Chapter 9
Chemistry Haematology Additional
Creatinine Haemoglobin Antinuclear antibodiesa
C-reactive protein (CRP) Haematocrit Hepatitis B/C serologya
Direct bilirubin White blood cell count Serum pregnancy testa
Total bilirubin White blood cell differentiation
Alkaline phosphatase (ALP) Platelet count
Alanine aminotransferase (ALT)
у-Glutamyl transferase (GGT)
Cholesterola
Triglyceridesa
Urinalysisa
Table 1. Pretreatment and monitoring laboratory investigations.
aThese laboratory tests were only performed at pretreatment. The other tests were performed at 
pretreatment, week 6 and 12 and every 12 weeks afterwards. 
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in laboratory parameters during etanercept or adalimumab treatment and 2) the 
percentage of patients having a laboratory abnormality requiring discontinuation of 
etanercept or adalimumab treatment. 
Laboratory parameters were analysed and represented separately for men and women 
when the grading scale differed for the two genders. The white blood cell differentiation 
into neutrophils, lymphocytes, monocytes, eosinophils and basophils was reported as 
percentages, as the percentage distribution of the different types of leukocytes should 
stay constant, irrespective of the absolute leukocyte count. Because of increased 
coefficients of analytical variation below the lower detection limits, C-reactive protein 
(CRP) results below 5 mg/L, direct bilirubin results below 5 μmol/L and total bilirubin 
Laboratory parameter
Grade
1a 2b 3c 4d
Creatinine (μmol/L) increased* ♂ >110 - 165 
♀ >90 - 135
♂ >165 - 330
♀ >135 - 270
♂ >330 - 660
♀ >270 - 540
♂ >660
♀ >540
C-reactive protein (CRP) (mg/L) 
increased**
≥10 - 29 ≥30 - 49 ≥50 - 99 ≥100
Direct bilirubin (μmol/L) increased* >5 - 7.5 >7.5 - 15 >15 - 50 >50
Total bilirubin (μmol/L) increased* ≥17 - 25 ≥26 - 50 ≥51 - 169 ≥170
Alkaline phosphatase (ALP) (U/L) 
increased*
>120 - 300 >300 - 600 >600 - 2400 >2400
Alanine aminotransferase (ALT) 
(U/L) increased*
≥45 - 112 ≥113 - 224 ≥225 - 899 ≥900
 у-Glutamyl transferase (GGT) (U/L) 
increased*
♂ ≥50 - 124
♀ ≥35 - 87
♂ ≥125 - 249
♀ ≥88 - 174
♂ ≥250 - 999
♀ ≥175 - 699
♂ ≥1000
♀ ≥700
Haemoglobin (mmol/L) decreased* ♂ <8.1 - 6.2 
♀ <7.3 - 6.2 
♂ <6.2 - 4.9
♀ <6.2 - 4.9
♂ <4.9 - 4.0
♀ <4.9 - 4.0
♂ <4.0
♀ <4.0
White blood cell count (x109/L) 
increased
White blood cell count (x109/L) 
decreased
>11.0 - 14.0**
<3.5 - 3.0*
>14.0 - 17.0**
<3.0 – 2.0*
>17.0 - 20.0**
<2.0 - 1.0*
>20.0**
<1.0*
Neutrophils (%) increased**
Neutrophils (%) decreased**
>70 – 75
<40 – 35 
>75 – 80
<35 – 30 
>80 – 85
<30 – 25 
>85
<25 
Lymphocytes (%) increased**
Lymphocytes (%) decreased**
>40 – 45
<20 – 15 
>45 – 50
<15 – 10 
>50 – 55
<10 – 5 
>55
<5
Monocytes (%) increased**
Monocytes (%) decreased**
>13 – 15
<4 – 3 
>15 – 17
<3 – 2 
>17 – 19
<2 – 1 
>19
<1
Eosinophils (%) increased** >6 - 8 >8 - 10 >10 - 12 >12
Basophils (%) increased** >2 - 4 >4 - 6 >6 - 8 >8
Platelet count (x109/L) increased
Platelet count (x109/L) decreased
>350.0 – 400.0**
<120.0 – 75.0*
>400.0 – 450.0**
<75 – 50.0* 
>450.0 – 500.0**
<50.0 – 25.0*
>500.0**
<25.0*
*CTCAE v4.03 grading scale. **Grading scale designed at our own discretion. aGrade 1; mild AE. bGrade 2; 
moderate AE. cGrade 3; severe AE. dGrade 4; life-threatening or disabling AE. 
Table 2. Grading scale for abnormal laboratory parameters. 
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results below 10 µmol/L were not specified and were imputed as being 5, 5, and 10, 
respectively.
Alanine aminotransferase (ALT) results were analysed for all patients, and separately for 
the group of patients who were not on concomitant methotrexate or acitretin. In addition, 
CRP results were analysed for all patients and for the group of patients with and without 
concomitant psoriatic arthritis. Serum cholesterol and triglycerides were measured under 
nonfasting conditions and were used as indicators for further investigation. 
Differences in mean laboratory parameters before the start of biologic treatment 
and during biologic treatment were analysed in all patients who were not on biologic 
treatment at the time they were screened for etanercept or adalimumab. In addition, 
trends in the course of the laboratory parameters were analysed using linear regression.
Statistics
Paired t-tests were performed for comparison of mean pretreatment laboratory results 
and mean results during treatment. P < 0.05 was considered statistically significant. Linear 
regression was used to calculate regression coefficients with 95% confidence intervals (CI). 
Results
Patient characteristics and treatment
Laboratory results were available for 162 patients with psoriasis who were treated with 
etanercept and/or adalimumab and were collected by 2077 different venipunctures. One 
hundred and three patients (64%) were male (Table 3). The mean age (± SD) was 50.9 (± 12.1)
years and the mean duration of psoriasis (± SD) was 26.4 (± 12.9) years. Forty-six patients 
(28%) had psoriatic arthritis.
One hundred and forty-six patients were treated with etanercept and 58 patients with 
adalimumab (Table 4). Forty-two patients had been treated with both etanercept and 
adalimumab. Five patients were treated with etanercept during two separate treatment 
episodes and two patients had three etanercept treatment episodes. The total number of 
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Patient characteristics n = 162
Male gender, n (%) 103 (64)
Age (years), mean ± SD 50.9 (12.1)
Duration of psoriasis (years), mean ± SD 26.4 (12.9)
Psoriatic arthritis, n (%) 46 (28)
Table 3. Patient characteristics.
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treatment episodes was 155 for etanercept and 58 for adalimumab. The mean treatment 
episode duration (± SD) was 2.0 (± 1.5) years for etanercept and 0.9 (± 0.5) years for 
adalimumab; the number of patient-years of follow-up was 316 for etanercept and 54 
for adalimumab. The mean weekly dose was 60.0 mg for etanercept and 25.2 mg for 
adalimumab. 
From 155 etanercept treatment episodes, 118 consisted of etanercept monotherapy, 
26 consisted of etanercept combined with methotrexate (24 patients) and 11 consisted 
of etanercept combined with acitretin (11 patients). From 58 adalimumab treatment 
episodes, 43 consisted of adalimumab monotherapy, 13 consisted of adalimumab 
combined with methotrexate (13 patients) and 2 consisted of adalimumab with acitretin 
(2 patients).
Patients used concomitant methotrexate or acitretin as bridge therapy when transitioning 
from the classic systemic treatment to biologic treatment, or as add-on therapy during 
the course of biologic treatment because of unsatisfactory efficacy. Methotrexate and 
acitretin as bridge therapies were applied for variable lengths of time, varying from 2 
weeks to continuously throughout the course of biologic treatment.
Severe laboratory abnormalities during biologic treatment
All laboratory investigations categorized as grade 3 or 4 adverse events observed during 
etanercept or adalimumab treatment are represented in Table 5. Thirty-eight patients of 
146 etanercept-treated patients (26%) had one or more grade 3 and/or grade 4 laboratory 
abnormalities. For adalimumab, this number was 8 of 58 (14%). 
In all patients with grade 3 or grade 4 laboratory abnormalities of CRP, total bilirubin, ALT 
and GGT, the abnormal results were pre-existent, (largely) transient or considered more 
likely related to comorbidity or the concomitant use of methotrexate. 
In 13 etanercept-treated patients (9%), severe haematological laboratory abnormalities 
were considered possibly or probably interrelated (grade 3 and/or 4 lymphocytosis (n = 10),
grade 3 lymphocytosis (n = 1), grade 4 thrombocytosis (n = 1), grade 3 leucopenia and 
grade 3 thrombocytopenia (n = 1)). In two patients on adalimumab (3%) the grade 3 
Table 4. Treatment characteristics.
Treatment characteristics Etanercept Adalimumab
Patients (n) 146 58
Treatment episode (n) 155 58
Treatment episode duration (years)
Mean ± SD 2.0 (1.5) 0.9 (0.5)
Median (range) 1.8 (0.07 – 5.2) 0.9 (0.02 – 1.9)
Patient-years 316.6 54.1
Mean weekly dose (mg) 60.0 25.2
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lymphocytosis that developed during treatment was considered possibly related. Clinical 
consequences of these laboratory abnormalities are described in the section entitled 
‘Laboratory abnormalities with clinical consequences’.
Laboratory parameters during etanercept treatment 
Mean CRP, alkaline phosphatase (ALP), platelet counts and neutrophil percentages were 
significantly lower during etanercept treatment than at pretreatment (Table 6). ALP and 
Etanercept
(n = 146)
Adalimumab
(n = 58)
Grade 3 Grade 4 Grade 3 Grade 4
CRP increased 2a 0 2b 2b
Total bilirubin increased 3c 0 0 0
Alanine aminotransferase increased 2d 0 1e 0
у-Glutamyl transferase increased ♂
♀
2f
0
2g
1h
1i
1i
1j
0
Leucocytosis 3 0 0 1
Leucopenia 1k 0 0 0
Neutrophilia 8 0 1 1
Neutropenia 0 1 0 0
Lymphocytosis 13 5 2 0
Lymphopenia 1 0 1 0
Monocytosis 1k 1 0 0
Monocytopenia 1 0 0 1
Eosinophilia 0 3 1 0
Thrombocytosis 3 3 1 1
Thrombocytopenia 1k 0 0 0
Table 5. Number of patients with grade 3 and grade 4 abnormal laboratory parameters during etanercept 
or adalimumab treatment. 
aOne patient had an exacerbation of psoriasis, recent erysipelas, urinary tract infection and arthritis. The 
second patient had a nonspecified infection. bGrades 3 and 4 increased CRP were found in the same 
patients. One of these patients had an active arthritis and psoriasis. In the other patient the increased CRP 
was assessed as possibly related to active psoriasis at one occasion and at the other occasion the patient 
had gastroenteritis. cIn all three patients the increased total bilirubin levels were pre-existing and transient. 
dPatient 1: pre-existent abnormal ALT activity, history of nonalcoholic fatty liver disease and alcohol use, 
partially transient. Patient 2: probably related to concomitant methotrexate use, partially transient after 
discontinuation of methotrexate. eProbably related to concomitant methotrexate use, partially transient 
after lowering the dose of methotrexate. fPatient 1: possibly related to alcohol use, partially transient. 
Patient 2: certainly related to alcohol abuse. gPatient 1: transient and probably related to alcohol use. 
Patient 2: pre-existing, partially transient and possibly related to fatty liver disease and diabetes mellitus. 
hTransient and probably related to alcohol use. iGrades 3 and 4 abnormal GGT activities were found in the 
same patient, certainly related to alcohol abuse. jPre-existing, partially transient, medical history of liver 
fibrosis. kIn patient with Felty’s syndrome. 
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neutrophil percentages also showed a significant declining trend. 
Mean ALT, haemoglobin, lymphocyte and basophil percentages were significantly 
higher during etanercept treatment compared with pretreatment. For ALT activities and 
lymphocyte percentages, a significant increasing trend was also detected. 
During etanercept therapy, all mean levels of laboratory parameters that were significantly 
different compared with pretreatment remained within normal reference ranges (Table 6).
In the group of patients who were not on concomitant methotrexate or acitretin 
treatment, mean (± SEM) ALT values also increased from 35 (± 2) U/L at pretreatment 
to 41 (± 2) U/L during etanercept therapy and linear regression also showed a significant 
incline (regression coefficient 0.11 (95% CI 0.03 - 0.19).
Laboratory parameters during adalimumab treatment
Mean ALP and neutrophil percentages were significantly lower during adalimumab 
Etanercept
Laboratory parameter No. of 
treatment 
episodesa
Pre-
treatmentb
During 
treatmentc
P-valued No. of 
treatment 
episodese
Regression 
coefficient (95% CI)f
Creatinine (μmol/L) 125 79 (1) 79 (1) 0.780 152 0.05 (-0.04-0.13)
C-reactive protein 
(mg/L)
123 9.0 (0.8) 6.4 (0.3) <0.001 152 -0.03 (-0.06-0.0008)
Direct bilirubin (μmol/L) 96 5.0 (0.02) 5.0 (0.003) 0.276 150 -0.0002 (-0.0006-0.0001)
Total bilirubin (μmol/L) 124 12.1 (0.5) 12.1 (0.4) 0.960 152 0.007 (-0.01-0.02)
Alkaline phosphatase 
(U/L)
71 86 (3) 76 (2) <0.001 135 -0.26 (-0.45, -0.07)
Alanine amino-
transferase (U/L)
124 35 (2) 40 (2) <0.001 152 0.08 (0.007- 0.16)
у-Glutamyl transferase 
(U/L)
92 40 (4) 38 (3) 0.306 146 -0.19 (-0.40-0.01)
Haemoglobin (mmol/L) 125 8.9 (0.1) 9.0 (0.1) <0.001 152 -0.001 (-0.008-0.006)
White blood cell count 
(x109/L)
125 7.9 (0.2) 7.6 (0.2) 0.073 152 0.006 (-0.005-0.02)
Neutrophils (%) 124 65 (1) 58 (1) <0.001 152 -0.12 (-0.20, -0.04)
Lymphocytes (%) 124 25 (1) 32 (1) <0.001 152 0.12 (0.03 – 0.21)
Monocytes (%) 124 6.2 (0.2) 6.3 (0.1) 0.597 152 -0.01 (-0.03-0.005)
Eosinophils (%) 124 2.6 (0.2) 2.6 (0.1) 0.975 152 0.002 (-0.005-0.009)
Basophils (%) 124 0.5 (0.04) 0.7 (0.03) 0.002 152 0.001 (-0.002-0.004)
Platelet count (x109/L) 125 265 (7) 244 (6) <0.001 152 -0.08 (-0.51-0.35)
Table 6. The effect of etanercept on laboratory parameters.
aNumber of treatment episodes available for comparison of mean pretreatment laboratory results and 
mean results during treatment. bValues are mean pretreatment values ± SEM. cValues are mean values 
during treatment ± SEM. dP-value for difference between pretreatment value and value during treatment. 
eNumber of treatment episodes available for linear regression. fLinear regression coefficients with 95% 
confidence intervals.
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treatment than at pretreatment. Mean haemoglobin and lymphocyte percentages were 
significantly higher during adalimumab treatment than at pretreatment. No significant 
trends were observed. During adalimumab therapy, all mean levels of laboratory 
parameters with a significant difference in pretreatment and treatment values remained 
within normal reference ranges.
Laboratory abnormalities with clinical consequences
Laboratory abnormalities did not lead to permanent discontinuation of biologic treatment 
in any patient. Biologic treatment was temporarily interrupted in patients presenting with 
an infection clinically with or without elevated infection parameters. Elevated infection 
parameters during biologic treatment without clinical signs of infection occasionally led 
to temporary discontinuation.
Two patients (1%) required a temporary interruption of biologic treatment due 
to severe haematological laboratory abnormalities. One patient had a leucopenia 
(grade 1), neutropenia (grade 2) and lymphocytosis (grade 3) 4 months after the start 
of adalimumab treatment per label. Consequently, adalimumab was temporarily 
discontinued for 4 weeks, during which time the laboratory abnormalities returned 
to normal. The laboratory abnormalities did not recur during the subsequent year of 
adalimumab treatment.
Etanercept was interrupted temporarily in a patient with Felty’s syndrome due to a grade 
3 leucopenia and a grade 3 thrombocytopenia 5 months after the start of etanercept at 
a dosage of 25 mg twice a week, which were considered possibly related. The laboratory 
abnormalities were partially transient. 
C-reactive protein
Mean CRP was significantly lower during biologic treatment than at pretreatment, both 
in the group of patient with psoriatic arthritis and the group of patients without psoriatic 
arthritis. In the group of patients with psoriatic arthritis mean (± SEM) CRP decreased 
from 9.5 (± 1.2) mg/L at pretreatment to 6.4 (± 0.7) mg/L during biologic treatment
(p < 0.05). In the group of patients without psoriatic arthritis mean (± SEM) CRP 
decreased from 8.5 (± 0.9) mg/L at pretreatment to 6.4 (± 0.3) mg/L during treatment 
(p < 0.01). 
Antinuclear antibodies
Etanercept
Seroconversion occurred in four patients during etanercept treatment, from negative to 
weakly positive in two patients, from negative to cytoplasmic dot pattern in one patient 
and from negative to 3+ in the fourth patient. None of these patients showed clinical 
signs of lupus erythematosus or other connective tissue diseases. 
In two patients on etanercept, ANA was weakly positive at the time of screening for 
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etanercept, but became 1+ positive (nucleoli and dot, respectively) during etanercept 
treatment. These patients did not have any signs or symptoms of autoimmune disease 
either. 
In a third patient, autoimmune antibody patterns changed from positive anti-SS-A at 
screening to positive anti-SS-A and anti-SS-B during etanercept treatment. This patient 
turned out to have Sjögren’s disease in combination with psoriasis. The relation between 
this seroconversion and etanercept therapy was uncertain, and etanercept was continued. 
No other autoimmune antibodies or symptoms developed afterwards. 
Adalimumab
Seroconversion occurred in two patients during adalimumab treatment from negative to 
weakly positive and from negative to 1+, respectively, without signs of autoimmune disease.
aNumber of treatment episodes available for comparison of mean pretreatment laboratory results and 
mean results during treatment. bValues are mean pretreatment values ± SEM. cValues are mean values 
during treatment ± SEM. dP-value for difference between pretreatment value and value during treatment. 
eNumber of treatment episodes available for linear regression. fLinear regression coefficients with 95% 
confidence intervals.
Table 7. The effect of adalimumab on laboratory parameters. 
Adalimumab
Laboratory parameter No. of 
treatment 
episodesa
Pre-
treatmentb
During 
treatmentc
P-valued No. of 
treatment 
episodese
Regression 
coefficient (95% CI)f
Creatinine (μmol/L) 17 75 (4) 72 (3) 0.226 54 0.001 (-0.1-0.1)
C-reactive protein 
(mg/L)
17 7.6 (1.1) 6.0 (0.4) 0.095 54 0.008 (-0.07-0.09)
Direct bilirubin (μmol/L) 16 5.1 (0.1) 5.1 (0) 0.164 53 0.001 (-0.004-0.006)
Total bilirubin (μmol/L) 17 11.5 (1.1) 10.4 (0.7) 0.129 54 -0.04 (-0.1-0.02)
Alkaline phosphatase 
(U/L)
17 73 (2) 68 (2) 0.022 54 -0.02 (-0.2-0.2)
Alanine amino-
transferase (U/L)
18 38 (4) 36 (5) 0.451 54 -0.1 (-0.4-0.08)
у-Glutamyl transferase 
(U/L)
17 35 (6) 34 (7) 0.816 54 -0.5 (-1.3-0.3)
Haemoglobin (mmol/L) 17 8.6 (0.2) 8.8 (0.2) 0.025 54 0.03 (-0.004-0.06)
White blood cell count 
(x109/L)
17 8.3 (0.6) 7.9 (0.5) 0.296 54 0.009 (-0.04-0.05)
Neutrophils (%) 16 65 (2) 58 (2) 0.003 54 -0.1 (-0.3-0.1)
Lymphocytes (%) 16 26 (2) 34 (2) <0.001 54 0.1 (-0.07-0.3)
Monocytes (%) 16 5.8 (0.6) 5.2 (0.4) 0.357 54 -0.02 (-0.06-0.02)
Eosinophils (%) 16 2.1 (0.3) 1.9 (0.4) 0.587 54 -0.006 (-0.03-0.02)
Basophils (%) 16 0.5 (0.1) 0.5 (0.1) 0.872 54 0.009 (-0.009-0.03)
Platelet count (x109/L) 17 258 (18) 247 (13) 0.165 54 0.1 (-0.5-0.7)
170
Discussion
Recommendations about laboratory testing in patients with psoriasis treated with 
biologics should be based on a consideration of the potential risks and benefits. To 
justify the patient burden of repeated venipunctures, possible further investigations and 
the use of healthcare resources, abnormal laboratory parameters should have clinical 
consequences and early detection and adjustment of treatment should result in a better 
outcome.6
 
In the present cohort, 38 patients treated with etanercept (26%) and eight patients 
treated with adalimumab (14%) had one or more grade 3 and/or grade 4 laboratory 
abnormalities. Severe laboratory abnormalities were mainly considered unrelated to the 
biologic therapy and changes in mean values remained within normal reference ranges.
Two patients (1%) required a temporary interruption of biologic treatment due to 
severe haematological laboratory abnormalities. Laboratory abnormalities did not 
lead to complete discontinuation of treatment, whereas a patient’s clinical signs and 
symptoms of, for example, infection without laboratory testing did lead to interruption or 
discontinuation of biologic treatment. 
Confounders in this study were comorbidity and comedication, which were taken into 
account when assessing the relation between serious laboratory abnormalities and the 
biologic therapy. Severe laboratory abnormalities were mainly considered unrelated to 
the biologic, although a causal relation could not be excluded with certainty. 
Laboratory panels for monitoring biologic therapy vary between guidelines, between 
guidelines and daily practice and between physicians. In addition, the frequency of 
testing differs considerably.1-8 
In a literature review (using the Cochrane databases and MEDLINE) evaluating the 
evidence for screening and monitoring tests in patients with psoriasis on biologic therapy, 
the authors were unable to make definitive recommendations either in favour or against 
them based on the available literature.2 Current recommendations for laboratory 
screening and monitoring are mainly based on short-term clinical trials and literature 
reviews, rather than cohort studies examining the relevance of different laboratory 
screening and monitoring strategies.2 
This study was based on prospectively collected laboratory data from a cohort of patients 
with psoriasis treated with biologics in daily practice for 5 years. As most patient-years of 
follow-up were available for etanercept and adalimumab, these therapies were evaluated.
A distinct finding in this study was a significant reduction in neutrophil counts for 
etanercept as well as adalimumab. This has been previously described in patients with 
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inflammatory arthritides with a few patients developing a serious infection. In our cohort, 
no serious infections associated with neutropenia were seen.11 
In the literature, elevated liver enzymes have been reported for anti-TNFα treatments.12-14 
In the present cohort, a significant increase of mean ALT during etanercept treatment was 
found as well, but mean ALT activities did not exceeding normal reference ranges. In the 
investigator’s judgement, severely elevated ALT activities in our cohort were more likely 
due to concomitant therapy or comorbid disorders than to the biologic treatment. 
Renal impairment has commonly been reported during adalimumab treatment in clinical 
trials,13 but was not found in our cohort. 
CRP decreased during biologic treatment in patients with and without psoriatic arthritis. 
This has been reported in several studies in the literature.15, 16 Also, a correlation with the 
PASI score has been reported. With the CRP assay used (Architect; Abbott, Abbott Park, IL, 
U.S.A.), levels below 5 mg/L were not specified and were imputed as 5. Still, a significant 
decrease was measured during biologic treatment. The relevance of low levels of CRP 
could be discussed, although Ridker et al.17 showed that achieving CRP levels of < 2 mg/L 
is associated with a significant improvement in event-free survival in patients with acute 
coronary syndrome in their history, regardless of their levels of low-density lipoprotein 
cholesterol. 
The purpose of laboratory investigations before starting treatment with biologics is to 
detect pre-existent abnormalities which form contraindications or risk factors for starting 
biologic therapy and to provide a baseline value. Baseline laboratory parameters are 
important for interpreting abnormal laboratory test results which evolve during biologic 
treatment in terms of clinical significance and causality. We therefore propose that the 
pretreatment laboratory panel should at least encompass the laboratory parameters 
assessed during treatment. 
During treatment, the monitoring of ALT, GGT and CRP can be considered. ALT testing 
seems useful, as a small but statistically significant increase in ALT was detected during 
etanercept treatment. ALT and GGT testing is also important because of common 
comorbidities in patients with psoriasis affecting liver function tests, such as nonalcoholic 
fatty liver disease, diabetes and alcohol use. CRP testing can be considered to detect 
infections, although most patients have infections in the interval between hospital visits. 
Monitoring of the full blood cell count and white blood cell differentiation can also be 
considered, as some severe haematological abnormalities and statistically significant 
declining trends were observed in our cohort. Previously these adverse effects have 
also been described in the literature and in the Summary of Product Characteristics of 
etanercept and adalimumab.12, 13
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In the present study no (biologic therapy-related) severe laboratory abnormalities or 
clinically significant changes of creatinine, direct and total bilirubin and ALP were found 
during treatment. Hence, routine laboratory monitoring of these parameters does not 
seem useful. 
 
A positive ANA is nonspecific and does not preclude a patient from starting biologic 
therapy. However, in our opinion, it is important to have a baseline test result, as 
seroconversion of ANA during TNF-α blocking therapy is a known phenomenon and rarely 
patients with a lupus-like syndrome have been reported in the literature.18 ANA can then 
be reassessed in case of signs or symptoms of lupus erythematosus.
A pregnancy test performed at pretreatment is recommended, as data on the use of 
biologic therapies during pregnancy are still sparse, together with data associating TNF-
antagonists with VACTERL.8 
HIV testing is recommended to be performed at screening only in patients at risk and 
hepatitis B and C testing is recommended to be performed in all patients at screening, 
although there is insufficient evidence to support this.1, 2, 4, 5, 7, 8 
The literature review of Huang et al.2 recommended against a standard urinalysis. 
Although not analysed in this study, we would suggest evaluating urine by strip analysis 
before starting treatment to have a baseline value and to repeat urinalysis only when 
there is clinical suspicion and symptoms of a urinary tract infection.
This study does not support routine laboratory testing in patients with psoriasis treated 
with biologics beyond the laboratory testing required for concomitant antipsoriatic 
systemic medication or comorbidities. Routine testing every 3 months may not be 
necessary either. However, this has not been investigated in other prospective studies. 
Additional evidence in a larger group of patients with a longer follow-up and future 
implementation studies could provide more evidence as to which laboratory panels and 
intervals are appropriate. 
At least as important as laboratory testing is obtaining an appropriate history and physical 
examination to estimate potential risks for the individual patient when deciding on 
treatment and monitoring strategies.
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Main study objective
The objective of the present thesis was to prospectively investigate the long-term efficacy 
and safety of biologics in the treatment of patients with moderate to severe psoriasis in 
daily clinical practice. The majority of the data analysed were extracted from a prospective 
registry, named the Bio-CAPTURE registry. In this registry, all consecutive patients with 
psoriasis starting biological therapy in routine clinical practice are enrolled.
The registry reflects to some extent the history of the introduction of biologics. Etanercept 
was one of the first biologics registered for psoriasis. Therefore, at the beginning of the 
biological era, etanercept was the first biological therapy for many patients. In case of 
insufficient efficacy of etanercept or adverse events during etanercept therapy, patients 
mainly switched to adalimumab. Therefore, most efficacy and safety data in this thesis 
concern etanercept and adalimumab. Efalizumab safety data are presented in chapter 7,
although this agent has been withdrawn from the market in 2009 because of serious 
safety concerns.
The registry also reflects the logistic organization of our department. In our department, 
infliximab is reserved for patients with very severe psoriasis who require rapid 
improvement and for patients who failed to respond to other biologics. This is due to 
the facilities required for the administration of infliximab and the infusion reactions 
sometimes observed. Therefore, infliximab has not been widely used in our department. 
Ustekinumab was registered for psoriasis in 2009. At the time the studies outlined in this 
thesis were performed, experience with ustekinumab was limited. Chapter 7 presents 
the data available in our registry on the long-term safety of infliximab and ustekinumab.
After having clarified these historical and logistical aspects, we will now revert to the 
research questions as defined in chapter 1. We will discuss the questions and come to 
conclusions based on these discussions as well as the studies presented in chapter 2-9.
Research question 1: What is the long-term efficacy of biologics for psoriasis 
in daily practice?
Efficacy or effectiveness
Efficacy and effectiveness are two terms that are both used for describing the effect of 
a certain treatment. However, these terms have different meanings. Efficacy describes 
the effect of a treatment in the controlled setting of an RCT, whereas effectiveness 
describes the effect in a real life clinical setting.1-3 In this thesis, the term efficacy is used 
mostly to describe the effects of biological therapies in daily practice, whereas the term 
effectiveness would actually have been more appropriate. To be consistent, the term 
efficacy will continued to be used in this chapter.
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Long-term efficacy of etanercept and adalimumab
Etanercept and adalimumab therapy for moderate to severe psoriasis in daily practice 
were effective in the long-term. In chapter 6, the long-term efficacy of etanercept 
in patients with a mean treatment duration of 2.7 years is shown to be substantial. In 
chapter 4, it is shown that the efficacy of adalimumab in patients with a mean treatment 
duration of 1.4 years was well maintained. 
Considering the results of the intention-to-treat (ITT) analysis with last observation 
carried forward (LOCF) and modified nonresponder imputation (modified NRI) in 
chapter 6 (Figures 2-4), there appears to be a gradual loss of efficacy of etanercept. This 
was already shown in open-label extension studies.4, 5 The phenomenon responsible for 
loss of efficacy has not been elucidated yet. Possible explanations could be biological 
adaptation to chronic TNF-α blockade (not by antibody formation in case of etanercept), 
decreased TNF-α dependency of the disease, increased metabolic clearance or 
compliance problems.5-7 
Open-label extension studies and daily practice experience have shown that there can be 
loss of efficacy with adalimumab therapy as well.8, 9 Explanations for loss of efficacy with 
adalimumab therapy include those mentioned for etanercept plus antibody formation 
against adalimumab, which has been shown to be associated with impaired treatment 
outcomes.10
Indirect comparisons between the long-term efficacy of etanercept and adalimumab should 
be made with caution due to differences in patient populations and dosing regimens. 
Daily clinical practice versus randomized controlled trials
The long-term efficacy of etanercept and adalimumab in our daily practice studies was 
lower than in RCTs and open-label extension studies of RCTs.5, 9, 11-22 However, it has to be 
kept in mind that comparisons between RCTs and daily practice are seriously hampered 
by differences in patient populations, outcome measures, time points of assessment, 
methods of analysis and dosing regimens used.
A few explanations can be given for the lower PASI 75 response rates in our study compared 
with RCTs. Firstly, our study concerned patients treated in a university hospital. Patients 
who are referred to a tertiary care centre probably are more therapy-resistant. Secondly, 
patients in daily practice have to fulfil strict reimbursement criteria, which is not an 
eligibility criterion for RCTs. This may also lead to the selection of more therapy-resistant 
patients in real-world practice. Thirdly, patients included in RCTs are in general ‘healthy’ 
patients, who fulfil strict inclusion and exclusion criteria, whereas patients in daily practice 
generally have comorbidities and concomitant medication. Furthermore, washout periods 
are applied in RCTs, leading to a high baseline PASI. As a result, some patients will be 
enrolled based on high PASI scores, that are not representative of their mean PASI. This 
favours a phenomenon called ‘regression to the mean’. In addition, investigators may have 
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the tendency to measure psoriasis severity using the higher end of the subjective range 
of the scale of the PASI at initial assessment visits, when eligibility for a clinical trial is 
determined. This phenomenon is called ‘eligibility creep’. These two phenomena may also 
partly explain the considerable placebo effects seen in psoriasis clinical trials.23
Other explanations for the lower efficacy found in daily practice may be compliance 
problems, inadequate use of the biologic and interruptions of treatment due to infections 
or elective surgery. On the other hand, treatment strategies applied in daily practice like 
the concomitant use of topical or classical systemic therapies and dose escalation of 
biologics, may bias efficacy in a positive way.
In conclusion: etanercept and adalimumab therapy for moderate to severe psoriasis in 
daily practice are effective in the long term. Daily clinical practice and RCTs differ in many 
aspects, which implies that daily practice studies provide important complementary 
information to RCTs.
PASI as outcome measure
PASI 50/75/90/100 are the outcome measures most frequently used in clinical trials and 
daily practice studies, which permits comparisons of study results. However, absolute 
outcome measures reflecting static psoriasis severity, like for example the static Physician’s 
Global Assessment (PGA), may be more reasonable for use in long-term studies than 
outcome measures that reflect change in relation to baseline, which is the focus of RCTs.24, 25
An important limitation of the PASI is that it does not include quality of life, psoriasis 
in ’high-impact’ sites (visible areas/scalp/genital) and nail involvement.26, 27 There is a 
need for a composite outcome measure that includes all relevant aspects of psoriasis. 
Another inherent limitation of the PASI is the low responsiveness in case of small areas 
of involvement.
Selection of the baseline PASI
As shown in chapter 2-6, efficacy is highly dependent on the baseline PASI used and 
the methodological approach chosen to analyse long-term efficacy. The influence of 
methodological approaches will be discussed later. 
In chapter 3, the response to adalimumab is evaluated in relation to the baseline PASI 
before the start of adalimumab (course baseline PASI) and the baseline PASI before the 
start of etanercept (original baseline PASI). In chapter 4, the response to adalimumab is 
evaluated in relation to the baseline PASI before the start of adalimumab (course baseline 
PASI) and the first available baseline PASI before the start of a biological therapy at the 
moment of enrolment in the registry (original baseline PASI). This was done because of 
a potential carry-over effect of the previous therapy, which often leads to a lower course 
baseline PASI than the original baseline PASI. 
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The current gold standard outcome measure PASI 75 is a measure of relative improvement 
with respect to baseline. In view of residual psoriasis that is frequently seen and the low 
responsiveness of the PASI in case of small areas of involvement, a PASI 75 response is 
difficult to attain starting from a low baseline PASI. 
In conclusion: efficacy results depend on which baseline PASI is used, when relative 
outcome measures are used (e.g. PASI 75). It is important to consider this for correctly 
interpreting efficacy results. An alternative could be the additional use of an absolute 
outcome measure.
Treatment goals
In 2011, a European consensus group published treatment goals for the treatment of 
moderate to severe plaque psoriasis with systemic therapies, on the analogy of treatment 
goals for other chronic diseases like diabetes mellitus.28 These treatment goals include 
the severity of psoriasis measured with the PASI and quality of life measured with the 
Dermatology Life Quality Index (DLQI). The use of treatment goals involves regular 
assessments of treatment response after the induction phase and during the maintenance 
phase, to see if treatment goals are met. In case treatment goals are not met, the 
treatment regimen should be modified. Treatment goals may help dermatologists in 
providing high-quality care for psoriasis patients and may lead to less undertreatment. 
The studies outlined in this thesis were largely performed before the publication of these 
treatment goals.
In rheumatoid arthritis (RA), treating-to-target or so called tight control treatment, 
showed better treatment results compared with standard care.29, 30 The efficacy of 
treatments for psoriasis could improve as well by using tight control approaches. However, 
before treatment goals are implemented for psoriasis, the added value should first be 
demonstrated. In addition, although treatment goals may be applied to all patients 
with moderate to severe psoriasis in the future, treatment modifications should still be 
personalized.31
In the first years after the registration of biological therapies for psoriasis, the treatment 
goal in the Netherlands, although not defined as such, was a PASI reduction of at least 
50% (PASI 50) at week 12 to get approval for continued treatment and reimbursement. 
The Dutch psoriasis guideline (2003, updated in 2005 and 2009) also required a PASI 50 
response at week 12 for etanercept and efalizumab and a PASI 50 response at week 8 for 
infliximab.32 The current gold standard treatment goal is PASI 75.33, 34 This may be changed 
into PASI 90 or even PASI 100 with the advent of highly effective therapies.
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In conclusion: treatment goals offer the possibility for standardized tight control 
treatment. Further studies in daily practice have to show which treatment goal correlates 
best with an optimal improvement from the perspective of the patient.
The clinical utility of observational studies
In the future, the efficacy and safety of biological therapies for psoriasis will be 
compared with data from a similar observational study performed in our department 
investigating the efficacy and safety of methotrexate for psoriasis (MTX-CAPTURE). A 
limitation of such a comparison and of observational studies in general is that there is 
nonrandom assignment to treatment leading to confounding by indication, e.g. when 
the patients treated with biologics have more severe psoriasis than the patients treated 
with methotrexate. Confounding by indication is a well-known limitation of comparisons 
using observational data. Confounding by indication occurs when the outcome of interest 
is related to the factors that determine the indication for treatment. However, results 
of observational studies can be confirmed in other studies and can lead to important 
modifications in clinical practice.
In conclusion: notwithstanding the methodological restrictions of observational studies, 
this form of research offers a valuable approach to assessing the efficacy and safety of 
biological therapies for psoriasis in daily practice. 
Research question 2: Is consecutive treatment with a second biologic 
therapy effective and safe? Is there an influence of biologic-naïvety versus 
non-naïvety on the efficacy results?
In chapter 3, switching from etanercept to adalimumab is shown to be effective and 
safe in patients who were naïve to biologics at the time of initiation of etanercept. On 
the analogy of studies in RA and a few studies in psoriasis, patients in this study were 
categorized as primary nonresponders to etanercept (patients not achieving PASI 50 at 
week 12), secondary nonresponders to etanercept (patients with loss of response after 
achieving PASI 50 at week 12) and patients who discontinued etanercept therapy due to 
adverse events (categorized as ‘intolerance’). 
Studies in RA have shown that the efficacy of a second TNF-inhibitor is less than the 
efficacy of the first TNF-inhibitor and that the response to a second TNF-inhibitor depends 
on the reason for discontinuation of the first TNF-inhibitor. This decline in efficacy with 
a second TNF-antagonist is suggested to be a result of a class effect or the selection of 
patients with more severe disease.35 Gniadecki et al. also showed that the drug survival 
of anti-TNFα agents for psoriasis, which is an indicator of treatment success, was higher 
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in anti-TNFα-naïve patients compared with patients who previously experienced lack of 
efficacy of one more anti-TNFα agents.36
In our study outlined in chapter 3, response rates to adalimumab compared with the 
original baseline PASI were generally better (although not statistically significant) than 
those previously achieved with etanercept. Irrespective of the reason for discontinuation 
of etanercept, the chance of having a primary response on adalimumab (defined as 
achieving PASI 50 at week 12) was higher than the chance of primary failure. This suggests 
that TNF-inhibitors demonstrate unique agent-specific profiles rather than ‘class effects’,37 
although the percentage of patients achieving a primary response was higher among the 
secondary nonresponders to etanercept (11 out of 14 (79%)) than among the primary 
nonresponders to etanercept (6 out of 11 (55%)). 
In chapter 4, it is shown that the PASI 75 response rates on adalimumab during 48 weeks 
were only significantly higher in biologic-naïve versus non-naïve patients at week 12. 
These findings are supported by a study from Ortonne et al., who found only modestly 
decreased efficacy of adalimumab in patients with prior exposure to one or more TNF-
antagonists compared with patients without prior exposure to TNF-antagonists.38 
Additional studies with larger numbers of patients are needed to address this further.
The efficacy of adalimumab in patients who failed to respond to etanercept may be 
explained by differences in molecule structure, mechanism of action or pharmacogenetics. 
The observation that adalimumab, in contrast with etanercept, is an effective therapy for 
granulomatous diseases, supports different biological properties of these two anti-TNFα 
agents.39 
In chapter 3, it is shown that previous treatment with etanercept did not increase the 
adverse event rate nor change the nature of the adverse events during subsequent 
adalimumab therapy up until 48 weeks. 
In conclusion, switching from etanercept to adalimumab is effective and safe, 
irrespective of the reason for discontinuation of etanercept. Further studies are needed 
to investigate whether previous treatment with biologics results in decreased efficacy 
of the subsequent biologic therapy in psoriasis patients.
Research question 3: What is the efficacy and safety of adalimumab dose 
escalation or combination therapy with methotrexate?
In case of insufficient efficacy of a biological agent, a treatment modification strategy can 
consist of dose escalation, the addition of another (systemic) therapy (combination therapy) 
or transition to another drug or modality.28 However, before switching to another treatment, 
one may want to use the full potential of a biological therapy, as switching reduces the 
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number of available treatment options. Dose escalation and combination therapy are not 
approved for use in psoriasis. However, both treatment strategies are used in daily practice.
Dose escalation includes increasing the amount of the biological agent per single dose 
or shortening the dosing interval. In patients with a very good response, dose reduction 
is sometimes tried. Dose reduction includes reducing the amount of the biologic per 
single dose or lengthening the dosing interval. A substantial proportion of the patients in 
the studies described in this thesis was (temporarily) treated with an escalated dose of 
adalimumab or etanercept or with combination therapy. Only some patients received a 
reduced dose of adalimumab or etanercept. 
Chapter 5 describes the efficacy and safety of adalimumab dose escalation (to 40 mg 
per week) and combination therapy (adalimumab 40 mg every other week combined 
with methotrexate). In addition, the efficacy and safety of both treatment strategies 
applied at the same time was investigated. It is shown that a subgroup of patients with 
an insufficient response to adalimumab 40 mg every other week benefits from dose 
escalation or combination therapy (25% of first treatment episodes of adalimumab dose 
escalation resulted in PASI 50 at week 12 and 9% of treatment episodes with combination 
therapy with methotrexate resulted in PASI 50 at week 12). In a small number of patients 
both treatment strategies were applied at the same time with variable results.
Leonardi et al. found comparable results in their study: one quarter of patients benefited 
from adalimumab dose escalation (27% achieved PASI 75 within 12 weeks).8 However, in 
the study of Leonardi et al., a responder was defined as a patient achieving PASI 75 relative 
to the baseline PASI of their first psoriasis study, whereas in our study, a responder was 
defined as a patient achieving PASI 50 in relation to the PASI at the start of the treatment 
modification. A phase II study also showed that a subgroup of patients can benefit from 
adalimumab dose escalation.11 In contrast, in RA, it was shown that there is no significant 
change in disease activity with adalimumab dose escalation.40 
Leonardi et al. retrospectively identified three patient characteristics that predicted a 
beneficial response to adalimumab dose escalation: secondary nonresponders, relatively 
low weight and relatively short disease duration.8 Additional studies are needed to 
identify patient characteristics that predict which patients will benefit from which 
treatment strategy, from the point of view of optimization of treatment and the high 
costs of adalimumab dose escalation. 
In patients receiving combination therapy with methotrexate, the dose of methotrexate 
was relatively low. In addition, in some patients the duration of combination therapy was 
short. Addition of methotrexate in a higher dose and for a longer period of time may lead 
to better results. Data on adalimumab combined with methotrexate for psoriasis in the 
literature are limited to studies with small numbers of patients successfully treated with 
combination therapy.22, 41, 42 
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Both adalimumab dose escalation and combination therapy with methotrexate were 
well tolerated. No therapy-related SAEs occurred. Safety data on non-standard dosing 
regimens with escalated doses of adalimumab and etanercept in the literature are 
limited. Up until now, there has been no evidence that treatment regimens with an 
escalated dose lead to increased adverse event rates.5, 8, 11, 13, 14, 43, 44 Further large and long-
term studies are needed to confirm the absence of safety issues with dose escalation or 
combination therapy in psoriasis.
The efficacy and safety of etanercept dose escalation or combination therapy of etanercept 
with a classical systemic therapy was not specifically addressed in this thesis, but has 
been described in the literature. Two studies investigated etanercept dose escalation to 
50 mg twice weekly in patients with an insufficient response to etanercept 50 mg once 
weekly.13, 45 Both studies showed greater efficacy with the escalated dose. With respect 
to combination therapy, most evidence is available for the combination of etanercept 
and methotrexate.46-51 Combining etanercept with methotrexate in patients with an 
insufficient response to etanercept monotherapy increased efficacy and had acceptable 
tolerability in these studies.46, 48
In conclusion: dose escalation of adalimumab and combination therapy with 
methotrexate enhance the efficacy of adalimumab in a subgroup of psoriasis patients 
and were safe in this study. 
Research question 4: What is the influence of different analytical methods 
on the efficacy results?
RCTs are most often analysed according the intention-to-treat (ITT) principle. An ITT 
analysis includes all randomized patients in the groups to which they were randomly 
assigned, regardless of the treatment they actually received and regardless of early 
withdrawal from the study or deviation from the protocol.2, 52, 53 In the Bio-CAPTURE study, 
patients are not randomized. However, the term ITT analysis is used in chapter 4-6, as all 
patients were analysed for the full period of analysis. This has also been done in other 
observational studies.17, 54
As the duration of a study increases, the number of patients continuing in the study usually 
declines, leading to missing data.52 Data can be missing for a variety of reasons, including 
withdrawal from the study due to lack or loss of efficacy or adverse events.2, 52, 53, 55 
Different approaches for providing an estimated value for missing data exist, commonly 
referred to as ‘imputation’ of missing data (Table 1). In our study, the efficacy outcome 
measures are PASI 50, PASI 75 and PASI 90. Imputation methods commonly used in RCTs 
are last observation carried forward (LOCF) and nonresponder imputation (NRI).
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With LOCF, the previous available value is used for the subsequent missing value(s). 
Although criticized by statisticians, LOCF is the most commonly used imputation method 
in RCTs. It is generally considered to provide a conservative estimate of efficacy.52
The most conservative approach is NRI. With NRI, a patient with a missing value is 
regarded as a nonresponder, also referred to as ‘missing equals failure’ (MEF). In an as-
treated analysis, missing values are excluded from the analysis, which is also referred to 
as ‘missing equals excluded’ (MEX).2, 53, 56 The as-treated analysis is sometimes also called 
observed values analysis (chapter 2) and is mainly being used in observational studies 
and open-label extension studies from RCTs.4, 56, 57
Based on the research question, different analytical methods can be chosen. The as-
treated analysis gives an idea of maximum efficacy. However, if one wants to know what 
treatment efficacy is under less ideal conditions, including patients who discontinue 
treatment due to insufficient efficacy, an ITT analysis will provide better information.2 
As shown in chapter 6, the methodological approach used has a major influence on the 
efficacy results. In our study, efficacy could double when the as-treated approach was 
used instead of the modified NRI approach.
Using NRI in an observational cohort study is problematic, as the inclusion of patients is 
continuously ongoing. Applying NRI for patients who were still using etanercept at the 
time of analysis, but did not reach all time points of analysis due to an insufficient duration 
Table 1. Description of different approaches for the analysis of data in clinical studies.52
Approach Abbreviation Description Equivalent 
terminology
Populations
Intention-to-treat ITT All randomized patients in the groups to which they 
were randomly assigned
Per-protocol PP All patients who did not deviate from the protocol Adherers only
Intention-to-observe ITO All patients entering the observational phase of a long-
term study
Maintenance ITT
Imputation of missing data
Missing equals succes MES Missing values are assigned as a success
Missing equals failure MEF Missing values are assigned as a failure Nonresponder 
imputation
Missing equals excluded MEX Missing values are excluded from the analysis As-treated
Missing completely at 
random
MCAR The missingness of data does not depend on the 
previously observed or current unobserved outcomes
Missing at random MAR The missingness of data depends on the previously 
observed values, but not the current unobserved values
Missing not at random MNAR The missingness of data depends on the current 
unobserved outcomes
Last observation carried 
forward
LOCF The previous observation is used for the missing value
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of follow-up, was considered inappropriate. Therefore, a less conservative modification 
of the NRI approach, named the modified NRI approach, was used in chapter 6.56
The influence of missing data on the efficacy outcomes of a study depends on the 
reasons for missing data. As shown in Figure 1 in chapter 6, the most frequent reason 
for discontinuing etanercept treatment in our study was loss of efficacy or a combination 
of loss of efficacy and adverse events.55 For this reason and for reason of the prolonged 
treatment duration of responders, the as-treated analysis gives a too positive view of the 
efficacy of etanercept. On the other hand, nonresponder imputation would probably give 
a too negative view of the efficacy of etanercept, as a substantial number of treatment 
episodes had missing data for other reasons than loss of efficacy or a combination of 
loss of efficacy and adverse events. The modified NRI method may underestimate the 
efficacy of etanercept as well, as some patients who discontinued etanercept due to lack 
of efficacy or a combination of lack of efficacy and adverse events, actually were PASI 75
responders (Figure 3). This means that a PASI 75 response is not always a sufficient 
response for patients and/or dermatologists. 
A way to overcome the bias introduced by each statistical method, is the use and 
development of other outcome measures. A possible outcome measure could be the 
amount of time patients continue to take a particular drug, which is also referred to as ‘drug 
survival’. Drug survival is an indirect measure of drug efficacy. However, drug survival is also 
dependent on side effects, general satisfaction with the treatment and the availability of 
other therapies.36, 55 An alternative outcome measure could be represented by a biomarker 
that measures psoriasis activity instead of an outcome measure that measures psoriasis 
severity like the PASI. However, reliable biomarkers are not available at this moment. 
In conclusion: every method of analysis has its advantages and disadvantages and can 
introduce a bias. As the method of analysis used has a large influence, we support the 
use of different methods of analysis. 
Research question 5: What is the safety profile of biologic treatment for 
psoriasis with extended exposure?
Chapter 7 shows that the safety profile of biological therapies was favourable in patients 
with prolonged treatment with one biologic or consecutive biological agents during 5 
years of follow-up. The incidence of serious adverse events was low. This corresponds 
with data from RCTs, meta-analyses and open-label extension studies.58
Most safety data in this thesis concern etanercept and adalimumab. Chapter 7 presents 
the available safety data on efalizumab, ustekinumab and infliximab. Data on the safety 
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of ustekinumab and infliximab are also available in the literature. The long-term safety of 
ustekinumab up to five years has been shown in a long-term extension study from RCTs.59 
The intermediate-term safety of infliximab in psoriasis has been shown in an RCT with 
50 weeks duration, an RCT with an open-label extension phase lasting 78 weeks and a 
retrospective study in patients treated with infliximab for a minimum of one year and a 
mean follow-up of 2.2 years.58, 60-62
As described in chapter 7, adverse events in our study were mainly mild and were of the 
same nature as described in earlier reports from our registry and in other studies. Twenty-
eight percent of the patients reported at least one SAE. However, only 24% of SAEs was 
considered to be possibly therapy-related, taking into account the time relationship and 
the patient’s medical history. Only one serious adverse event (infusion reaction) was 
considered to be certainly causally related to infliximab treatment.
Criteria for determining causality in epidemiological studies have been established, the so 
called Bredford-Hill criteria.63 In addition, WHO causality categories exist.64 However, the 
best way to attribute causality in adverse events detected or to measure their magnitude, 
is to make a comparison with a control group.65 In the study described in chapter 7, 
observed numbers of malignancies, serious infections and serious cardiovascular events 
are compared with the expected rate in the general population. It is shown that the 
incidence of these serious adverse events was comparable with the population incidence 
rate, except for nonmelanoma skin cancer (NMSC). However, the number of patients 
was too small to detect possible differences in the incidence of other less frequent SAEs. 
The increased incidence of NMSC could also be explained by previous phototherapy 
and nonbiologic systemic agents or a higher awareness for skin malignancies among 
dermatologists than among general practitioners. It was  shown that 5 out of 7 psoriasis 
patients with NMSC were diagnosed with their first NMSC within 5 months after the 
start of biological treatment, which suggests that these NMSC cases can be explained by 
previous therapies like phototherapy instead of by the biological therapy.
All biologics were analysed as one group, as the majority of patient-years of follow-up 
concerned etanercept and because some adverse effects like malignancies may appear 
after a long latency period, which makes it difficult to attribute them to a specific 
therapy. However, ideally all biological agents should be analysed separately, as inter-
class and even intra-class differences in the risk of inducing SAEs may exist. TNF-inhibitors 
as a class for example, have been associated with reactivation of latent tuberculosis, 
development or worsening of heart failure, demyelinating diseases and drug-induced 
lupus erythematosus.26, 34
The incidence of SAEs observed with adalimumab therapy in daily practice (0.23 SAEs 
per patient-year (chapter 4)) was higher than the incidence of SAEs reported with 
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adalimumab therapy in the REVEAL randomized controlled trial (0.06 SAEs per patient-
year), an open-label extension study (0.07 SAEs per patient-year) and a comprehensive 
analysis of all adalimumab exposure in all clinical trials (0.09 events per patient-year).9, 16, 66
However, the number of SAEs, the number of patients and the number of patient-years of 
follow-up in our study were too low to draw definitive conclusions. 
A possible explanation for the higher morbidity associated with adalimumab therapy in 
our study could be that daily practice patients have more comorbidity and concomitant 
medication. This is supported by a study from Garcia-Doval et al., who showed that 30% 
of patients receiving systemic therapy (biologic and nonbiologic) for psoriasis in daily 
practice were not eligible for RCTs and that the risk of SAEs in these patients was higher 
than in patients eligible for RCTs.67 
Biologics are currently seen as third-line therapies after topical therapies, phototherapy 
and conventional nonbiologic systemic agents, due to remaining concerns about their 
long-term safety and their high cost. Present intermediate-term data show a favourable 
risk-benefit profile, but there is not yet enough insight into the safety of biological 
therapies for psoriasis in the very long term. There are still long-term concerns regarding 
the possibility of certain adverse events like malignancies with possible long latency 
periods, although up until now, there have been no signs of cumulative toxicity with the 
currently available biologics.58
In 2009, the EMA withdraw the market authorization of efalizumab, due to three fatal 
cases of progressive multifocal leucoencephalopathy (PML) in patients who had been 
treated with efalizumab for 3 years or longer.26 PML is related to reactivation of the John 
Cunningham (JC) virus in immunosuppressed persons. This emphasizes the importance 
of continuous pharmacovigilance of biological therapies. If longer-term follow-up 
continuous to show a good safety profile, biologics might become second-line alternative 
treatments options when only considered from the safety perspective.
TNF-inhibitors have been in use longer for RA and inflammatory bowel disease than 
for psoriasis. However, safety data from these other patient populations cannot just be 
extrapolated to psoriasis. Patients with psoriasis differ from patients with RA with respect 
to gender distribution, BMI, previous exposure to phototherapy, comorbidity, dosing 
regimens and the concomitant use of other immunosuppressive drugs.6, 26, 34, 68
Other challenges encountered in biologics safety research include the rarity of some 
adverse events, the choice of comparator groups, inconsistent coding of adverse events 
and reporting bias.43 Large-scale registries, postmarketing surveillance databases and 
pooling of data are essential for providing information on the long-term safety of biologics 
and possible rare adverse events. Registries are preferred over postmarketing data, as the 
latter face underreporting and the lack of an internal control group.69 
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So far the safety concerns about long-term treatment with biologics have decreased 
and at present, the limited safety concerns associated with biologic treatment can be 
interpreted in the light of the high benefits of these agents in patients with moderate to 
severe psoriasis. However, in daily practice, the choice for a certain biologic is often not 
only based on efficacy and safety. The choice for a certain biologic will be determined by 
the overall picture of short-term and long-term efficacy, safety, the severity of psoriasis, 
the presence or absence of psoriatic arthritis, costs, the way of administration, injection 
frequency, comorbidity, the possibility of interrupted therapy in relation to antibody 
formation and patient preference.
In conclusion: in this cohort, the long-term safety of biological therapies for psoriasis 
was favourable with a low incidence of therapy-related serious adverse events. 
Research question 6: Is there a difference in time to first NMSC and the 
incidence of NMSC between patients with psoriasis and patients with 
rheumatoid arthritis treated with TNF-inhibitors?
In the study presented in chapter 8, it is shown that the risk of developing NMSC was 
significantly higher in the psoriasis group compared with the RA group with a shorter 
time until first NMSC in the psoriasis group. The results also indicate that disease related 
factors like phototherapy may be an important contributing factor to NMSC diagnosed in 
psoriasis patients treated with TNF-inhibitors.
Ideally, a comparison would have been made with a group of psoriasis patients (instead 
of a group of RA patients) who have received TNF-inhibitor therapy and conventional 
systemic antipsoriatic therapies but no phototherapy, as the incidence of NMSC could be 
influenced by the specific disease (i.e. psoriasis or RA). However, as TNF-inhibitors can 
only be prescribed to patients who failed to respond to phototherapy in the largest part 
of the world, this control group is not available. 
A comparison with a group of psoriasis patients who have been treated with phototherapy 
and conventional systemic therapies but no anti-TNFα therapy would be an adequate 
approach to investigate the influence of TNF-inhibitors on NMSC development. However, 
this was not possible as this group of patients was not available. A comparison with 
data from the literature has many limitations due to differences in study procedures, 
differences in the classification of adverse events, different time periods covered with 
increasing skin cancer rates over time and differences in the degree of sun exposure with 
latitude, as was shown in the studies from Burmester et al. and Pariser et al.44, 70 These 
studies and the studies presented in this thesis show that comparisons should preferably 
be made with an internal control cohort with a parallel follow-up.
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In conclusion: the risk of developing NMSC was significantly higher in psoriasis 
compared with RA with a shorter time until first NMSC in psoriasis. Disease related 
factors like phototherapy may be an important contributing factor to NMSC diagnosed 
in psoriasis patients treated with TNF-inhibitors. 
Research question 7: Is monitoring with regard to laboratory investigations 
needed in patients with psoriasis with extended exposure to etanercept or 
adalimumab? 
Patients with psoriasis treated with biologics are monitored routinely with laboratory 
investigations according to existing guidelines. However, to justify the invasiveness 
of a venipuncture and the costs of this procedure and possible further investigations, 
abnormal laboratory values should have clinical consequences and should result in a 
better outcome. 
In the literature, cytopenias and elevated liver enzymes have been reported for TNF-
inhibitors.71, 72 In our study only, two patients (1%) experienced clinical consequences 
of abnormal haematological laboratory values in terms of a temporary interruption 
of treatment due to severe abnormalities. A significant increase of mean alanine 
aminotransferase (ALT) during etanercept treatment was also found, but the mean value 
did not exceed normal reference ranges. Severely elevated ALT activities (grade 3 and 
grade 4) were probably due to the concomitant use of methotrexate or comorbidities.
Statistically significant changes in mean values during treatment compared with 
pretreatment as well as significant trends were also detected for certain other haematology 
and chemistry parameters. However, mean values during treatment remained within 
normal reference ranges.
Biological treatment was temporarily interrupted in patients presenting with an infection 
clinically with or without laboratory testing and with or without elevated infection 
parameters.
Further studies in other groups of patients, preferably with a longer follow-up, and 
implementation studies could provide more evidence as to which laboratory panels 
and intervals are appropriate. At least as important as laboratory testing is to instruct 
patients to contact their dermatologist when health problems, including infections, occur 
in between hospital visits.
In conclusion: in this cohort, the incidence of biological therapy-related serious 
laboratory abnormalities was low. Our findings do not support a need for routine 
laboratory testing during etanercept or adalimumab treatment in psoriasis patients 
beyond the laboratory testing required for concomitant therapies, comorbidities or 
symptoms. Further studies could provide more evidence as to which laboratory panels 
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and intervals are appropriate. Screening tests before the start of biological treatment 
are necessary to detect contraindications or risk factors and to provide a baseline value.
Future directions
There is a need for direct comparisons of various aspects of biological therapies and 
other systemic therapies for psoriasis in daily practice. By using information from the 
Bio-CAPTURE registry and the MTX-CAPTURE registry, comparisons can be made of 
the efficacy, safety, cost-effectiveness, quality of life and treatment satisfaction of the 
biological therapies and methotrexate. 
Most efficacy and safety data in this thesis concern etanercept and adalimumab. Data on 
the use of ustekinumab in routine practice will be analysed in the near future.
In our studies, etanercept and adalimumab showed lower efficacy in a daily practice 
setting compared with RCTs. It would be interesting to evaluate the efficacy of biological 
agents in daily practice patients who are eligible and patients who are ineligible for RCTs. 
In RA, it was shown that patients eligible for RCTs had higher response percentages and 
responses more similar to RCTs than ineligible patients.73 
In RA, it was also shown that treating according to treatment goals improved efficacy 
compared with standard care.29, 30 A prospective implementation study, investigating 
treatment according to treatment goals compared with routine outpatient care, can be 
performed in psoriasis patients from the Bio-CAPTURE registry. 
The Bio-CAPTURE network offers the opportunity to compare the efficacy of biological 
agents between academic and nonacademic patients and to perform safety analyses in a 
larger group of patients. 
The development of algorithms of care would be helpful for dermatologists to help them 
decide which treatment modifications to implement in case of insufficient efficacy of a 
biological agent. To establish these algorithms of care, more information is needed. In the 
future, the effect of dose escalation or combination therapy with a traditional systemic 
agent can be compared in a larger group of patients. The duration of dose escalation and 
the duration and dose of combination therapy needed, can also be further characterized. 
Furthermore, the effect of switching to a biologic agent with the same mechanism of 
action can be compared with switching to a biologic with a different mode of action. 
From the point of view of the high costs of biological therapies and remaining concerns 
about the safety of biological therapies in the very long term, it would be interesting to 
investigate the efficacy and safety of dose reduction, intermittent therapy and a possible 
biologic-sparing effect of combination therapy. At present, the number of patients 
treated with reduced doses is too low to analyse. Interruption of therapy has been done 
194
in patients with infections, patients undergoing invasive surgery and patients with a 
desire for pregnancy. The efficacy and safety of intermittent therapy can be analysed in 
this group of patients to begin with. Interrupted therapy or discontinuation of a biological 
agent is at present not considered in other patients, as there are no biomarkers for 
remission of psoriasis. In addition, interrupted therapy has a risk of disease rebound, 
antibody formation and possibly also decreased efficacy with retreatment. 
Perspective
Psoriasis is a chronic disease and every patient has his or her own psoriasis. A scientific 
approach to the treatment of psoriasis in daily clinical practice is important to develop 
tools for a personalized approach to the long-term treatment of psoriasis. Stratification 
of patients based on patient characteristics, clinical characteristics, pharmacogenetics 
and biomarkers will result in individualized long-term management of psoriasis, utilizing 
available therapies and new treatment options. Registries with detailed information 
on patient and treatment characteristics are essential for developing the personalized 
healthcare of the future.
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Doelstelling
Het doel van dit proefschrift was het prospectief onderzoeken van de lange termijn 
effectiviteit en veiligheid van biologicals bij de behandeling van patiënten met matige tot 
ernstige psoriasis in de dagelijkse praktijk. Het merendeel van de geanalyseerde gegevens 
werd verkregen uit een prospectieve database (registry), de Bio-CAPTURE registry. In 
deze registry worden gegevens verzameld over alle patiënten met psoriasis die starten 
met een biological in de dagelijkse praktijk. 
De registry weerspiegelt in zekere mate de geschiedenis van de introductie van 
biologicals. Etanercept was een van de eerste biologicals die geregistreerd werd voor 
psoriasis. Etanercept was daarom de eerste biological voor veel patiënten. In het geval 
van onvoldoende effectiviteit of adverse events tijdens behandeling met etanercept, 
switchten patiënten met name naar adalimumab. Dit proefschrift bevat daarom met 
name gegevens over de effectiviteit en veiligheid van etanercept en adalimumab. 
Veiligheidsgegevens over efalizumab zijn beschreven in hoofdstuk 7, hoewel efalizumab 
in 2009 van de markt is gehaald vanwege een risico op ernstige bijwerkingen.
De registry weerspiegelt ook de logistieke organisatie van onze afdeling. Op onze afdeling 
wordt behandeling met infliximab alleen toegepast bij patiënten met zeer ernstige 
psoriasis, waarbij een snelle respons vereist is en bij patiënten waarbij andere biologicals 
onvoldoende effectief waren. Dit heeft te maken met de faciliteiten die nodig zijn voor 
de toediening van infliximab en de infusiereacties die soms voorkomen. Behandeling 
met infliximab is daarom niet veelvuldig toegepast op onze afdeling. Ustekinumab is 
geregistreerd voor psoriasis sinds 2009. Op het moment dat de onderzoeken beschreven 
in dit proefschrift werden uitgevoerd, was de ervaring met ustekinumab nog beperkt. In 
hoofdstuk 7 zijn de beschikbare gegevens over de lange termijn veiligheid van infliximab 
en ustekinumab beschreven.
Na deze historische en logistieke aspecten te hebben verduidelijkt, zullen nu de 
onderzoeksvragen zoals geformuleerd in hoofdstuk 1 worden bediscussieerd en zullen 
conclusies worden geformuleerd gebaseerd op deze discussies en de onderzoeken 
beschreven in hoofdstuk 2-9.
Onderzoeksvraag 1: Wat is de lange termijn effectiviteit van biologicals bij 
de behandeling van psoriasis in de dagelijkse praktijk?
De begrippen efficacy en effectiveness
De Engelse termen ‘efficacy’ en ‘effectiveness’ worden beide gebruikt om het effect van een 
bepaalde behandeling te beschrijven. Deze twee termen hebben echter een verschillende 
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betekenis. In het Nederlands bestaan geen aparte termen voor deze twee begrippen. 
Efficacy duidt op het effect van een behandeling in de context van een gerandomiseerde 
gecontroleerde trial (randomized controlled trial (RCT)), terwijl effectiveness duidt op het 
effect van een behandeling in de dagelijkse praktijk.1-3 In dit proefschrift is meestal de 
term efficacy gebruikt voor het beschrijven van het effect van biologicals in de dagelijkse 
praktijk, terwijl de term effectiveness eigenlijk geschikter zou zijn geweest. 
Lange termijn effectiviteit van etanercept en adalimumab
Behandeling met etanercept en adalimumab voor matige tot ernstige psoriasis in 
de dagelijkse praktijk was effectief op de lange termijn. De resultaten beschreven in 
hoofdstuk 6 laten zien dat de lange termijn effectiviteit van etanercept bij patiënten met 
een gemiddelde behandelduur van 2,7 jaar aanzienlijk is. In hoofdstuk 4 is beschreven 
dat de effectiviteit van adalimumab behouden blijft bij patiënten met een gemiddelde 
behandelduur van 1,4 jaar. 
Wanneer men kijkt naar de resultaten van de intention-to-treat (ITT) analyse met last 
observation carried forward (LOCF) en gemodificeerde nonresponder imputation 
(modified NRI) in hoofdstuk 6 (Figuur 2-4), dan lijkt er sprake te zijn van een geleidelijke 
afname van de effectiviteit van etanercept. Dit is ook beschreven in open-label extensie 
onderzoeken.4, 5 Het is niet bekend waardoor deze geleidelijke afname van de effectiviteit 
veroorzaakt wordt. Mogelijke verklaringen zouden kunnen zijn: biologische adaptatie aan 
chronische blokkade van TNF-α (door een ander mechanisme dan antistofvorming in het 
geval van etanercept), verminderde afhankelijkheid van de ziekte van TNF-α, verhoogde 
metabole klaring of compliance problemen.5-7
Op basis van de resultaten van open-label extensie onderzoeken en vanuit de dagelijkse 
praktijk is bekend dat er ook tijdens behandeling met adalimumab sprake kan zijn van 
verlies van effectiviteit.8, 9 Mogelijke verklaringen hiervoor zijn dezelfde als hierboven 
beschreven voor etanercept. Voor adalimumab geldt daarnaast dat antistofvorming 
tegen adalimumab geassocieerd is met een slechtere effectiviteit.10
Een indirecte vergelijking van de lange termijn effectiviteit van etanercept en adalimumab 
kan niet goed gemaakt worden, vanwege verschillen in patiëntengroepen en gebruikte 
doseringen.
Dagelijkse praktijk vergeleken met RCT’s
De lange termijn effectiviteit van etanercept en adalimumab in onze onderzoeken in de 
dagelijkse praktijk was lager dan in de RCT’s en open-label extensie onderzoeken van 
RCT’s.5, 9, 11-22 RCT’s en onderzoeken uit de dagelijkse praktijk kunnen echter niet zomaar 
vergeleken worden, vanwege verschillen in patiëntenpopulaties, uitkomstmaten, 
analysemethoden en gebruikte doseringen. Daarnaast verschillen de tijdstippen waarop 
de effectiviteit wordt beoordeeld.
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Er zijn een aantal factoren die de lagere PASI 75 respons in ons onderzoek vergeleken 
met RCT’s kunnen verklaren. Ten eerste zijn de patiënten uit ons onderzoek behandeld 
in een academisch ziekenhuis. Patiënten die verwezen worden naar een tertiair centrum 
hebben waarschijnlijk een hogere therapieresistentie. Ten tweede moeten patiënten in 
de dagelijkse praktijk voldoen aan strenge vergoedingscriteria, hetgeen niet geldt voor 
patiënten die deelnemen aan RCT’s. Ook dit kan leiden tot de selectie van patiënten met 
een hogere therapieresistentie in de dagelijkse praktijk. Daarnaast zijn patiënten die 
geïncludeerd worden in RCT’s over het algemeen ‘gezond’, omdat ze voldoen aan strenge 
inclusie- en exclusiecriteria. Patiënten in de dagelijkse praktijk daarentegen hebben over 
het algemeen comobiditeit en comedicatie. 
Tevens worden in RCT’s ‘washout’ periodes toegepast, hetgeen leidt tot een hoge PASI 
bij aanvang van de RCT (baseline PASI). Als gevolg hiervan worden sommige patiënten 
geïncludeerd op basis van een hoge PASI, die niet representatief is voor hun gemiddelde 
PASI. Dit leidt tot een fenomeen dat ‘regressie naar het gemiddelde’ wordt genoemd. 
Daarnaast kunnen onderzoekers op het moment dat bepaald wordt of een patiënt kan 
deelnemen aan een RCT de neiging hebben om bij het scoren van de subjectieve items 
van de PASI de hoogst passende score te kiezen, een fenomeen dat ‘eligibility creep’ 
wordt genoemd. Deze twee fenomenen kunnen mogelijk ook deels de grote placebo-
effecten in RCT’s bij psoriasis verklaren.23
Andere verklaringen voor de lagere effectiviteit in de dagelijkse praktijk zijn 
compliance problemen, inadequaat gebruik van de biological en onderbrekingen van 
de behandeling als gevolg van infecties of electieve operaties. Aan de andere kant 
kunnen behandelstrategieën die toegepast worden in de dagelijkse praktijk, zoals het 
gelijktijdig gebruik van lokale of klassieke systemische therapieën en dosisverhogingen 
van biologicals, leiden tot een hogere effectiviteit.
Conclusie: behandeling met etanercept en adalimumab voor matige tot ernstige 
psoriasis in de dagelijkse praktijk is effectief op de lange termijn. Er zijn veel verschillen 
tussen de dagelijkse praktijk en RCT’s, hetgeen impliceert dat onderzoeken in de 
dagelijkse praktijk belangrijke informatie verschaffen als aanvulling op de informatie 
die beschikbaar is vanuit RCT’s.
PASI als uitkomstmaat
PASI 50/75/90/100 zijn de meest gebruikte uitkomstmaten in klinische trials en 
onderzoeken in de dagelijkse praktijk, hetgeen vergelijkingen van onderzoeksresultaten 
mogelijk maakt. Absolute uitkomstmaten die de ernst van de psoriasis op een bepaald 
moment weergeven, zoals bijvoorbeeld de statische Physician’s Global Assessment 
(PGA), zijn echter mogelijk geschikter voor gebruik in lange termijn onderzoeken dan 
uitkomstmaten die de verandering ten opzichte van baseline weergeven. Dit laatste is 
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de focus van onderzoek in RCT’s.24, 25 Een belangrijke beperking van de PASI is dat deze 
uitkomstmaat geen rekening houdt met de invloed van psoriasis op de kwaliteit van 
leven, de lokalisatie van de psoriasis (zichtbare plekken/behaarde hoofd/genitaal) en het 
wel of niet aanwezig zijn van nagelpsoriasis.26, 27 Er is behoefte aan een samengestelde 
uitkomstmaat, waarin alle relevante aspecten van psoriasis aan bod komen. Een andere 
beperking van de PASI is dat de score bij een klein aangedaan lichaamsoppervlak weinig 
veranderlijk is.
Selectie van de baseline PASI
In hoofdstuk 2-6 wordt getoond dat de effectiviteit erg afhangt van welke baseline PASI 
en welke analysemethode gebruikt wordt. De invloed van de gebruikte analysemethode 
zal later bediscussieerd worden. 
In hoofdstuk 3 is de respons op adalimumab berekend in relatie tot de baseline PASI voor 
de start van adalimumab (course baseline PASI) en de baseline PASI voor de start van 
etanercept (original baseline PASI). In hoofdstuk 4 is de respons op adalimumab berekend 
in relatie tot de baseline PASI voor de start van adalimumab (course baseline PASI) en de 
eerste beschikbare baseline PASI voor de start van een biological op het moment van 
inclusie in de registry (original baseline PASI). Dit is gedaan vanwege het feit dat de course 
baseline PASI meestal lager is dan de original baseline PASI, als gevolg van het effect van 
de voorafgaande behandeling.
De huidige gouden standaard uitkomstmaat PASI 75 is een relatieve uitkomstmaat, die 
de verbetering van de PASI ten opzichte van baseline weergeeft. Omdat patiënten vaak 
restplekken overhouden en omdat de PASI weinig veranderlijk is bij een klein aangedaan 
lichaamsoppervlak, is een PASI 75 respons moeilijk te bereiken wanneer een behandeling 
gestart wordt bij een lage baseline PASI. 
Conclusie: resultaten voor effectiviteit zijn afhankelijk van welke baseline PASI gebruikt 
wordt, wanneer gebruikt wordt gemaakt van relatieve uitkomstmaten (bijv. PASI 75).
Het is belangrijk dat men zich dit realiseert voor een correcte interpretatie van 
resultaten. Een alternatief zou kunnen zijn het gebruik van een absolute uitkomstmaat 
in combinatie met een relatieve uitkomstmaat. 
Treatment goals
In 2011 publiceerde een Europese consensusgroep treatment goals (behandeldoelen) 
voor de behandeling van matige tot ernstige plaque psoriasis met systemische 
therapieën, naar analogie van treatment goals voor andere chronische ziekten zoals 
diabetes mellitus.28 Deze treatment goals omvatten de ernst van de psoriasis (gemeten 
met de PASI) en de kwaliteit van leven (gemeten met de Dermatology Life Quality Index 
(DLQI)). Het gebruik van treatment goals houdt in dat de respons op een behandeling 
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na de inductiefase en tijdens onderhoudsbehandeling regelmatig geëvalueerd wordt, 
om te zien of de treatment goals gehaald worden. Wanneer de treatment goals niet 
gehaald worden, moet de behandeling aangepast worden. Het gebruik van treatment 
goals zou dermatologen kunnen helpen bij het leveren van hoge kwaliteit van zorg aan 
psoriasis patiënten en zou kunnen leiden tot minder onderbehandeling. De onderzoeken 
beschreven in dit proefschrift zijn grotendeels uitgevoerd vóór de publicatie van deze 
treatment goals.
In onderzoeken bij patiënten met reumatoïde artritis (RA) is aangetoond dat het gebruik 
van treatment goals leidt tot betere behandelresultaten vergeleken met reguliere 
behandeling.29, 30 Het gebruik van treatment goals zou ook bij psoriasis kunnen leiden tot 
betere behandelresultaten. Echter, voordat er treatment goals geïmplementeerd kunnen 
worden voor psoriasis, moet de toegevoegde waarde van het gebruik van treatment 
goals eerst aangetoond worden. Daarnaast geldt dat ook wanneer patiënten behandeld 
worden volgens treatment goals, het aanpassen van de behandeling maatwerk blijft.31
In de eerste jaren na de registratie van biologicals voor psoriasis was de treatment goal in 
Nederland, alhoewel niet als zodanig genoemd, het bereiken van een PASI 50 respons na 
12 weken behandeling ter verkrijging van goedkeuring voor vergoeding van voortgezette 
behandeling. De Nederlandse psoriasis richtlijn (2003, update in 2005 en 2009) vereiste 
ook een PASI 50 respons na 12 weken voor etanercept en efalizumab en een PASI 50 
respons na 8 weken voor infliximab.32 De huidige gouden standaard treatment goal is
PASI 75.33, 34 Mogelijk komen er in de toekomst dusdanig effectieve behandelingen op de 
markt dat dit veranderd kan worden in PASI 90 of PASI 100.
Conclusie: het gebruik van treatment goals maakt het mogelijk om het effect van een 
behandeling strak te monitoren. Vervolgonderzoek in de dagelijkse praktijk moet 
aantonen welke treatment goal het best overeenkomt met een optimale verbetering 
vanuit het perspectief van de patiënt.
Het belang van observationeel onderzoek
In de toekomst zal de effectiviteit en veiligheid van biologicals bij de behandeling 
van psoriasis vergeleken worden met gegevens uit een vergelijkbaar onderzoek van 
onze afdeling naar de effectiviteit en veiligheid van methotrexaat bij de behandeling 
van psoriasis (MTX-CAPTURE). Een beperking van een dergelijke vergelijking en van 
observationele onderzoeken in het algemeen, is dat patiënten niet op basis van toeval een 
bepaalde behandeling voorgeschreven krijgen (nonrandom assignment to treatment). Dit 
leidt tot een verschijnsel genaamd confounding by indication, hetgeen zich bijvoorbeeld 
voordoet wanneer patiënten die met biologicals behandeld worden een ernstigere 
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psoriasis hebben dan patiënten die behandeld worden met methotrexaat. Confounding 
by indication is een bekende beperking van vergelijkingen waarbij gebruik gemaakt 
wordt van observationele data. Confounding by indication doet zich voor wanneer de 
uitkomstmaat waarin men geïnteresseerd is, gerelateerd is aan factoren die de indicatie 
voor de behandeling bepalen. Resultaten van observationele onderzoeken kunnen echter 
in andere onderzoeken bevestigd worden en kunnen leiden tot belangrijke veranderingen 
in de dagelijkse praktijk.
Conclusie: observationeel onderzoek kent methodologische beperkingen, maar is zeer 
waardevol bij het onderzoeken van de effectiviteit en veiligheid van biologicals bij de 
behandeling van psoriasis in de dagelijkse praktijk. 
Onderzoeksvraag 2: Is behandeling met een tweede biological effectief 
en veilig? Heeft voorafgaande behandeling met biologicals invloed op de 
effectiviteit van de volgende biological?
De resultaten van het onderzoek beschreven in hoofdstuk 3 laten zien dat switchen van 
etanercept naar adalimumab effectief en veilig is bij patiënten die nog niet eerder met 
een biological waren behandeld (naïef waren voor behandeling met biologicals) op het 
moment dat ze startten met etanercept. Naar analogie van onderzoeken bij patiënten 
met RA en een paar onderzoeken bij patiënten met psoriasis, werden patiënten in dit 
onderzoek ingedeeld in 3 categorieën: primaire nonresponders op etanercept (patiënten 
die geen PASI 50 respons halen in week 12), secundaire nonresponders op etanercept 
(patiënten met verlies van effectiviteit na het behalen van een PASI 50 respons in week 
12) en patiënten die gestopt waren met etanercept vanwege adverse events (categorie 
‘intolerance’). 
Onderzoeken bij patiënten met RA hebben laten zien dat de effectiviteit van een tweede 
TNF-antagonist lager is dan de effectiviteit van de eerste TNF-antagonist en dat de 
respons op een tweede TNF-antagonist afhangt van de reden voor het stoppen van de 
eerst TNF-antagonist. De afname van de effectiviteit bij een tweede TNF-antagonist 
zou het gevolg kunnen zijn van een klasse-effect of van de selectie van patiënten met 
ernstigere RA.35 Gniadecki et al. vonden in hun onderzoek bij psoriasis patiënten ook 
dat de drug survival van TNF-antagonisten (hetgeen een indicator is voor de effectiviteit 
van een behandeling) hoger was bij patiënten die naïef waren voor behandeling met 
TNF-antagonisten, vergeleken met patiënten die eerder behandeld waren met één of 
meerdere TNF-antagonisten en hiermee gestopt waren i.v.m. onvoldoende effectiviteit.36
Hoofdstuk 3 laat zien dat in ons onderzoek de respons op adalimumab vergeleken met de 
originele baseline PASI over het algemeen beter was (hoewel niet statistisch significant) 
dan de voorafgaande respons op etanercept. Onafhankelijk van de reden voor staken 
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van etanercept was de kans op het bereiken van een primaire respons op adalimumab 
(PASI 50 in week 12) hoger dan de kans op primair falen. Dit pleit tegen een klasse-effect 
van TNF-antagonisten,37 hoewel het percentage patiënten met een primaire respons op 
adalimumab hoger was onder de secundaire nonresponders op etanercept (11 van de 14 
(79%)) dan onder de primaire nonresponders op etanercept (6 van de 11 (55%)). 
Hoofdstuk 4 laat zien dat het percentage patiënten met een PASI 75 respons tijdens 
behandeling met adalimumab gedurende 48 weken alleen in week 12 significant hoger 
was bij patiënten die naïef waren voor biologicals vergeleken met patiënten die niet naïef 
waren voor biologicals. Deze bevindingen worden ondersteund door een onderzoek van 
Ortonne et al., waarin slechts een geringe afname van de effectiviteit van adalimumab werd 
gevonden bij patiënten die eerder behandeld waren met één of meerdere TNF-antagonisten 
vergeleken met patiënten die naïef waren voor behandeling met TNF-antagonisten.38 Meer 
onderzoeken met grotere aantallen patiënten zijn nodig om dit verder te onderzoeken.
Het feit dat adalimumab effectief was bij het merendeel van de patiënten die 
gefaald hadden op etanercept, kan mogelijk verklaard worden door verschillen in 
molecuulstructuur of werkingsmechanisme of door farmacogenetische verschillen. Het 
feit dat adalimumab in tegenstelling tot etanercept effectief is bij de behandeling van 
granulomateuze aandoeningen, pleit voor verschillende biologische eigenschappen van 
deze twee biologicals.39
Hoofdstuk 3 laat zien dat voorafgaande behandeling met etanercept niet leidde tot 
meer adverse events of andere adverse events tijdens behandeling met adalimumab 
gedurende 48 weken. 
Conclusie: switchen van etanercept naar adalimumab is effectief en veilig, onafhankelijk 
van de reden voor staken van etanercept. Verder onderzoek is nodig om de vraag te 
beantwoorden of voorafgaande behandeling met biologicals leidt tot verminderde 
effectiviteit van de volgende biological bij patiënten met psoriasis.
Onderzoeksvraag 3: Wat is de effectiviteit en veiligheid van dosisverhoging 
van adalimumab of combinatietherapie met methotrexaat?
Wanneer een biological onvoldoende effectief is, kan de behandeling op verschillende 
manieren aangepast worden. De dosis van de biological kan verhoogd worden, er kan 
een andere (systemische) therapie toegevoegd worden (combinatietherapie) of er kan 
geswitcht worden naar een ander geneesmiddel of een andere modaliteit.28 Omdat 
switchen het aantal behandelingsmogelijkheden verkleint, kan men er voor kiezen 
om eerst de werking van de biological volledig te proberen te benutten door middel 
van dosisverhoging of combinatietherapie. Dosisverhoging en combinatietherapie zijn 
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niet geregistreerd voor psoriasis, maar worden in de dagelijkse praktijk wel toegepast. 
Dosisverhoging betekent het verhogen van de dosis van de biological per toediening of 
verkorting van het toedieningsinterval. Bij patiënten met een zeer goede respons wordt 
soms geprobeerd om de dosis te verlagen. Dosisverlaging houdt in het verlagen van de 
dosis van de biological per toediening of verlenging van het toedieningsinterval. In de 
onderzoeken beschreven in dit proefschrift is bij een substantieel deel van de patiënten 
(tijdelijk) dosisverhoging van adalimumab of etanercept of combinatietherapie toegepast. 
Slechts bij enkele patiënten is dosisverlaging van adalimumab of etanercept toegepast. 
Hoofdstuk 5 beschrijft de effectiviteit en veiligheid van dosisverhoging van adalimumab 
(naar 40 mg per week) en combinatietherapie (adalimumab 40 mg om de week 
gecombineerd met methotrexaat). Daarnaast is de effectiviteit en veiligheid onderzocht 
wanneer beide behandelstrategieën tegelijkertijd worden toegepast. De resultaten laten 
zien dat een subgroep van patiënten met een onvoldoende respons op adalimumab
40 mg om de week, baat heeft bij dosisverhoging of combinatietherapie (27% van de 
eerste behandelepisodes met dosisverhoging resulteerde in PASI 50 na 12 weken en 9% 
van de behandelepisodes met combinatietherapie resulteerde in PASI 50 na 12 weken). 
Bij een klein aantal patiënten werden beide behandelstrategieën tegelijkertijd toegepast. 
Hierbij werden wisselende resultaten gezien.
Leonardi et al. vonden een vergelijkbaar resultaat: een kwart van de patiënten had 
baat bij dosisverhoging van adalimumab (27% behaalde PASI 75 binnen 12 weken).8 
In het onderzoek van Leonardi et al. was een responder echter gedefinieerd als een 
patiënt die een PASI 75 respons behaalt vergeleken met de baseline PASI van het eerste 
psoriasis onderzoek waar de patiënt aan deelgenomen had. In ons onderzoek was een 
responder gedefinieerd als een patiënt die een PASI 50 respons behaalt ten opzichte van 
de PASI op het moment dat de dosis van adalimumab werd verhoogd of methotrexaat 
werd toegevoegd. In een fase II onderzoek met adalimumab werd ook gevonden dat 
een subgroep van patiënten baat kan hebben bij dosisverhoging.11 Bij patiënten met 
RA daarentegen is gevonden dat dosisverhoging van adalimumab niet leidt tot een 
significante verbetering van de ziekte-activiteit.40 
In het onderzoek van Leonardi et al. werden retrospectief drie patiëntkarakteristieken 
geïdentificeerd, die voorspellend waren voor een goede respons op dosisverhoging van 
adalimumab. Dit waren: secundaire nonresponders, een relatief laag lichaamsgewicht 
en een relatief korte ziekteduur. Vervolgonderzoek is nodig om patiëntkarakteristieken 
te identificeren waarmee voorspeld kan worden welke patiënten baat zullen hebben bij 
welke behandelstrategie. Dit is belangrijk om patiënten een optimale behandeling te 
kunnen bieden en vanwege de hoge kosten van dosisverhoging.
De dosering van methotrexaat bij patiënten die behandeld werden met 
combinatietherapie was relatief laag. Daarnaast was de duur van combinatietherapie bij 
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sommige patiënten slechts kort. Het toevoegen van methotrexaat in een hogere dosering 
en gedurende een langere periode zou kunnen leiden tot betere resultaten. Gegevens 
over combinatietherapie van adalimumab met methotrexaat bij psoriasis in de literatuur 
blijven beperkt tot publicaties over kleine groepen patiënten die succesvol zijn behandeld 
met combinatietherapie.22, 41, 42 
Zowel bij dosisverhoging van adalimumab als bij combinatietherapie werden weinig 
adverse events gezien. Er traden geen ernstige adverse events op die gerelateerd waren 
aan de behandeling. Er zijn weinig gegevens over de veiligheid van dosisverhoging van 
adalimumab en etanercept in de literatuur. Tot nu toe zijn er geen aanwijzingen dat 
dosisverhoging leidt tot meer adverse events.5, 8, 11, 13, 14, 43, 44 Vervolgonderzoeken met grote 
aantallen patiënten zijn nodig om de veiligheid van dosisverhoging en combinatietherapie 
bij psoriasis te bevestigen.
In dit proefschrift is geen specifieke aandacht besteed aan de effectiviteit en veiligheid van 
dosisverhoging van etanercept of combinatietherapie van etanercept met een klassieke 
systemische therapie. Dit is wel beschreven in de literatuur. In twee onderzoeken is het 
effect van dosisverhoging van etanercept naar 2 keer 50 mg per week onderzocht bij 
patiënten die onvoldoende gereageerd hadden op etanercept 1 keer 50 mg per week.13, 45
Beide onderzoeken lieten zien dat dosisverhoging leidt tot een verhoogde effectiviteit. 
Wat betreft combinatietherapie is het meeste bewijs voorhanden voor de combinatie van 
etanercept en methotrexaat.46-51 Combinatietherapie met methotrexaat bij patiënten met 
een onvoldoende respons op etanercept monotherapie leidde in deze onderzoeken tot 
een betere effectiviteit en ging gepaard met weinig bijwerkingen.46, 48
Conclusie: dosisverhoging van adalimumab en combinatietherapie met methotrexaat 
verhogen de effectiviteit van adalimumab bij een subgroep van psoriasis patiënten. 
Beide behandelstrategieën waren veilig in dit onderzoek.
Onderzoeksvraag 4: Wat is de invloed van verschillende analysemethoden 
op de effectiviteit?
RCT’s worden meestal geanalyseerd volgens het intention-to-treat (ITT) principe. In een 
ITT analyse worden patiënten geanalyseerd in de groep waarin ze zijn gerandomiseerd. 
Dit gebeurt onafhankelijk van de behandeling die patiënten daadwerkelijk gekregen 
hebben, vroegtijdige beëindiging van deelname aan het onderzoek of schendingen van 
het onderzoeksprotocol.2, 52, 53 In het Bio-CAPTURE onderzoek wordt geen randomisatie 
toegepast. De term ITT analyse wordt in hoofdstuk 4-6 echter wel gebruikt, omdat alle 
patiënten voor de volledige duur van de geanalyseerde periode zijn meegenomen in de 
analyse. Dit is ook zo gedaan in andere observationele onderzoeken.17, 54 
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Met de toename van de duur van een onderzoek neemt het aantal patiënten dat uitvalt 
uit het onderzoek meestal toe, hetgeen leidt tot ontbrekende onderzoeksgegevens.52 
Gegevens kunnen ontbreken om verschillende redenen, waaronder het beëindigen van 
het onderzoek vanwege onvoldoende effectiviteit of adverse events.2, 52, 53, 55 
Onbrekende gegevens kunnen op verschillende manieren benaderd en ingevuld worden, 
ook wel ‘imputation’ genoemd (Tabel 1). De uitkomstmaten voor effectiviteit in ons 
onderzoek zijn PASI 50, PASI 75 en PASI 90. Imputation methoden die vaak gebruikt 
worden in RCT’s, zijn last observation carried forward (LOCF) en nonresponder imputation 
(NRI). Bij LOCF wordt de laatst beschikbare waarde gebruikt voor het invullen van de hier 
op volgende ontbrekende waarde(n). Ondanks kritiek van statistici op de LOCF methode 
is dit de meest gebruikt methode in RCT’s. De LOCF methode wordt over het algemeen 
beschouwd als een conservatieve methode.52 
De meest conservatieve methode is de NRI methode. Bij de NRI methode wordt een 
patiënt in het geval van een ontbrekende waarde beschouwd als een nonresponder. 
Dit wordt ook wel ‘missing equals failure’ (MEF) genoemd. In een ‘as-treated’ analyse 
worden ontbrekende gegevens niet meegenomen in de analyse. Dit wordt ook wel 
‘missing equals excluded’ (MEX) genoemd.2, 53, 56 De ‘as-treated’ analyse wordt soms ook 
wel ‘observed values’ analyse genoemd (hoofdstuk 2) en wordt voornamelijk gebruik in 
observationele onderzoeken en open-label extensie onderzoeken van RCT’s.4, 56, 57 
Afhankelijk van de onderzoeksvraag kunnen verschillende analysemethoden gebruikt 
worden. Een as-treated analyse geeft een idee van de maximale effectiviteit. Als men 
echter een reëler beeld wil hebben van de effectiviteit, waarbij patiënten die uitvallen 
vanwege onvoldoende effectiviteit meegenomen worden in de analyse, kan beter 
voor een ITT analyse gekozen worden.2 De resultaten in hoofdstuk 6 laten zien dat de 
gebruikte analysemethode een grote invloed heeft op de resultaten; de effectiviteit kan 
verdubbelen wanneer de as-treated methode gebruikt wordt in plaats van de modified 
NRI methode.
De NRI methode is problematisch bij observationele onderzoeken, omdat er voortdurend 
nieuwe patiënten geïncludeerd worden. Het toepassen van NRI bij patiënten met nog maar 
een korte follow-up waarbij waarden voor veel tijdenstippen in de analyse nog ontbreken, 
beschouwden wij als incorrect. Daarom is in hoofdstuk 6 gebruik gemaakt van een minder 
conservatieve gemodificeerde NRI methode, de ‘modified NRI’ methode genaamd.56
De invloed van ontbrekende gegevens op de effectiviteit hangt af van de redenen voor 
het ontbreken van gegevens. Figuur 1 in hoofdstuk 6 laat zien dat verlies van effectiviteit 
of een combinatie van verlies van effectiviteit en adverse events de meest voorkomende 
redenen waren voor het stoppen van etanercept.55 Daarom en vanwege de lange 
behandelduur van patiënten die goed reageren op behandeling met etanercept, geeft 
de as-treated analyse de effectiviteit van etanercept te positief weer. De NRI methode 
Chapter 11
Samenvatting en Discussie
213
11
Chapter 11
daarentegen zou de effectiviteit van etanercept waarschijnlijk te negatief weergeven, 
aangezien bij een substantieel deel van de behandelepisodes gegevens ontbraken 
om andere redenen dan verlies van effectiviteit of een combinatie van verlies van 
effectiviteit en adverse events. De gemodificeerde NRI methode geeft mogelijk ook een 
onderschatting van de effectiviteit van etanercept, aangezien sommige patiënten die 
gestopt waren met etanercept vanwege onvoldoende effectiviteit of een combinatie van 
onvoldoende effectiviteit en adverse events, in werkelijkheid PASI 75 responders waren 
(Figuur 3). Dit betekent dat een PASI 75 respons niet altijd als een voldoende respons 
beschouwd wordt door patiënten en/of dermatologen. 
Een manier om de bias die elke statistische methode met zich meebrengt te omzeilen, 
is het gebruik en de ontwikkeling van andere uitkomstmaten, zoals bijvoorbeeld ‘drug 
survival’. De term drug survival staat voor de duur van het gebruik van een bepaald 
geneesmiddel, hetgeen een indirecte maat is voor de effectiviteit van het geneesmiddel. 
De drug survival van een geneesmiddel is echter niet alleen afhankelijk van de effectiviteit, 
maar ook van bijwerkingen, algemene tevredenheid over het geneesmiddel en de 
beschikbaarheid van andere geneesmiddelen.36, 55 Een alternatief zou kunnen zijn het 
gebruik van een biomarker, die de activiteit van de psoriasis weergeeft in plaats van de 
ernst van de psoriasis, zoals bijvoorbeeld weergegeven wordt door de PASI. Betrouwbare 
biomarkers zijn op dit moment echter niet beschikbaar.
Tabel 1. Beschrijving van verschillende methoden voor de analyse van gegevens in klinisch onderzoek.52
Approach Abbreviation Description Equivalent 
terminology
Populations
Intention-to-treat ITT All randomized patients in the groups to which they 
were randomly assigned
Per-protocol PP All patients who did not deviate from the protocol Adherers only
Intention-to-observe ITO All patients entering the observational phase of a long-
term study
Maintenance ITT
Imputation of missing data
Missing equals succes MES Missing values are assigned as a success
Missing equals failure MEF Missing values are assigned as a failure Nonresponder 
imputation
Missing equals excluded MEX Missing values are excluded from the analysis As-treated
Missing completely at 
random
MCAR The missingness of data does not depend on the 
previously observed or current unobserved outcomes
Missing at random MAR The missingness of data depends on the previously 
observed values, but not the current unobserved values
Missing not at random MNAR The missingness of data depends on the current 
unobserved outcomes
Last observation carried 
forward
LOCF The previous observation is used for the missing value
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Conclusie: elke analysemethode heeft voor- en nadelen en kan leiden tot vertekende 
resultaten. Omdat de invloed van de gebruikte analysemethode groot is, ondersteunen 
wij het gebruik van verschillende analysemethoden.
Onderzoeksvraag 5: Wat is het veiligheidsprofiel van biologicals bij de 
behandeling van psoriasis bij langdurige behandeling?
In hoofdstuk 7 is beschreven dat het veiligheidsprofiel van biologicals bij patiënten die 
langdurig behandeld waren met één biological of opeenvolgende verschillende biologicals 
gunstig was gedurende 5 jaar follow-up. De incidentie van ernstige adverse events was 
laag. Dit komt overeen met resultaten uit RCT’s, meta-analyses en open-label extensie 
onderzoeken.58 
Het merendeel van de gegevens over adverse events in dit proefschrift heeft betrekking 
op etanercept en adalimumab. In hoofdstuk 7 zijn de beschikbare gegevens over de 
veiligheid van efalizumab, ustekinumab en infliximab beschreven. Gegevens over 
de veiligheid van ustekinumab en infliximab zijn tevens beschikbaar in de literatuur. 
Behandeling met ustekinumab in een open-label extensie onderzoek van RCT’s was veilig 
gedurende 5 jaar follow-up.59 Behandeling met infliximab bij psoriasis was veilig in een 
RCT met een duur van 50 weken, een RCT met een open-label extensiefase met een 
duur van 78 weken en een retrospectief onderzoek bij patiënten die minimaal één jaar 
behandeld waren met infliximab en een gemiddelde follow-up hadden van 2,2 jaar.58, 60-62
In hoofdstuk 7 is beschreven dat de adverse events in ons onderzoek met name mild van 
aard waren en niet verschilden van de adverse events beschreven in eerdere publicaties 
over onze registry en in andere onderzoeken. Achtentwintig procent van de patiënten 
meldde één of meer ernstige adverse events. Slechts 24% van deze ernstige adverse 
events beschouwden wij echter als mogelijk gerelateerd aan de behandeling, op basis 
van de tijdsrelatie en de medische voorgeschiedenis van de patiënt. Slechts één ernstige 
adverse event (infusiereactie) beschouwden wij als zeker gerelateerd aan de behandeling 
met infliximab.
Er zijn criteria opgesteld voor het bepalen van causaliteit in epidemiologische studies, de 
zogenaamde Bredford-Hill criteria.63 Daarnaast bestaan er categorieën voor causaliteit van 
de WHO.64 Echter de beste manier om te bepalen of er een causaal verband is tussen een 
geneesmiddel en een bepaalde adverse event, is het maken van een vergelijking met een 
controlegroep.65 In het onderzoek beschreven in hoofdstuk 7 is het aantal geobserveerde 
maligniteiten, ernstige infecties en ernstige cardiovasculaire gebeurtenissen vergeleken 
met het aantal dat verwacht werd op basis van gegevens over de algemene bevolking. 
De incidentie van deze ernstige adverse events was vergelijkbaar met de incidentie die 
verwacht werd op basis van gegevens over de algemene bevolking, met uitzondering 
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van nonmelanoma huidmaligniteiten. Het aantal patiënten was echter te klein om 
eventuele verschillen te kunnen ontdekken in de incidentie van andere minder frequent 
voorkomende ernstige adverse events.
De verhoogde incidentie van nonmelanoma huidmaligniteiten zou ook verklaard 
kunnen worden door voorafgaande lichttherapie en klassieke systemische therapieën of 
doordat dermatologen bekwamer zijn in het diagnosticeren van huidmaligniteiten dan 
huisartsen. Bij 5 van de 7 psoriasis patiënten met nonmelanoma huidkanker werd de 
eerste huidmaligniteit gediagnosticeerd binnen 5 maanden na de start van de biological. 
Dit suggereert dat deze gevallen van nonmelanoma huidkanker verklaard kunnen 
worden door voorafgaande behandelingen zoals lichttherapie en niet het gevolg zijn van 
behandeling met biologicals.
Alle biologicals zijn als één groep geanalyseerd, aangezien het merendeel van de 
patiëntjaren follow-up etanercept betrof en omdat bepaalde bijwerkingen zoals 
bijvoorbeeld maligniteiten, mogelijk pas na een lange latentieperiode optreden en 
daardoor lastig toe te schrijven zijn aan een bepaalde behandeling. Idealiter worden alle 
biologicals apart geanalyseerd, aangezien er verschillen bestaan tussen klassen biologicals 
en zelfs binnen klassen met betrekking tot het risico op bepaalde ernstige adverse events. 
De klasse van TNF-antagonisten  is bijvoorbeeld geassocieerd met reactivatie van latente 
tuberculose, het ontstaan of verergeren van hartfalen, demyeliniserende aandoeningen 
en lupus erythematosus.26, 34
De incidentie van ernstige adverse events tijdens behandeling met adalimumab in de 
dagelijkse praktijk (0.23 ernstige adverse events per patiëntjaar (hoofdstuk 4)) was hoger 
dan de incidentie van ernstige adverse events tijdens behandeling met adalimumab in 
de RCT REVEAL (0.06 ernstige adverse events per patiëntjaar), een open-label extensie 
onderzoek (0.07 ernstige adverse events per patiëntjaar) en een analyse van alle klinische 
trials met adalimumab (0.09 ernstige adverse events per patiëntjaar).9, 16, 66 Het aantal 
ernstige adverse events, het aantal patiënten en het aantal patiëntjaren follow-up in ons 
onderzoek was echter te klein om definitieve conclusies te kunnen trekken.
De hogere morbiditeit tijdens behandeling met adalimumab in ons onderzoek zou 
mogelijk verklaard kunnen worden door meer comorbiditeit en comedicatie bij patiënten 
in de dagelijkse praktijk. Dit wordt ondersteund door een onderzoek van Garcia-Doval et 
al., waarin aangetoond werd dat 30% van de psoriasis patiënten die behandeld werden 
met systemische therapieën (biologicals of klassieke systemische therapieën) in de 
dagelijkse praktijk niet voldeden aan de inclusiecriteria voor RCT’s en dat het risico op 
ernstige adverse events bij deze patiënten hoger was dan bij patiënten die wel voldeden 
aan de inclusiecriteria voor RCT’s.67 
Biologicals worden op dit moment beschouwd als derdelijns behandelingen na lokale 
therapieën, lichttherapie en klassieke systemische therapieën. Dit is een gevolg van 
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resterende onzekerheid over de veiligheid van biologicals op de lange termijn en de 
hoge kosten van biologicals. De op dit moment beschikbare gegevens tonen een gunstige 
verhouding tussen werking en bijwerkingen. Het is op dit moment echter nog onduidelijk 
of er risico’s verbonden zijn aan zeer langdurige behandeling met biologicals, zoals 
bijvoorbeeld het ontstaan van maligniteiten, eventueel na een lange latentietijd. Tot op 
heden zijn er bij de op dit moment beschikbare biologicals echter geen aanwijzingen voor 
cumulatieve toxiciteit.58
In 2009 werd efalizumab van de markt gehaald door de EMA, nadat 3 patiënten die 
gedurende 3 jaar of langer behandeld waren met efalizumab waren overleden aan 
progressieve multifocale leukoencefalopathie (PML).26 PML is gerelateerd aan reactivatie 
van het John Cunningham (JC) virus bij immuungecompromitteerde personen. Deze 
gebeurtenis onderschrijft het belang van continue farmacovigilantie met betrekking tot 
biologicals. Indien het veiligheidsprofiel van zeer langdurige behandeling met biologicals 
gunstig blijft, zouden biologicals tot de tweedelijns behandelingen kunnen gaan behoren 
wanneer alleen gekeken wordt naar het veiligheidsaspect.
Behandeling met TNF-antagonisten wordt al langer toegepast bij RA en inflammatoire 
darmziekten dan bij psoriasis. Veiligheidsgegevens van deze andere patiëntenpopulaties 
kunnen echter niet zomaar vertaald worden naar psoriasis. Patiënten met psoriasis 
verschillen bijvoorbeeld van patiënten met RA wat betreft geslachtsverdeling, BMI, 
voorafgaande blootstelling aan lichttherapie, comorbiditeit, gebruikte doseringen en het 
gelijktijdig gebruik van andere immunosuppressiva.6, 26, 34, 68
Andere uitdagingen van het onderzoek naar de veiligheid van biologicals zijn de 
zeldzaamheid van sommige adverse events, de keuze van controlegroepen, inconsistente 
codering van adverse events en verschillen in rapportage van adverse events (reporting 
bias).43 Grote registries, postmarketing surveillance databases en het combineren 
van gegevens uit verschillende onderzoeken zijn belangrijk om meer inzicht te krijgen 
in de lange termijn veiligheid van biologicals, inclusief mogelijke zeldzame adverse 
events. Registries hebben de voorkeur boven postmarketing surveillance, aangezien 
postmarketing surveillance databases geen eigen controlegroep hebben en hierbij sprake 
is van onderrapportage.69
Op dit moment kunnen de beperkte zorgen wat betreft de veiligheid van biologicals gezien 
worden in het licht van de grote voordelen die patiënten met matige tot ernstige psoriasis 
ondervinden van deze behandelingen. De keuze voor een bepaalde biological is in de 
dagelijkse praktijk echter vaak niet alleen gebaseerd op effectiviteits- en veiligheidsaspecten. 
De keuze is gebaseerd op het totaalplaatje van effectiviteit op de korte en lange termijn, 
veiligheid, de ernst van de psoriasis, de aan- of afwezigheid van artritis psoriatica, kosten, 
toedieningswijze, injectiefrequentie, comorbiditeit, de mogelijkheid van het onderbreken 
van de behandeling in relatie tot antistofvorming en de voorkeur van de patiënt.
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Conclusie: het lange termijn veiligheidsprofiel van biologicals bij de behandeling van 
psoriasis was gunstig in dit cohort met een lage incidentie van ernstige adverse events 
gerelateerd aan de behandeling.
Onderzoeksvraag 6: Is er een verschil in tijd tot het optreden van de 
eerste nonmelanoma huidmaligniteit en de incidentie van nonmelanoma 
huidmaligniteiten tussen patiënten met psoriasis en patiënten met 
reumatoïde artritis die behandeld worden met TNF-antagonisten?
Het onderzoek beschreven in hoofdstuk 8 laat zien dat het risico op het ontwikkelen van 
nonmelanoma huidmaligniteiten (nonmelanoma skin cancer; NMSC) significant hoger 
was in de psoriasis groep vergeleken met de RA groep en dat de tijd tot het optreden 
van de eerste NMSC korter was in de psoriasis groep. De resultaten geven ook aan dat 
ziektegerelateerde factoren zoals lichttherapie een belangrijke bijdrage zouden kunnen 
leveren aan NMSC die gediagnosticeerd worden bij psoriasis patiënten die behandeld 
worden met TNF-antagonisten.
Idealiter zou een vergelijking zijn gemaakt met een groep psoriasis patiënten (in plaats van 
een groep RA patiënten) die behandeld zijn met TNF-antagonisten en klassieke systemische 
therapieën maar niet met lichttherapie, omdat de specifieke ziekte (d.w.z. psoriasis of RA) 
van invloed zou kunnen zijn op de incidentie van NMSC. Deze controlegroep is echter niet 
beschikbaar, omdat biologicals in het grootste deel van de wereld alleen voorgeschreven 
kunnen worden aan patiënten die gefaald hebben op lichttherapie. 
Om de invloed van TNF-antagonisten op het ontwikkelen van NMSC te onderzoeken, 
zou een vergelijking moeten worden gemaakt met een groep psoriasis patiënten die 
behandeld zijn met lichttherapie en conventionele systemische therapieën, maar niet 
met TNF-antagonisten. Dit was echter niet mogelijk, omdat deze groep patiënten niet 
beschikbaar was. Het maken van een vergelijking met gegevens uit de literatuur kent vele 
beperkingen vanwege verschillen in de opzet van onderzoeken, verschillen in classificatie 
van adverse events, verschillende onderzoeksperiodes bij een toenemende incidentie 
van NMSC en verschillen in de incidentie van NMSC op basis van de breedtegraad, zoals 
beschreven in de onderzoeken van Burmester et al. en Pariser et al.44, 70 Deze onderzoeken 
en de onderzoeken in dit proefschrift laten zien dat een vergelijking bij voorkeur gemaakt 
wordt met een interne controlegroep met een parallelle follow-up.
Conclusie: het risico op het ontwikkelen van NMSC was hoger en de tijd tot de diagnose 
van de eerste NMSC was korter bij psoriasis vergeleken met RA. Ziektegerelateerde 
factoren zoals lichttherapie zouden een belangrijke bijdrage kunnen leveren aan NMSC 
die gediagnosticeerd worden bij psoriasis patiënten die behandeld worden met TNF-
antagonisten. 
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Onderzoeksvraag 7: Is bloedonderzoek bij patiënten met psoriasis die 
langdurig worden behandeld met etanercept of adalimumab nodig?
Bij patiënten met psoriasis die behandeld worden met biologicals wordt regelmatig 
bloedonderzoek gedaan volgens de huidige richtlijnen. Een venapunctie is echter invasief, 
gaat gepaard met kosten en kan leiden tot onnodig vervolgonderzoek. Om deze nadelige 
aspecten van een venapunctie te kunnen rechtvaardigen, moeten abnormale labwaarden 
klinische consequenties hebben en leiden tot een betere uitkomst voor de patiënt.
In de literatuur is beschreven dat cytopenieën en verhoogde leverenzymen voorkomen 
tijdens behandeling met TNF-antagonisten.71, 72 In ons onderzoek hadden abnormale 
hematologische parameters slechts bij 2 patiënten (1%) klinische consequenties. Bij 
deze patiënten werd de behandeling tijdelijk onderbroken vanwege ernstige afwijkingen 
van het bloedbeeld. De gemiddelde alanine aminotransferase (ALAT) waarde tijdens 
behandeling met etanercept was significant hoger dan de gemiddelde waarde voor de 
start van etanercept, maar bleef wel binnen de normale range. Ernstig verhoogde ALAT 
waarden (graad 3 en graad 4) waren waarschijnlijk gerelateerd aan het gelijktijdig gebruik 
van methotrexaat of comorbiditeit.
Statistisch significante veranderingen van gemiddelde labwaarden tijdens behandeling 
vergeleken met voor de start van de behandeling evenals significante trends werden 
ook gevonden voor een aantal andere hematologische en chemische parameters. De 
gemiddelde waarden tijdens behandeling bleven echter allemaal binnen de normale range.
De behandeling met biologicals werd tijdelijk onderbroken bij patiënten die zich 
presenteerden met klachten passend bij een infectie, met of zonder het verrichten van 
bloedonderzoek en met of zonder verhoogde infectieparameters.
Vervolgonderzoeken in andere patiëntengroepen, bij voorkeur met een langere follow-up, 
en implementatieonderzoeken zouden meer bewijs kunnen leveren voor de benodigde 
frequentie van bloedonderzoek en de te bepalen laboratoriumwaarden. Minstens zo 
belangrijk als bloedonderzoek is de instructie aan patiënten om contact op te nemen 
met hun dermatoloog wanneer zich gezondheidsproblemen, inclusief infecties, voordoen 
tussen ziekenhuisbezoeken door.
Conclusie: de incidentie van ernstig afwijkende laboratoriumwaarden gerelateerd aan 
de behandeling was laag in dit cohort. Op basis van de resultaten van dit onderzoek 
lijkt routinematig bloedonderzoek tijdens behandeling met etanercept of adalimumab 
bij patiënten met psoriasis niet nodig. Bloedonderzoek dat nodig is in verband met 
gelijktijdig gebruikte medicatie, comorbiditeit of klachten dient wel plaats te vinden. 
Vervolgonderzoek zou meer bewijs kunnen leveren voor de benodigde frequentie 
van bloedonderzoek en de te bepalen laboratoriumwaarden. Screening voor de start 
van een biological is nodig om contraindicaties of risicofactoren op te sporen en om 
uitgangswaarden te bepalen.
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Vervolgonderzoek in de toekomst
Er is behoefte aan directe vergelijkingen van verschillende aspecten van behandeling met 
biologicals en andere systemische therapieën voor psoriasis in de dagelijkse praktijk.
Met behulp van gegevens uit de Bio-CAPTURE registry en de MTX-CAPTURE registry 
kunnen in de toekomst de effectiviteit, veiligheid, kosteneffectiviteit, kwaliteit van leven 
en tevredenheid over de behandeling van verschillende biologicals vergeleken worden en 
kan een vergelijking gemaakt worden met methotrexaat.
In dit proefschrift zijn met name effectiviteits- en veiligheidsgegevens over etanercept en 
adalimumab beschreven. Gegevens over het gebruik van ustekinumab in de dagelijkse 
praktijk zullen in de nabije toekomst geanalyseerd worden.
De effectiviteit van etanercept en adalimumab in de dagelijkse praktijk was lager dan 
in RCT’s. Het zou interessant zijn om een vergelijking te maken van de effectiviteit van 
biologicals bij patiënten in de dagelijkse praktijk die voldoen aan de inclusiecriteria voor 
RCT’s en patiënten die hier niet aan voldoen. In een onderzoek bij patiënten met RA werd 
bij patiënten die voldeden aan de inclusiecriteria voor RCT’s een hoger responspercentage 
gevonden vergeleken met patiënten die hier niet aan voldeden.73
In onderzoeken bij RA is ook aangetoond dat behandeling volgens treatment goals leidt tot 
een betere effectiviteit vergeleken met standaardzorg.29, 30 Behandeling volgens treatment 
goals vergeleken met standaardzorg kan in een prospectief implementatieonderzoek bij 
psoriasis patiënten uit de Bio-CAPTURE registry onderzocht worden.
Het Bio-CAPTURE netwerk biedt de mogelijkheid om een vergelijking te maken van 
de effectiviteit van biologicals bij patiënten die behandeld worden in een academisch 
ziekenhuis en patiënten die in een niet-academisch ziekenhuis behandeld worden. Tevens 
kan de veiligheid van de biologicals onderzocht worden in een grotere patiëntengroep. 
De ontwikkeling van een behandelalgoritme zou dermatologen kunnen helpen bij het 
nemen van beslissingen omtrent het aanpassen van de behandeling in het geval van 
onvoldoende effectiviteit van een biological. Er zijn echter meer gegevens nodig voordat 
een dergelijk behandelalgoritme opgesteld kan worden. In de toekomst kan het effect 
van dosisverhoging of combinatietherapie met een klassieke systemische therapie 
vergeleken worden in een grotere patiëntengroep. Tevens kunnen de benodigde duur van 
dosisverhoging en de benodigde duur en dosering van combinatietherapie vastgesteld 
worden. Daarnaast kan het effect van switchen naar een biological met hetzelfde 
werkingsmechanisme vergeleken worden met switchen naar een biological met een 
ander werkingsmechanisme.
Vanuit het oogpunt van de hoge kosten van biologicals en resterende onzekerheid 
over de veiligheid van biologicals op de lange termijn, zou het interessant zijn om de 
effectiviteit en veiligheid van dosisverlaging, intermitterende behandeling en een mogelijk 
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‘biological sparend’ effect van combinatietherapie te onderzoeken. Op dit moment is het 
aantal patiënten waarbij dosisverlaging is toegepast nog te klein. Onderbreking van de 
behandeling is toegepast bij patiënten met infecties, patiënten die een electieve operatie 
moesten ondergaan en bij patiënten met een zwangerschapswens. De effectiviteit en 
veiligheid van intermitterende behandeling kan om te beginnen worden onderzocht in 
deze groep patiënten. Intermitterende behandeling of het stoppen van de behandeling 
met een biological wordt op dit moment niet bij andere patiënten toegepast, omdat 
er geen biomarkers voor remissie van psoriasis bestaan. Daarnaast bestaat bij 
intermitterende behandeling het risico op een rebound van de psoriasis, antistofvorming 
en verminderde effectiviteit bij herbehandeling. 
Perspectief
Psoriasis is een chronische ziekte en elke patiënt heeft zijn of haar eigen psoriasis. Een 
wetenschappelijke benadering van de behandeling van psoriasis in de dagelijkse praktijk is 
belangrijk om gezondheidszorg op maat te kunnen bieden bij de lange termijn behandeling 
van psoriasis. Het stratificeren van patiënten op basis van patiëntkarakteristieken, klinisch 
beeld, farmacogenetica en biomarkers zal leiden tot geïndividualiseerde lange termijn 
behandeling van psoriasis, waarbij gebruik gemaakt kan worden van de bestaande 
behandelingen en nieuwe behandelingsmogelijkheden. Registries met gedetailleerde 
informatie over patiënt- en behandelkarakteristieken zijn essentieel voor het ontwikkelen 
van gezondheidszorg op maat.
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